<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/233339-tricyclic-derivatives-or-pharmaceutically-acceptable-salts-thereof-their-preparations-and-pharmaceutical-compositions-containing-them by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:39:17 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 233339:&quot;TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention relates to tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. More precisely, the present invention relates to tricyclic derivatives as colchicine derivatives, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them. Tricyclic derivatives of the present invention show very powerful cytotoxicity to cancer cell lines but were much less toxic than colchicine or taxol, confirmed through animal toxicity test. Tricyclic derivatives of the invention also decrease the volume and weight of a tumor and have a strong angiogenesis inhibiting activity in HUVEC cells. Thus, tricyclic derivatives of the present invention can effectively be used as an anticancer agent, anti-proliferation agent and an angiogenesis inhibitor.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY<br>
ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS<br>
AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br>
FIELD OF THE INVENTION<br>
The present invention relates to tricyclic<br>
derivatives represented by following <formula>, or<br>
pharmaceutically acceptable salts thereof, their<br>
preparations and pharmaceutical compositions containing<br>
them.<br><formula><br>
(Wherein; RI, R2/<br>
the description. )<br>
-i and X are as defined in<br>
BACKGROUND<br>
One of pseudo-alkaloid compounds, colchicine has<br>
an anti-inflammation action, making it a therapeutic<br>
agent for rheumatoid arthritis [Internal Medicine, 86,<br>
1<br>
Mo.2, 342-345, 2000] . Colchicine and thiocolchicine<br>
derivatives have functions of muscle relaxation and<br>
anti-inflammation (USP 5 973 204, EP 0870761 Al) .<br>
Thiocolchicoside has been used for the treatment of<br>
contracture and inflammation in skeletal muscles. Also,<br>
»<br>
colchicine inhibits infiltration of monocytes and Tcells<br>
in a transplanted organ in animal experiment and<br>
at the same time restrains the production of TNF-a, IL-<br>
1 and IL-6, inflammatory cytokines, suggesting an<br>
inhibiting effect on immune response [<j. am. soc.></j.>
Nephrol., 4(6), 1294-1299, 1993; Transplantation<br>
Proceedings, 32, 2091-2092, 2002] . Thus, colchicine is<br>
very attractive candidate for the development of an<br>
immune response inhibitor (WO 02/100824) .<br>
Colchicine inhibits a inicrotubule assembly by the<br>
interaction with tubulin, resulting in the suppression<br>
of cell division [The Alkaloids, 1991, 41, 125-176; USP<br>
4 533 675] . Such colchicine has been used for the<br>
treatment of gout and other inflammatory diseases<br>
related to gout. However, the • use of colchicine is<br>
limited to an acute inflammatory .disease because of the<br>
limitation in therapeutic index and toxicity to<br>
gastrointestinal tract [Pharmacotherapy, 11, 3, 196-211,<br>
1991].<br>
All the endeavors to develop colchiciue<br>
derivatives as an anbicancer drug have not been<br>
successful so far [USP 3 222 253; USP 00/6080739; WO<br>
97/01570] , and only demecolcine has been used for the<br>
treatment of leukemia. However, toxicity to<br>
gastrointestinal tract and limitation in therapeutic<br>
index are still problems of demecolcine.<br>
The present inventors have completed this<br>
invention by developing colchicine derivatives having<br>
excellent activities of anticancer, anti-proliferation<br>
and angiogenesis inhibition that have now stable<br>
therapeutic index resulted from decreased toxicity.<br>
SUMMARY OF THE INVENTION<br>
It is an object of the present invention to<br>
provide tricyclic derivatives or pharmaceutically<br>
acceptable salts thereof having excellent activities of<br>
anti-cancer, anti-proliferation and angiogenesis<br>
inhibition with stable therapeutic index by reduced<br>
toxicity.<br>
It is also an object of this invention to provide<br>
a preparation method for- tricyclic derivatives or<br>
pharmaceutically acceptable salts thereof.<br>
It is a further object of this invention to<br>
provide a pharmaceutical composition containing<br>
tricyclic derivatives or pharmaceutically acceptable<br>
salts thereof as an effective ingredient.<br>
BRIEF DESCRIPTION OF THE DRAWINGS<br>
PIG. 1 is a graph showing the changes of the<br>
volume of a tumor in a BALB/c nude mouse transplanted<br>
with human lung cancer cell line NCI-H460 after the<br>
administration of tricyclic derivatives of the present<br>
invention (Example 8),<br>
FIG. 2 is a graph showing the changes of the body<br>
weight of a BALB/c nude mouse transplanted with human<br>
lung cancer cell line NCI-H4GO after the administration<br>
of tricyclic derivatives of the present invention<br>
(Example 8),<br>
FIG. 3 is a graph showing the changes of the<br>
volume of a tumor in a BALB/c nude mouse transplanted<br>
with human lung cancer cell line NCI-H460 after the<br>
administration of tricyclic derivatives of the present<br>
invention (Example 12) by different concentrations (1,<br>
3, 10 ing/kg) ,<br>
v. FIG. 4 is a graph showing the changes of the body<br>
#<br>
weight of a BALB/c nude mouse transplanted with human<br>
lung cancer cell line NCI-H460 after the administration<br>
of tricyclic derivatives of the present invention<br>
(Example 12) by different concentrations (1, 3, 10<br>
rag/kg) ,<br>
FIG. 5 is a set of photographs showing the volume<br>
of a tumor growing in a BALB/c nude mouse transplanted<br>
with human lung cancer cell line NCI-H460, which was<br>
separated on the 14th day after the administration of<br>
tricyclic derivatives of the present invention,<br>
PIG. 6 is a set. of photographs showing the<br>
activity of tricyclic derivatives of the present<br>
invention to inhibit angiogenesis in HUVEC cells.<br>
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS<br>
The present invention relates to tricyclic<br>
derivatives represented by following <formula>, or<br>
pharmaceutically acceptable salts '.thereof.<br><formula><br>
(Wherein,<br>
(1) R1 is -T1-B1;<br>
in which T1 is -X1-, -X1-C(X2)-, -N(R5)-/ -N(R5)C (X3) -, -<br>
N(R5)S(0)n1-, -N(R5)C(0) -X1- or -N(RS) C (X1)NH-, in that<br>
X1 and X2 are each 0 or S, R5 is each H or C1-C5 alkyl<br>
group, nx is an integer of 1-2; and Bx is selected from<br>
a group consisting of following (a) ~ (j) ,<br>
(a)<br>
&amp;<br>
(CH2)n3-R7<br>
— (CH2)n2<br>
R»<br>
~(<br>
CHj)n2<br>
-ZfR7<br>
(b)<br>
(c)<br>
(CH2)n3-T2-B2<br>
-CCH-CH—o)n4-R7 (d)<br>
Z2 Z3<br>
-(CH2)n5-CH-(CH2)n6-R7<br>
^(<br>
CH2)n2<br>
ZfT2-B2<br>
—(CH-CH-0)n4-T2-B2<br>
(g)<br>
(h)<br>
z, z3<br>
~-(CII2)n5-CII-(CH2)n6-T2-B2<br>
Wherein, Rs and Ra are each H, halogen, hydroxy,<br>
Ci~C3 alkoxy, amino, nitro, cyano or Ci^Ca lower alkyl<br>
group; R7 and R9 are each independently halogen, hydroxy,<br>
mercapto, -ONO, -ON02 or SNO, in which R7 and R9 are<br>
same or different;<br>
is C5-C6 membered saturated or<br>
unsaturated heterocyclic ring containing 1~2 of hetero<br>
atom, in which the hetero atom is selected from a group<br>
S and N, preferably,<br>
v vj -v~ ~v Y Y<br>
Cl C! C3 01 cs C6<br>
/r-i
N<br>
H<br>
C7<br>
_jr-N<br>
^ ~y~<br>
H<br>
Cti<br>
/ — ^<br>
fi<br>
C9<br>
/— NH<br><x> fi<br>
CIO Cll C12<br>
more preferably, Cl (pyridyl group) substituted at<br>
position 2 and 6 or position 2 and 5, C7 (pyrrolyl<br>
group) substituted at position 2 and 5 or position 2<br>
and 4, Cll (thiophenyl group) or C12 (furanyl group) ;<br>
Z1 is C1 - C10 straight -chain or branched-chain alkyl<br>
group, preferably C2-Cs straight-chain, or branchedchain<br>
alkyl group or cycloalkyl group having<br>
substituent; Z2 and Z3 are each independently H or<br>
methyl group, in which Z3 is H when Z2 is methyl group,<br>
Z2 is H when Z3 is methyl group; T2 is -X1- or -X1-C(X2)-,<br>
in that X1 and X2 are each independently O or S; B2 is<br>
selected from a group consisting of said (a) , (b) , (c) ,<br>
(d) or (e) ; n2 is an integer of 0-3, n3 is an integer of<br>
0~5, n4 is an integer of 1-5, ns and n6 are each<br>
independently an integer of 1-6;<br>
(2) R2 and R3 are each independently H, -P03H2,<br>
phosphonate, sulfate, C3~C7 cycloalkyl, C2 ~ C7 alkenyl,<br>
C2~C7 alkynyl,, Cx ~ C7 alkanoyl , GI ~ C7 straight-chain or<br>
branched-chain alkyl or sugar, in which sugar is a<br>
8<br>
monosaccharide such as glucuronyl, glucosyl or<br>
galactosyl;<br>
(3) R4 is OCH3, SCH3 or NR10R11, in which R10 and R1X<br>
are each independently H or C1-5 alkyl;<br>
(4) X is 0 or S.)<br>
Preferably in the compound of <formula>,<br>
(1) R1 is -T1-B1;<br>
in which TO. is -N (R5) C (X2) - , -N(RS) C (0) -Xx- or -<br>
N(R5)C(X1)NH-, in that X1 and X2 are each O, R5 is each<br>
H or C1~C5 alkyl group; and B1 is selected from a group<br>
consisting of following (a) ~ (j) ,<br>
(a)<br>
(Cl I2)n3-T2-B2<br>
— (CH2)n2<br>
(CH2)n3-R7<br>
CH2)n2<br>
-ZfR7<br>
(b)<br>
(c)<br>
-(CH-CH-0)n4-R7 (d)<br>
22 Z3<br>
(CH2)n3-T2-B2<br>
(8)<br>
CH2)n2<br>
ZfT2-B2<br>
-(CH-CH—O)n4-T2-B2<br>
Z2 Z3<br>
00<br>
-(CH2)n5— CH-(CH2)n6-R7 (CH2)n5—CH— (CH2)n6-T2-B2<br>
Wherein, R6 and RB are each H, halogen, hydroxy,<br>
C1~C3 alkoxy, amino, nitro, cyano or C1~C3 lower alkyl<br>
group; R7 and R9 are each independently halogen, hydroxy,<br>
mercapto(thiol) , -ONO, -ON02 or SNO, in which R7 and R9<br>
are same or different}<br>
is C5-C6 rnembeied saturated or<br>
unsaturated heterocyclic ring containing 1-2 of hetero<br>
atom, in which the hetero atom is selected from a group<br>
consisting of 0, S and N, preferably, •<br>
N N ^N'<br>
Cl C2 C3<br>
/r-N ,—v<br>
V*<br>
C4<br>
/— NH V<br>
~V V<br>
H H<br>
C5 C6<br>
/ ^ "V" "V<br>
C7 C8 C9 CIO Cll C12<br>
more preferably, Cl (pyridyl group) substituted at<br>
position 2 and 6 or position 2 and 5, C7 (pyrrolyl<br>
group) substituted at position 2 and 5 or position 2<br>
and 4, Cll (thiophenyl group) or C12 (furanyl group),a<br>
bond of substituents may be at symmetrical or<br>
asymmetrical position; Za is C1~C10 straight-chain or<br>
branched-chain alkyl group, preferably C2-CS straightchain<br>
or branched-chain alkyl group or cycloalkyl group<br>
10<br>
having substituent; Z2 and Z3 are each independently H<br>
or methyl group, in which Z3 is H when Z2 is methyl<br>
group, Z2 is H when Z3 is methyl group; T2 is -X1- or -<br>
V<br>
X1-C(X2)-, in that X1 and X2 are each O or S; B2 is<br>
selected from a group consisting of said (a), (b), (c),<br>
(d) or (e) ; n2 is an integer of 0-3,. n3 is an integer of<br>
0-5, n4 is an integer of l~3, ns and n6 are each<br>
independently an integer of 1-3;<br>
(2) R2 and R3 are each independently C3 ~ C7<br>
cycloalkyl or C1~C7 alkyl;<br>
(3) R4 is SCH3 or OCH3;<br>
(4) X is 0 or S.<br>
Preferably, the compounds of <formula><br>
comprise:<br>
1) 6-nitrooxymethyl-N-[(7S)-1,2,3-trimethoxy-10-<br>
methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen -7-yl]-nicotineamide; "<br>
2) 5-nitrooxymethyl-furan-2-carboxylic acid-<br>
[ (7S) -l^^-trimethoxy-lO-methylsulfanyl-g-oxo-SfS,?, 9-<br>
tetrahydro-benzo[a]heptalen-7-yl]-amide;<br>
3) N-[(7S)-3-isopropoxy-l,2-dimethoxy-10-methylsulfanyl-<br>
9-oxo-5, 6,7, 9-tetrahydro-benzo [a] heptalen-7-<br>
yl] -3-nitrooxymethyl-benzamide;<br>
11<br>
4) N-[(7S)-3-ethoxy-l,2-dimethoxy-10-methylaulfanyl-<br>
9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-<br>
yl]-3-nitrooxymethyl-benzamide;<br>
5) 6-nitrooxymethyl-pyridine-2-carboxylic acid-<br>
[ (7S) -1, 2 , 3-trimethoxy-10~rnethylsulf anyl-9-oxo-5, 6,7,9-<br>
*<br>
tetrahydro-benzo[a]heptalen-7-yl]-amide;<br>
6) 5-nitrooxymethyl-thiophene-2-carboxylic acid-<br>
[(7S)-l,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-<br>
tetrahydro-benzo[a]heptalen-7-yl] -amide;<br>
7) N- [ (7S) -3-cycloperityloxy-l, 2-dimethoxy-10-<br>
methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a] heptalen -7-yl]-3-nitrooxymethyl-benzamide;<br>
8) N-[(73)-3-ethoxy-l,2-dimethoxy-10-<br>
methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a]heptalen-7-yl]-2-fluoro-3-nitrooxymethylbenzamide;<br>
9) 2-fluoro-N-[(7S)-3-isopropoxy-l,2-dimethoxy-<br>
10-methylsulfanyl-9-oxo-5,6,7, 9-tetrahydrobenzo<br>
[a]heptalen-7-yl]-3-nitrooxymethyl-benzamide;<br>
10) 2-fluoro-3-nitrooxymethyl-N-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a] heptalen-7-yl ] -benzatnide ;<br>
11) N-[(7S)-3-cyclopentyloxy-l,2-dimethoxy-10-<br>
methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-<br>
12<br>
benzo [a]heptalen-7-yl] -2-fluoro-3-nitrooxytnethylbensamide<br>
,-<br>
12) 3-fluoro-5-nitrooxymethyl-N-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide ;•<br>
13) N- [ ( I S ) -3-ethoxy-l,2-ditnethoxy-10-<br>
methylsulfanyl-9-oxo-5, 6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-3-fluoro-5-nitrooxymethylbenzamide;<br>
14) 3-fluoro-N-[(7S) -3-isopropoxy-l,2-dimethoxy-<br>
10-methylsulfanyl-9-oxo-5, 6,7, 9-tetrahydrobenzo<br>
[a] heptalen-7-yl] -5-nitrooxymethyl-benzamide;<br>
15) N- [ (7S) -3-cyclopentyloxy-l, 2-dimethoxy-10-<br>
methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl] -3-fluoro-5-nitrooxymethylbenzamide<br>
;<br>
16) 4-fluoro-3-nitrooxymethyl-N-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide;<br>
17) 2-fluoro-5-nitrooxymethyl-N-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide;<br>
18) 3-hydroxy-5-nitrooxymethyl-N-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide;<br>
13<br>
19) 3,5-Jbis-nitrooxymethyl-N- [ (IS) -1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide;<br>
20) 2-hydroxy-4-nitrooxymethyl-N- [ (IS)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,*6,7, 9-tetrahydro-<br>
*<br>
benzo[a]heptalen-7-yl]-benzamide;<br>
21) 4-nitrooxymethyl-thiophene-2-carboxylic acid<br>
[(IS)-l,2,3-trimethpxy-10-methylsulfanyl-9-oxo-5,6,7,2-<br>
tetrahydro-benzo[a]heptalen-7-yl]-amide;<br>
22) 3-nitrooxymethyl-thiophene-2-carboxylic acid<br>
[(IS)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-<br>
tetrahydro-benzo[a]heptalen-7-yl]-amide;<br>
23) 2-(3-nitrooxymethyl-phenyl)~N- [ (7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-acetamide;<br>
24) 3-(2-nitrooxy-ethyl)-N-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide;<br>
25) 3-nitrooxybenzoic acid-5-[(7S)-1,2,3-<br>
tritnethoxy-10-methylsulfanyl-9-oxo-5, 6,7, 9-tetrahydrobenzo[<br>
a]heptalen-7-yl-carbamoyl]-pyridine-2-ylmethylester;<br>
;<br>
26) 4-nitrooxybutyric acid-5-[ (7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-<br>
14<br>
benzo [a]heptalen-7-yl-carbamoyl]-pyridine-2-ylmethylester;<br>
27) 3-nitrooxymethyl-benzole acid-6-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl-carbamoyl]-pyridine-2-yl-<br>
»<br>
methylester;<br>
28) 4-nitrooxybutyric acid-6-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl-carbamoyl]-pyridine-2-yltnethylester;<br>
29) 3-nitrooxymethyl-benzole acid-2-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl-carbamoyl]-phenylester;<br>
30) 4-nitrooxybutyric acid-2-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl-carbamoyl]-phenylester;<br>
31) 3-nitrooxymethyl-benzole acid-3-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a]heptalen-7-yl-carbamoyl]-phenylester;<br>
32) 4-nitrooxybutyric acid-3-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl-carbamoyl]-phenyleater;<br>
33) 3-nitrooxymethyl-benzoic acid-3-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl-carbamoyl]-benzylester;<br>
15<br>
34) 4-nitrooxybutyric acid-3-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7, 9-tetrahydrobenzo<br>
[a]heptalen-7-yl-carbamoyl] -benzylester;<br>
35) 2-nitrosothio-N-[(7S)-1,2,3-trimethoxy-10-<br>
Tnethylsulfanyl-9-oxo-5, 6 , 7 , 9-tetrahydro- " '<br>
•<br>
benzo[a]heptalen-7-yl]-benzamide;<br>
36) 3-nitrosooxymethyl-N-[(7S)-1,2,3-trimethoxy-<br>
10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide;<br>
37) 3-fluoro-5-nitrosooxymethyl-N-[(73)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide;<br>
38) 3-nitroaothiomethyl-N-[(7S)-1,2,3-trimethoxy-<br>
10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a] heptalen-7 -yl] -beirzam.ide ;<br>
39) 3-fluoro-5-nitrosothiomethyl-N- [ (7S) -1,2,3;-<br>
triraethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide;<br>
. 40) 3-fluoro-5-nitrooxymethyl-N-[(7S)-1,2,3,10-<br>
tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-<br>
7-yl] -benzamide;<br>
41) 3-nitrooxymethyl-N-methyl-N- [(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a] heptalen-7-yl] -benzamide;<br>
16<br>
42) 3-fluoro-N-methyl-5-nitrooxymethyl-N-[(7S)-<br>
1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-<br>
tetrahydro-benzo[a]heptalen-7-yl]-benzamide;<br>
43) 2- (3-fluoro-5-nitrooxymethyl-phenyl)-N-[(7S)-<br>
1,2, 3 -trimethoxy-10-methylsulf anyl -9 -oxo-5,6,7,9-<br>
*<br>
tetrahydro-benzo[a]heptalen-7-yl]-acetamide; or<br>
44) 2- (2-fluoro-5-nitrooxymethyl-phenyl)-N-[(7S)-<br>
l,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6, 7,9-<br>
tetrahydro-benzo[a]heptalen-7-yl]-acetamide.<br>
The present invention also provides<br>
pharmaceutically acceptable salts of the compound<br>
represented by <formula>. Pharmaceutically acceptable<br>
salts of the present invention can include acid<br>
addition salt of a compound according to the invention<br>
when the compound is fully basic. Such acid addition<br>
salt includes salts holding inorganic acid providing<br>
pharmaceutically acceptable anion such as hydrogen<br>
halide, or organic acid, or salts holding sulfuric acid<br>
or phosphoric acid, or salts holding trifluoroacetic<br>
acid, citric acid or maleic acid. And, it include for<br>
example hydrochlorides, hydrobromides, phosphonates,<br>
sulfates, alkylsulfonates, arylsulfonates, acetates,<br>
benzoates, citrates, maleates, fumarates, succinates,<br>
lactates and tartarates by suitable salts. When a<br>
17<br>
compound of the present invention . is fully acidic,<br>
pharmaceutically acceptable salts can include inorganic<br>
salts or organic salts providing pharmaceutically<br>
acceptable cation. Said inorganic salts include sodium<br>
salts, potassium salts, calcium salts or magnesium<br>
salts, etc., said organic salts include methylamine<br>
salts, dimethylamine salts, trimethylamine salts,<br>
piperidine salts or morpholine salts, etc.<br>
The present invention also provides a preparation<br>
method for tricyciic derivatives represented by the<br><formula>. The preparation method for tricyclic<br>
derivatives of the present invention is described in<br>
the below Scheme 1 ~ Scheme 8. Precisely, in the<br><formula>, when RX is -T1-B1 and BI is one. of said (a) ,<br>
(b) , (c) , (d) and (e), the derivatives are prepared<br>
according to the method of Scheme 1 ~ Scheme 6. In the<br>
meantime, in the <formula>, when Rx is -T1-B1 and Bj.<br>
is one of said (f) , (g) , (h) , (i) and (j), the<br>
derivatives are prepared by the method of Scheme 7 and<br>
Scheme 8. And a concrete compound of the <formula><br>
is represented by general formulas (IIa), (IIb), (IIe),<br>
(IId), (IIe), (IIf), (IIg), (IIh), (IIi), (II j), (IIk),<br>
(II1) , (IIm) , (IIn) , (IIo) and (IIp) in Scheme 1 ~<br>
Scheme 8.<br>
18<br><scheme></scheme>
VIII<br>
,ON(0)n7<br>
lla<br><scheme><br>
Hal—Y-OH<br>
XI<br>
XII<br>
RS<br>
,^SNOn<br>
d<br><scheme><br>
19<br>
D-X2H<br>
Hal<br>
XIV<br>
VI1<br>
,OP<br>
XVII<br>
rv 1 JL<br>
XVI<br>
&gt; D-A xvm<br>
,JCON(0)n:<br>
lie<br>
JL.<br>
XIX<br>
Xv:; ^vY'SNO<br>
nr<br><scheme><br>
D-NHR5<br>
m<br>
XX<br>
(0)n,<br>
II<br>
XXI<br>
(0)ns<br>
•^'S"Y ON(0)n7<br><scheme><br>
(OK<br>
xxn IIli<br>
20<br>
D-NHR,<br>
0 nrV OP<br>
ra ii) deprotecting<br>
o<br>
D-NAxr<br>
XXIV<br>
XXV<br>
o<br>
Hi<br>
Uj<br><scheme g><br>
m ii) deprotecting<br>
xxvn<br>
R5 xxvm<br>
1<br>
Ilk<br>
ni<br><scheme><br>
21<br>
XXXIII<br>
•'?«<br>
j- Y'^°<br>
Ilk<br><scheme><br>
In the above Scheme, E is following El ~ E6<br>
respectively;<br>
22<br>
x<br>
El E2 E3<br>
(O)n7 O ?M<br>
-N Y ~N X, ^ N<br>
E4 E5 E6<br>
Wherein, Xi( X2 and X3 are each 0 or S.<br>
In the above Scheme, D i s , a n d R2,R3, R4<br>
and X are same as defined in the <formula>;<br>
R5 is H or lower alkyl; X1, X2 and X3 are each<br>
independently 0 or S; Hal1 and Hal2 are halogens; Hal1<br>
and Hal2 of general formula (IV) and (IX) are each same<br>
or different halogens, for example F, Cl, Br or I; P is<br>
conventional protecting group of hydroxy such as<br>
methoxymethyl, t-butyldimethylsilyl or benzyl; Y and Y1<br>
are same or different, and indicate following general<br>
formula (a1), (b1); (c1), (d1) and (e1) respectively,<br>
23<br>
-(CH2)n2 (a1)<br>
-(CH-CH—0)n4-<br>
Z, Z3<br>
(d')<br>
zf~<br>
(c1)<br>
-(CH2)n5-CH~(CH2)n6-<br>
(e')<br>
Wherein, R6, R8, R9, Z1, Z2, Z3, n2, n3,<br>
n4, n5 and n6 are same as defined in the <formula>, n?<br>
and na are integers of 1-2.<br>
The preparation method for tricyclic derivatives<br>
of the present invention is illustrated more precisely<br>
hereinafter.<br><method><br>
According to method 1 of the present invention<br>
for the preparation of compounds of formula (lla) and<br>
(l1b), the compound represented by formula (V) is<br>
prepared by amidation reaction making amine compound of<br>
formula (III) be reacted with halogen compound of<br>
formula (IV), which is step 1. In step 1, a base might<br>
be excluded, but the reaction is generally performed<br>
with a solvent such as dichloromethane, chloroform,<br>
24<br>
tetrahydrofuran, diethylether, toluene or<br>
dimethylformamide etc., which have no influence on<br>
amidation reaction, in the presence of pyridine,<br>
triethylamine, diethylisopropylamine or Nmethylmorpholine<br>
etc., a base that can be acceptable<br>
»<br>
for amidation reaction in general. Reaction temperature<br>
is not limited in particular, but generally reaction<br>
can performed under cold temperature or elevated<br>
temperature, is performed preferably at room<br>
temperature.<br>
In step 2, conversion of the compound of formula<br>
(V) prepared in the above step 1 to nitrooxy compound<br>
(n7 = 2) of formula (IIa) and to nitrosooxy compound<br>
(n7 = 1 ) of formula (IIa) was accomplished by nitration<br>
reaction and nitrosation reaction, respectively.<br>
Nitration reaction needs a compound that is able to<br>
convert halogen into nitrate, arid is performed using<br>
silver nitrate (AgN03) , t-butylammonium nitrate<br>
(Bu4NN03) , etc., in the presence of chloroform,<br>
acetonitrile, a mixture of acetonit.rile and aqueous<br>
solution, or dichloromethane, which are all solvents<br>
not affecting the reaction. Nitrosation reaction might<br>
use a compound that is able to convert halogen into<br>
nitrosate, too, and is performed preferably using<br>
silver nitrite (AgN02) or sodium nitrite (NaN02) in the<br>
25<br>
presence of chloroform, acetonitrile, a mixture of<br>
acetonitrile and aqueous solution, aqueous solution, or<br>
dichloromethane, which are also solvents not affecting<br>
the reaction. Reaction temperature is not limited in<br>
particular, but generally reaction can performed under<br>
»<br>
cold temperature or elevated temperature, is performed<br>
preferably at room temperature.<br>
Another way to give the compound of formula (IIa)<br>
is as follows; reaction of the compound of formula<br>
(III) with the compound of formula (VI) is performed to<br>
give the compound of formula (VII) , and then,<br>
conversion of the compound of formula (VII) to the<br>
compound of formula (Ila) is accomplished. The<br>
reaction of the compound of formula (III) and the<br>
compound of formula (VI) is performed in the presence<br>
of a coupling agent such as 1-(3-ditnethylaminopropyl) -<br>
3-ethylcarbodiimide(EDGI), 1-hydroxybenzotriazole<br>
hydrate(HOBT) or 1,3-dicyclohexyl carbodiimide(DCC).<br>
This reaction might be performed without a base, but<br>
generally with a base such as 4-dimethylaminopyridine,<br>
pyridine, triethylamine, diethylisopropylamine, Nmethylmorpholine<br>
or dimethylphenylamine etc., which can<br>
be used in amidation reaction, in a solvent having no<br>
negative effect on the reaction, for example<br>
acetonitrile, dimethylformamide, dichloromethane, etc.<br>
26<br>
Reaction temperature is not limited in particular, but<br>
generally reaction can performed under cold temperature<br>
or elevated temperature, is performed preferably at<br>
room temperature. Direct conversion of the compound of<br>
formula (VII) to the compound of formula (Ila) is<br>
»<br>
accomplished by the reaction of alcohol with<br>
triphenylphosphin (PPh3) , N-bromosuccineimide (NBS) and<br>
silver nitrate, or silver nitrite. The reaction is<br>
performed in a solvent having no effect on the reaction<br>
such as chloroform, acetonitrile, dichloromethane, a<br>
mixture of acetonitrile and dichloromethane, etc.<br>
Reaction temperature is not limited in particular, but<br>
generally reaction is performed under cold temperature<br>
or at room temperature. Another way for conversion of<br>
the compound of formula (VII) to the compound of<br>
formula (Ila) is as follows; conversion of the compound<br>
of formula (VII) to halogen compound of formula (V) is<br>
accomplished first, and then conversion thereof to the<br>
compound of formula (Ila) is accomplished again. At<br>
this time, the conversion into halogen compound is<br>
performed by using a reagent that generally converts<br>
hydroxy group to halogen, for example tribromophosphin,<br>
tetrabromomethane etc., in the presence of chloroform*<br>
acetonitrile, dichloromethane etc., which are solvents<br>
having no negative effect on the reaction. Reaction<br>
27<br>
temperature is not limited in particular, but generally<br>
reaction is performed under cold temperature or at room<br>
temperature.<br>
Processes for preparing the compound of formula<br>
(IIb) of the method 1 of the present invention are as<br>
follows; conversion of hydrogen included in alcohol of<br>
formula (VII) to a leaving group such as mesylate,<br>
tosylate or triplate is accomplished, followed by<br>
reaction with potassium thioacetate, to give<br>
thioacetate ester compound. Hydrolysis of the compound<br>
in the presence of a base is accomplished to give the<br>
compound of formula (VIII) . At this time, a base is<br>
selected among general bases that are able to hydrolyze<br>
an ester compound, for example sodium hydroxide,<br>
potassium hydroxide or sodium thiomethoxide. And an<br>
alcohol solution such as methanol or ethanol is<br>
preferred as a solvent for the reaction. Reaction<br>
temperature is not limited in particular, but generally<br>
reaction can performed under cold temperature or<br>
elevated temperature, is performed preferably at room<br>
temperature. Reaction of the compound of formula (VIII)<br>
with sodium nitrite under an acidic condition, leads to<br>
the conversion of the compound to nitrosothio compound<br>
of formula (IIb) . A solvent for the reaction is<br>
selected from a group consisting of methanol, ethanol,<br>
28<br>
acetonitrile, a mixture of acetonitrile and aqueous<br>
solution, or dichloromethane etc., which is not to<br>
affect the reaction. Reaction temperature is not<br>
limited in particular, but generally reaction can<br>
performed under cold temperature "or elevated<br>
»<br>
temperature, is performed preferably at room<br>
temperature.<br><methgd><br>
According to method 2 of the present invention,<br>
compounds of formula (IIe) and (IId) are prepared.<br>
Particularly, in step 1, reaction of the compound of<br>
formula (III) with the compound of formula (IX) is<br>
accomplished to give the compound of formula (X) . This<br>
reaction is performed in analogy to the procedure<br>
described in method 1 in which conversion of the<br>
compound of formula (III) to the compound of formula<br>
(V) was accomplished by amidation reaction.<br>
In step 2, conversion of the compound of formula<br>
(X) prepared in step 1 to the compound of formula (IIe)<br>
is accomplished by nitration reaction along with<br>
nitrosation reaction. This reaction is performed in<br>
analogy to the procedure described in method 1 in which<br>
conversion of the compound of formula (V) to the<br>
compound of formula (IIa) was accomplished.<br>
29<br>
Another way to give the compound of formula (IIe)<br>
is as follows; reaction of the compound of formula<br>
(III) with the compound of formula (XI.) is performed to<br>
give the compound of formula (XII) , and then,<br>
conversion of . the compound of formula (XII) to the<br>
compound of formula (IIe) is accomplished. Reaction of<br>
the compound of formula (XI) with the compound of<br>
formula (III) is performed in analogy to the procedure<br>
described in method 1 in which conversion of the<br>
compound of formula (III) to the compound of formula<br>
(V) was accomplished by amidation reaction. Conversion<br>
of the compound of formula (XII) to the compound of<br>
formula (IIe) is accomplished under the same condition<br>
as provided for the conversion of the compound of<br>
formula (VII) to the compound of formula (IIa) in<br>
method 1.<br>
Conversion of the compound of formula (XII) to<br>
the compound of formula (IId) is accomplished under the<br>
same condition as provided for the conversion of the<br>
compound of formula (VII) to the compound of formula<br>
(IIb) in method 1.<br><method><br>
According to method 3 of the present invention,<br>
compounds of formula (IIe) and (IIf) are prepared.<br>
30<br>
Particularly, in step 1, reaction of the compound of<br>
formula (XIV) with the compound of formula (IV) is<br>
accomplished to give the compound of formula (XV). The<br>
reaction in this method is esterification reaction of<br>
.alcohol (X2=0) or thioalcohol (X2=S) with acyl or<br>
thioacyl halide, which is performed in the presence of<br>
a base that is generally acceptable for esterification<br>
reaction. Preferable bases are pyridine, 4-<br>
dimethylaminopyridine, triethylamine,<br>
diethylisopropylamine, 2,6-lutidine, sodium hydride<br>
(NaH) , cesium carbonate, or sodium hydroxide and can be<br>
used along with a phase transfer catalyst such as<br>
benzyltriethylammoniumchloride. Also, above reaction is<br>
preferably performed in a solvent having no negative<br>
effect on the reaction, for example dichloromethane,<br>
chloroform, tetrahydrofuran, diethylether, toluene,<br>
dimethylformamide, acetonitrile or aqueous solution.<br>
Reaction temperature is not limited in particular, but<br>
generally reaction can performed under cold temperature.<br>
or elevated temperature, is performed preferably at<br>
room temperature.<br>
In step 2, conversion of the compound of formula<br>
(XV) prepared in step 1 to the compound of formula<br>
(IIe) is accomplished by nitration reaction along with<br>
nitrosation reaction. This reaction is performed in<br>
31<br>
analogy to the procedure described in method 1 in which<br>
conversion of the compound of formula (V) to the<br>
compound of formula (IIa) was accomplished.<br>
Another way to give the compound of formula (IIe)<br>
is as follows; reaction of the compound of formula<br>
(XIV) with the compound of formula (VI} having a<br>
protective group in alcohol group is performed to give<br>
the compound of formula (XVII), followed by<br>
deprotection reaction to give the compound of formula<br>
(XVIII). Conversion of the resultant compound to the<br>
compound of formula (lie) is accomplished. The<br>
reaction of the compound of formula (XIV) with the<br>
compound of formula (VI') is processed by<br>
esterification reaction of alcohol (X2=O) or<br>
thioalcohol (X2=S) and carboxylic acid or<br>
thiocarboxylic acid. The reaction is performed either<br>
in an aqueous solution supplemented with an acid such<br>
as hydrochloric acid, sulfuric acid, dodecylbenzene<br>
sulfonic acid or p-toluenesulfonic acid, at room<br>
temperature or under elevated temperature, or under the<br>
same condition provided for conversion of the compound<br>
of formula (III) to the compound of formula (VII) in<br>
method 1. Another esterification reaction is performed<br>
by Misunobu reaction using triphenylphosphine and<br>
diethyl azodicarboxylate in a solvent not affecting the<br>
32<br>
reaction. And the solvent is preferably selected from<br>
a group consisting of dichloromethane, chloroform,<br>
tetrahydrofuran, diethylether, toluene or acetonitrile.<br>
Reaction temperature is not limited in particular, but<br>
general-ly reaction is performed under cold temperature<br>
or at room temperature. Protecting and deprotecting<br>
reaction of alcohol group is performed by known method<br>
in general organic synthesis.<br>
Reaction of the compound of formula (XIV) with<br>
the compound of formula (XVI) is performed to give the<br>
compound of formula (XVIII) in analogy to the procedure<br>
described in method 3 in which conversion of the<br>
compound of formula (XIV) to the compound of formula<br>
(XV) was accomplished.<br>
Conversion of the compound of formula (XVIII) to<br>
the compound of formula (Ie) is performed under the<br>
same condition provided for conversion of the compound<br>
of formula (VII) to the compound ' of formula (IIa) in<br>
method 1.<br>
Conversion of the compound of formula (XVIII) to<br>
the compound of formula (IIf) is performed under the<br>
same condition provided for conversion, of the compound<br>
of formula (VII) to the compound of formula (IIb) in<br>
method 1.<br>
33<br><method><br>
According to method 4 of the present invention,<br>
compounds of formula (IIg) and (IIh) are prepared.<br>
Particularly, in step 1, reaction of the compound of<br>
formula (III) with the compound of formula (XX) is<br>
accomplished to give the compound of formula (XXI).<br>
When the compound of formula (IIg) is<br>
sulfinylamide (na=l) , the reaction of the compound of<br>
formula (III) with sulfinylhalide of formula (XX) is<br>
performed without a base or with a base that is<br>
applicable to amidation reaction, for example pyridine,<br>
triethylamine, diethylisopropylamine, Nmethylmorpholine<br>
or dimethylphenylamine, in a solvent<br>
having no negative effect on the reaction such ns<br>
dichloromethane, chloroform, tetrahydrofuran,<br>
diethylether, toluene or dimethylformamide. Reaction<br>
temperature is not limited in particular, but generally<br>
reaction can performed under cold temperature or<br>
elevated temperature, is performed preferably at room<br>
temperature.<br>
When the compound of formula (Ilg) is<br>
sulfonylamide (nB=2) , the reaction of the compound of<br>
formula (III) with sulfonylhalide of formula (XX) is<br>
performed either without a base or with a base that is<br>
applicable to amidation reaction in general, for<br>
34<br>
example pyridine, triethylamine, diethylisopropylamine,<br>
N-methylmorpholine, sodium hydroxide, sodium carbonate<br>
or potassium carbonate, in a solvent having no negative<br>
effect on the reaction such as dichloromethane,<br>
chloroform, tstrahydrofuran, diethylether, toluene or<br>
dimethylformaraide. Reaction temperature is not limited<br>
in particular, but generally reaction can performed<br>
under cold temperature or elevated temperature, is<br>
performed preferably at room temperature.<br>
In step 2, conversion of the compound of formula<br>
(XXI) prepared in step 1 to the compound of formula<br>
(IIg) is performed under the same condition provided<br>
for conversion of the compound of formula (VII) to the<br>
• compound of formula (IIa) in method 1.<br>
Conversion of the compound of formula (XXI) to<br>
the compound of formula (IIh) is performed under the<br>
same condition provided for conversion of the compound<br>
of formula (VII) to the compound of formula (IIb) in<br>
method l.<br><method><br>
According to method 5 of the present invention,<br>
compounds of formula (Hi) and formula (IIj) are<br>
prepared as follows. In step 1, reaction of the<br>
compound of formula (III) with the compound of formula<br>
35<br>
(XXIII) having a protecting group to alcohol group is<br>
performed, followed by deprotection reaction.<br>
Conversion of the compound of formula (XXIV) resulted<br>
from the above reaction to the compound of formula<br>
(Hi) is accomplished. At this time, the reaction of<br>
the compound of formula (III) with the compound of<br>
formula (XXIII) is performed by using a coupling<br>
reagent such as carbonyl dichloride, triphosgen, di-tbutyl<br>
dicarbonate or 1,1'-carbonyl diimidazole etc.<br>
The reaction can be performed either without a base or<br>
with a base that is generally acceptable for amidation<br>
reaction, for example pyridine, triethylamine,<br>
diethylisopropylamine, N-methylmorpholine or<br>
dimethylphenylamine, in a solvent having no negative<br>
effect on the reaction such as dichloromethane,<br>
chloroform, tetrahydrofuran, diethylether, ethanol or<br>
dimethylformamide. Reaction temperature is not limited<br>
in particular, but generally reaction is performed<br>
under cold temperature or at room temperature. And<br>
deprotection reaction is performed by known method in<br>
general organic synthesis.<br>
In step 2, conversion of the compound of formula<br>
(XXIV) prepared in step 1 to the compound of formula<br>
(Hi) is performed under the same condition provided<br>
36<br>
for conversion of the compound of formula (VII) to the<br>
compound o£ formula (IIa) in method 1.<br>
Conversion of the compound of formula (XXIV) to<br>
the compound of formula (IIj) is performed under the<br>
same condition provided for conversion of the compound<br>
of formula (VII) to the compound of formula (IIb) in<br>
method 1.<br><method><br>
According to method 6 of the present invention,<br>
compounds of formula (IIk) and formula (II1) are<br>
prepared as follows. In step 1, reaction of the<br>
compound of formula (III) with the compound of formula<br>
(XXVI) having a protecting group to alcohol group is<br>
performed, followed by deprotection reaction. Then,<br>
conversion of the resultant compound of formula (XXVII)<br>
to the compound of formula (IIk) is accomplished. At<br>
this time, the reaction of the compound of formula<br>
(III) with the compound of formula (XXVI) is performed<br>
either without a base or with a base that is acceptable<br>
for amidation reaction, for example pyridine,<br>
triethylamine, diethylisopropylamine or Nmethylmorpholine<br>
etc, in a solvent having no negative<br>
effect on the reaction such as dichloromethane,<br>
chloroform, tetrahydrofuran, diethylether, benzene,<br>
37<br>
acetonitrile, etc. Reaction temperature is not limited,<br>
in particular, but generally reaction is performed<br>
under cold temperature or at room temperature.<br>
Protecting and deprotecting reaction of alcohol group<br>
is performed by known method in general organic<br>
synthesis.<br>
In step 2, conversion of the compound of formula<br>
(XXVII) prepared in step l to the compound of formula<br>
(IIk) is performed under the same condition provided<br>
for conversion of the compound of formula (VII) to the<br>
compound of formula (IIa) in method 1.<br>
Conversion of the compound of formula (XXVII) to<br>
the compound of formula (II1) is performed under the<br>
same condition provided for conversion of the compound<br>
of formula (VII) to the compound of formula (IIb) in<br>
method 1.<br><method><br>
According to method 7 of the present invention,<br>
compounds of formula (IIm) and formula (IIn) are<br>
prepared from the compound of formula (XXIX) in analogy<br>
to the procedure described in method 3.<br><method><br>
38<br>
According to method 8 of the present invention,<br>
compounds of formula (IIo) and formula (IIp) are<br>
prepared as follows. In step 1, reaction of the<br>
compound of formula (XXIX) with the compound of formula<br>
(IX) is performed to give a compound of formula<br>
(XXXIV). This reaction is performed by etherification<br>
reaction of alcohol (X2=0) or thioalcohol (X2=S) with<br>
alkylhalide in the presence of a base acceptable for<br>
etherification reaction. As a base suitable for that<br>
purpose, sodium hydride (NaH), t-potassium butoxide (t-<br>
BuOK), n-BuLi, sodium hydroxide, potassium hydroxide<br>
and a phase transfer catalyst such as<br>
benzyltriethylammoniumchloride etc, or crown ether is<br>
preferred. The reaction is performed preferably in a<br>
solvent having no negative effect on the reaction, for<br>
example dichloromethane, chloroform, tetrahydrofuran,<br>
diethylether, toluene, dimethylformamide, aqueous<br>
solution, dimethylsufoxide or benzene, etc. Reaction<br>
temperature is not limited in particular, but generally<br>
reaction can performed under cold temperature or<br>
elevated temperature, is performed under cold<br>
temperature or at room temperature.<br>
In step 2, conversion of the compound of formula<br>
(XXXIV), prepared in the above step 1, to the compound<br>
of formula (IIo) is accomplished by nitration reaction<br>
39<br>
or nitrosation reaction. This reaction is performed in<br>
analogy to the procedure described in method 1 in which,<br>
conversion of the compound of formula (V) to the<br>
compound of formula (IIa) was accomplished.<br>
Another way to prepare the compound of formula<br>
(IIo) is as follows. Reaction of the compound of<br>
formula (XXIX) with the compound of formula (XI')<br>
having a protecting group to alcohol group is performed,<br>
followed by deprotection reaction to give the compound<br>
of. formula (XXXV) . Conversion of the compound of<br>
formula (XXXV) to the compound of formula (IIo) is<br>
accomplished. Reaction of the compound of formula<br>
(XXIX) with the compound of formula (XI') is performed<br>
under the same condition given for conversion of the<br>
compound of formula (XXIX) to the compound of formula<br>
(XXXIV) accomplished by etherification reaction in<br>
method 8.<br>
Conversion of the compound of formula (XXXV) to<br>
the compound of formula (IIo) is performed under the<br>
same condition provided for conversion of the compound<br>
i<br>
of formula (VII) to the compound of formula (Ila) in<br>
method 1.<br>
Conversion of the compound of formula (XXXV) to<br>
the compound of formula (IIp) is performed under the<br>
same condition provided for conversion of the compound<br>
40<br>
of formula (VII) to the compound of formula (IIb) in<br>
method 1.<br>
The target compounds given by the above reactions<br>
can be separated and purified by general methods such<br>
as column chromatography, recrystallisation, etc.<br>
The present invention provides also a<br>
pharmaceutical composition containing tricyclic<br>
derivatives represented by the <formula> or<br>
pharmaceutically acceptable salts thereof as an<br>
effective ingredient.<br>
Tricyclic derivatives according to the present<br>
invention or pharmaceutically acceptable salts thereof<br>
show very strong cytotoxicity to cancer cell lines but<br>
have much less toxicity 'to test animals than colchicine<br>
or taxol injection has.<br>
When tricyclic derivatives of the present<br>
invention were administered to a BALB/c nude mouse<br>
transplanted with human lung cancer cell line NCI-H460,<br>
\the size and the weight of a tumor were remarkably<br>
decreased in proportion to the dosage.<br>
Tricyclic derivatives of the present invention<br>
also have a strong activity of antiangiogenesis in<br>
HUVEC cells.<br>
41<br>
Therefore, tricyclic derivatives of the present<br>
invention or pharmaceutically acceptable salts thereof<br>
can be effectively used as an anticancer agent, an<br>
anti-proliferation agent and an angiogenesis inhibitor.<br>
The composition of the present invention might<br>
additionally include, in addition to tricyclic<br>
derivatives or pharmaceutically acceptable salts<br>
thereof, at least one of active ingredients having the<br>
same or similar function to the mentioned tricyclic<br>
derivatives or pharmaceutically acceptable salts<br>
thereof.<br>
The said tricyclic derivatives or<br>
pharmaceutically acceptable salts thereof can be<br>
administered orally or parenterally and be prepared in<br>
general forms of pharmaceutical formulation. The<br>
tricyclic derivatives of the present invention or<br>
pharmaceutically acceptable salts thereof can be<br>
prepared for oral or parenteral administration by<br>
mixing with generally used fillers, extenders, binders,<br>
wetting agents, disintegrant, diluents such as<br>
surfactants, or excipients. Solid formulations for<br>
oral administration are tablets, pills, powders,<br>
granules and capsules. These solid formulations are<br>
prepared by mixing one or more suitable excipients such<br>
42<br>
as starch, calcium carbonate, sucrose, lactose and<br>
galatin, etc. Except for the simple excipients,<br>
lubricants, for example magnesium stearate, talc, etc,<br>
can be used. Liquid formulations for oral<br>
administrations are suspensions, solutions, emulsions<br>
and syrups, and the above mentioned formulations can<br>
contain various excipients such as wetting agents,<br>
sweeteners, aromatics and preservatives in addition to<br>
generally used simple diluents such as water and liquid<br>
paraffin. Formulations for parenteral administration<br>
are sterilized aqueous solutions, water-insoluble<br>
excipients, suspensions, emulsions, lyophilized agent<br>
and suppositories. Water insoluble excipients and<br>
suspensions can contain, in addition to the active<br>
compound or compounds, propylene glycol, polyethylene<br>
glycol, vegetable oil like olive oil, injectable ester<br>
like ethylolate, etc. Suppositories can contain<br>
witepsol, macrogol, tween 61, cacao butter, laurin<br>
butter, glycerol and gelatin.<br>
The composition of the present invention can be<br>
prepared for either oral or parenteral administration<br>
(for example, intravenous, subcutaneous,<br>
intraperitoneal or local injection), and dosage is<br>
determined by weight, age, gender, condition of health<br>
and diet of a patient and administration method,<br>
43<br>
excretion rate and severity of a disease. The<br>
preferable effective dosage of the tricyclic<br>
derivatives of the present invention is 3-300 nig/kg<br>
(body weight), and administration times are once or<br>
several times per day.<br>
EXAMPLES<br>
Practical and presently preferred embodiments of<br>
the present invention are illustrative as shown in the<br>
following Examples.<br>
However, the present invention is not limited by<br>
following examples.<br>
7-Deacetylcolchicine used in the below examples<br>
was prepared by the method described in [EP 0493064;<br>
Synthetic Communications 1997, 27(2), 293-296].<br>
7-Amino-l,2,3-trimethoxy-10-methylsulfanyl-6,7-<br>
dihydro-5H-benzo[a]-heptalen-9-one was prepared by the<br>
method described in (WO 9421598; Bioorganic &amp; Medicinal<br>
Chemistry, Vol 5, No. 12, pp 2277-2282, 1997).<br>
Thiodemecolcine was prepared by the method<br>
described in (J. Med. Chem, 1985, 28, 1204-1208).<br>
(7S)-7-Amino-3-cyclopentyloxy-l,2-dimethoxy-10-<br>
methylsulfanyl-6,7-dihydro-5H-benzo[a]heptalen-9-one,<br>
44<br>
(7S)-7-amino-3-isopropoxy-l,2-dimethoxy-lOmethylsulfanyl-<br>
6,7-dihydro-5H-benzo[a]heptalen-9-one,<br>
(7S)_7_amino-3-ethoxy-l,2-dimethoxy-10-methylsulfanyl-<br>
6,7-dihydro-5H-benzo[a]heptalen-9-one were prepared by<br>
the method described in (WO 9611184).<br>
Example 1: Preparation of 6-n:.trooxymethyl-,N- [ (7S) -<br>
l,2,3-trimethoxy-10-methyleulfanyl-9-oxo--5, 6,7,9-<br>
tetrahydro-benzo[a]heptalen-7-yl]-nicotineamide<br><step> Preparation of 6-hydroxymethyl-Jr- [ (7S) -1,2,3-<br>
tritnethoxy-10-tnethylsulfanyl-9-oxo-5, 6,7, 9-tetrahydrobenzo<br>
[a]heptalen-7-yl3-nicotineamide<br>
CO2H<br>
EDCI, DMAP<br>
MeCN<br>
MeS ° MeS<br>
6-Hydroxymethyl-nicotinic acid was synthesized by<br>
the method described in (Bioorg. Med. Chem. Lett, 1996,<br>
6, 3025-3028) .<br>
45<br>
To a solution of 7-amino-l,2,3-trimethoxy-10-<br>
methylsulfanyl-6, 7-dihydro-5H-benzo [a] -heptalen-9-one<br>
(300 mg, 0.80 tnmol) , 6-hydroxymethylnicotinic acid (135<br>
mg, 0.88 tnmol) and DMAP (60 rag, 0.48 tnmol) in 10 mfi of<br>
acetonitrile was added EDCI (308 mg, 1.60 mmol) at 0°C.<br>
*<br>
The reaction mixture was stirred at room temperature<br>
for 2 hours. Water was added to quench the reaction,<br>
and aqueous layer was extracted with ethyl acetate.<br>
Combined organic layer was dried over anhydrous, sodium<br>
sulfate, filtered and concentrated under reduced<br>
pressure. The residue was purified by column<br>
chroma tography (ethyl acetate: methanol = 8:1), to give<br>
244 mg (yield: 60%, solid having yellow color) of the<br>
target compound.<br>
1H'NMR (400MHz, CDC13) : 52.07-2.15(m, 1H) , 2.31-<br>
2.44(m, 2H) , 2.45(s, 3H) , 2.56-2.59(m, 1H) , 3.75(s, 3H)<br>
3.91(s, 3H) , 3.97(s, 3H) , 4.66(q, J=10.2Hz, 2H) , 4.90-<br>
4.93(m, 1H) , 6.56(s, 1H) , 7.13(t, J=9.1Hz, 2H) , 7.40(d,<br>
J=10.2Hz, 1H) , 7.52(8, 1H) , B.15(dd, J=2.2, 5.8Hz,<br>
8.80(d, J=6.9Hz, 1H) , 8.96(s,<br>
46<br><step> Preparation of 6-nitrooxymethyl-JJ~ [ (7S) -1_, 2/3-<br>
trimethoxy-10-methylsulf anyl-9-oxo-S ,6,7 , 9~tetrahydrobenzo[<br>
a]heptalen-7-yl]-nicotineamide<br>
MeQ<br>
ON02<br>
The compound (100 mg, 0.19 mmol) prepared in the<br>
step 1 of Example 1 and triphenylphosphine (57 rag, 0.21<br>
mmol) were dissolved in acetonitrile/dichloromethane<br>
(1.25 ml/0.5 ml), therein NBS (42 mg, 0.23 mmol) was<br>
added at -35°C. The reaction mixture was stirred for<br>
20 minutes. Thereafter, therein silver nitrate (40 mg,<br>
0.23 mmol) was slowly added dropwise at room<br>
temperature , the reaction mixture was stirred at room<br>
temperature for 18 hours. Water was added to quench<br>
the reaction, and aqueous layer was extracted with<br>
chloroform. Combined organic layer was dried over<br>
anhydrous sodium sulfate, filtered and concentrated<br>
under reduced pressure. The residue was purified by<br>
column chroma tography ( chloroform rmethanol = 10:1), to<br>
47<br>
give 18 mg (yield: 35%, solid having yellow color) of<br>
the target compound.<br>
NMR (400MHz, CDC13): 52. 09-2 .13.(m, 1H) , 2.31-<br>
2.43(m, 2H) , 2.46(s, 3H) , 2 .55-2 . 64 (m, 1H) , 3.75(s, 3H) ,<br>
3.91(s, 3H) , 3.97(s, 311), 4.93-4.98 (m, *1H) , 5.50(s,<br>
2H) , S.56(s, 1H) , 7.16(t, J=10.9Hz, 1H) , 7.26(d,<br>
J=8.8Hz, 1H), 7.40(d, J=10.6Hz, 1H), 7.59(s,<br>
8.27(dd, J=2.2, 5.8Hz, 1H), 8.77(d, J=7.3Hz,<br>
9.08(s,<br>
Example 2-4<br>
Compounds of Example 2 - Example 4 were<br>
synthesized in analogy to the procedure as described in<br>
Example 1, and intermediates were prepared by the<br>
method described as follows.<br><intermediate> Preparation of 5-hydroxymethyl-furan-<br>
2-carboxylic acid<br>
5 r-Hydroxymethyl-f uran-2 -carboxylic acid was<br>
synthesized by the method described in (Helv. Chim.<br>
Acta, 1926, 9, 10S8) .<br>
48<br><intermediate> Preparation of 3-hydroxymethylbenzoic<br>
acid<br>
nw 2NNaOH<br>
OH<br>
EtOH<br>
Isophthalic acid diethylester (9.100 g, 40.95<br>
mmol) was dissolved in tetrahydrofuran (20ml).<br>
Thereafter, therein lithiumborohydride. (11.26 ml, 22.52<br>
mmol, 2M tetrahydrofuran solution) was slowly added<br>
dropwise, and the reaction mixture was refluxed for 3<br>
hours. Water was added to quench the reaction, and<br>
aqueous layer was extracted with ethyl acetate.<br>
Combined organic layer was dried over anhydrous<br>
magnesium sulfate, filtered and concentrated under<br>
reduced pressure. The residue was purified by column<br>
chromatography (hexane:ethyl acetate = 2:1), to give<br>
5.76 g (yield: 77.1%, colorless liquid) of 3-<br>
hydroxymethylbenzoic acid ethylester.<br>
Ester compound (1.317 g, 7.311 mmol) prepared<br>
above was dissolved in ethanol (6 ml) . Thereafter,<br>
therein 2N NaOH aqueous solution (11.0 ml, 21.93 mmol)<br>
was slowly added dropwise, and the reaction mixture was<br>
stirred at room temperature for 1 hour. The reaction<br>
mixture was neutralized with 1% HCl aqueous solution,<br>
49<br>
extracted with ethyl acetate, and washed with saturated<br>
NaCl solution. Combined organic layer was dried over<br>
anhydrous magnesium sulfate, filtered and concentrated<br>
under reduced pressure. The residue was purified by<br>
column chromatography (ethyl acetate:methyl alcohol =<br>
5:1), to give 1.03 g (yield: 99.2%, white solid) of the<br>
target compound.<br>
H NMR (400MHz, CD3OD) : 54.66(s, 2H) , 7 . 4 4 ( t ,<br>
J=7.7HZ, 1H) , 7.5G(d, J=7.7Hz, 1H) , 7.92(d, J-=7.7Hz,<br>
1H) , 8.04(3, 1H)<br>
* Example 2; 5-nitrooxymethyl-furan-2-carboxylic acid-<br>
[ (7S) -1,2, 3-trimethoxy-10-methylsulfanyl-9-oxo-5, 6, 7,_9-<br>
tetrahydro-benzo [a] heptalen-7-yl] -amide<br>
Me.O;-<br>
-QM02<br>
aH NMR (400MHz, CDG13) : 52. 37-2 . 51 (m, 3H) , 2.46(s,<br>
3H) , 2.61-2.92(m, 1H) , 3.74(s, 3H) , 3.93(s, 3H), 3.98(s,<br>
3H) , 4. 82-4. 85 (m, 1H) , 4.85(d, J=13.2Hz, 1H) , 4.90(d,<br>
50<br>
J=13.2Hz, 1H), 6.39(3, 1H) , 6.58(s, 1H) , 6.64(8, 1H) ,<br>
7.16(d, J=10.6Hz, 1H) , 7.42(d, J=10.2Hz, 1H) , 7.72 (s,<br>
1H) , 8.99(s, 1H)<br>
Example _ 3j _ N- [ (7S) -3-isopropoxy-l, 2-^dimethoxy-10-<br>
methylsulf anyl-9-oxo-5 , 6 ,1 , 9-tetrahydrobenzo<br>
[a] heptalen-7-yl] -3 -nitrooxymethyl-benzamlde<br>
fylpO?<br>
Q,N'Q<br>
lll NMR (400MHz, CDC13) : 61,42 (t, ; J=6.6Hz, 6H),<br>
2 . 2 2 - 2 . 2 7 ( m , 1H) , 2 . 3 4 - 2 . 4 9 ( s , 2H) , 2.54-2.57(m, 1H) ,<br>
3.75(s, 3H) , 3.96(3, 3H) , 4 . 59-4 . 63 (m, 1H) , 4.93-4.97(01,<br>
1H) , 5.23(q, J=13.0H2, 2H) , 6.56(s, 1H) , 7.15(d,<br>
J=10.6Hz, Hi), 7. 18-7.25 (m, 1H) , 7.33(cl, J=O.OHz, 2H) ,<br>
7.46(d, J=10.2Hz, 1H) , 7.64(s, lH),7.71.(d, J=8.0Hz,<br>
7.88 (s,. 1H) , 8.40 (s, 1H)<br>
51<br>
Example 4 : N- [ (_7_s) -3 -ethgxy_-1, 2 -dimethoxy-1 Qjmethylsulf<br>
anyl- Q-oxo- 5,6,7, 9 -tetrarahydrobenzo<br>
[a] heptalen-7-yl]-3-nitr-oxymethyl-benzamide<br>
•0"<br>
XH NMR (400MH2, CDC13) : 61.49(t, J=6.9Hz, 3H) ,<br>
2.17-2. 24. (m, 1H) , 2. 34-2. 47 (in, 211) , 2.45(s, 3H) , 2.49-<br>
2.58(m, 1H) , 3.75(3, 3H) , U.iT/U, 311), 4 .12-4 .15 (m, 2H) ,<br>
4.89-4.96 (tn, 1H) , 5.24(q, J=12.0Hz, 2H) , 6.56(s, III),<br>
7.15(d/ J=10.2Hz, 1H) , 7.21-7.25(m/ III), 7.31-7.35(01,<br>
1H) , 7.41(d, J=10.6Hz, 1H) , 7.60(s, 1H) , 7.71(d,<br>
J=7.3Hz, 1H) , 7.78(s, 111), 0.23(3, 1H)<br>
52<br>
Example 5; Preparation of __6-nitrooxymethyl_-pyridine-2-<br>
carboxylic acid- [(75) -1,2,3-trimethoxy-lQmethylsulfanyl-<br>
9-oxo-5, 6,7,9-tetrahydrpbenzolfa]<br>
heptal en - 7 -yl ] - amide<br><step> Preparation of 6-hydroxymethyl-pyridine-2-<br>
carboxylic acid- [ (75) -l,2,3-trimethoxy-10-<br>
methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen -7-yl]-amide<br>
EDCI.DMAP<br>
MeCN<br>
MeS<br>
According to the similar procedure in the step l<br>
of Example 1l, by using 6-hydroxymethyl pyridine-2-<br>
carboxylic acid (23 mg, 0.17 mmol), 35 mg (yield: 53%,<br>
yellow solid) of the target compound was obtained.<br>
XH NMR (400MHz, CDC13) : 52.45(s, 3H), 2.33-2.50(m,<br>
3H) 2.52-2.73 (m, 1H) , 3.75(s, 3H) , 3.92(s, 3H) , 3.97(s",<br>
53<br>
3H) , 4.28(d, J-14Hz., Ill), 4 , 4 4 ( d , J-l-lHz, 1H) 4 . f - ; G -<br>
- l . D 2 ( m , HI), C . b V ; , , , : : . . , . •, . 1 ' ( a , J- : 1 0 . 4 z . , 1.H) , V . . 7 -<br>
7.48(m, 4H) , 7.73(3, 111), 9 . 80 (d, J^CHK, 111)<br><step> Preparation oi: 6-b/romomethyl-pyrji.diiv.- 2<br>
carboxylic acid-1 l-iLLzi-JL-r': trimethoxy - I 0 -<br>
methylsul£anyl-9-oxo-5, 6 , 7 , 9 -<br>
tetrahydroObenzo [a] heptalen -7 - vlj -<br>
MeS<br>
PBl'3<br>
CH-.CI,<br>
MeO—V/ --r<br>
t'Tf<br>
MeS<br>
Br<br>
A compound (50,45,mmol prepared in the<br>
step 1 was dissolved in dichlorometharie (6 ml) .<br>
Thereafter, therein tribromophosphine (PBr3, 0.005 ml,<br>
0.05 mmol) was slowly added dropwise at 0°C, and the<br>
reaction mixture was stirred at room temperature for 3<br>
hours. Methanol was added to quenen the reaction.<br>
Combined organic layer was dried over anhydrous<br>
magnesium sulfate, filtered arid and concentrated under<br>
reduced pressure. The residence was purified by column<br>
chromatography (chloroform:methanol = 99:1), to give 40<br>
mg (yield: 71%, yellow solid) of the target compound.<br>
XH NMR (400MHz, cnc!3): 52 . 06- 2 . 14 (in, 1H) , 2.33-<br>
2.41(m, 1H). , 2.4l(s, 3H) , 2. 46-2. 54 (m, 1H) 2 . 58-2 . 63 (m,<br>
1H) , 3.72(s, 3H), 3.90(3, 3H) , 3.95(S,*3H), 4.55(d,<br>
J=2.8Hz, 2H) , 4. 77-4, 83 (m, 1H) , 6.57(s, 1H) , 7.04(d,<br>
•7-10. 4Hz, 1H) , 7.29(s, 1H) , 7.31(d, J-10.4HZ, III),<br>
7.58(d, J=7.6Hs, 1H) , 7.78(t, J = 7 . GHz , • HI), 7.90(d,<br>
i7=»8.0Hz, 1H) , 8.53(d, J"=7.$Hz, 1H)<br><step> Preparation of 6-nibrooxyniet:hyl-pyridine-2-<br>
carboxylic acid- [ (7S) -1, 2 , 3 -r.rimethoxy-lQmethylsulfanyl-<br>
9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a]heptalen -7-yl]-amide<br>
AgNOa<br>
MeCN<br>
MeS<br>
'ON02<br>
MeS<br>
A compound (40 mg, 0.070 utmol) prepared in the<br>
step 2 was dissolved in acetonitrile (3rnl) . Thereafter,<br>
therein silver nitrate (23 mg, 0.14 mmol) was slowly<br>
55<br>
added dropwise, and the reaction mixture was stirred at<br>
room temperature for 12 hours. The reaction mixture<br>
was washed with water and concentrated under reduced<br>
pressure. The residue was purified by column<br>
chromatography ( chloroform: met: hano 1 = 99:1), to give 17<br>
mg (yield: 44.7%, yellow solid) of the target compound.<br>
XH NMR (400MHz, CDC13) : 52. 03-2.10 (m, 1H) , 2.33-<br>
2.41(m, 1H) , 2.43(s, 3H) , 2.46-2.54(m, 1H) 2.58-2.65(m,<br>
1H) , 3.73(s, 3H) , 3.92(3, 3H) , 3.95(S, 3H) , 4.77-4.83(m,<br>
1H) , 5.63(d, i7=3.2Hz:, 2H) , 6.58(s, 1H) , 7.06(d,<br>
J=10.4Hz, 1H) , 1.21(3, 1H) , 7.31(d, J=»10.4Hz, 1H) ,<br>
7.53(d, J=7.6Hz, 1H) , 7.88(t, J=B.OHz, 1H) , 8.02(d,<br>
J=7.2Hz, 1H) , 8.39(d, J-7.2Hz,<br>
Example 6-24<br>
Compounds of Example 6 - Example 24 were<br>
synthesized in analogy to the procedure as described in<br>
Example 5, and intermediates were prepared by the<br>
method described as follows.<br>
56<br><intermediate> Preparation of 6-hydroxymethylpyridine-<br>
2-carboxylic acid<br>
NaOH<br>
MeOH<br>
6- Hydroxyme thyl- pyr idine-2-carboxy lie acid<br>
ethylester (200 mg, 1.1 rtimol) (<j. aiaer. chem. soc></j.>
104, 2251-2257) was dissolved in methanol (1 ml) .<br>
Thereafter, therein 2N NaOH aqueous solution (1 ml) was<br>
slowly added dropwise, and the reaction mixture was<br>
stirred at room temperature for 1 hour. The reaction<br>
mixture was acidified (pH=3) with 2N HC1 . Solvent was<br>
concentrated under reduced pressure, then, dissolved inmethanol<br>
and filtered. The filtrate was concentrated<br>
under reduced pressure to give 150 mg (yield: 89%,<br>
white solid) of the target compound.<br>
XH NMR (400MHz, CD3OD) : 55.05(s, 2H) , 8.34(d,<br>
J=8.0Hz, 1H) , 8.47(d, J=8.0Hz, 1H) 8.73(d, J=8.0Hz,<br>
57<br><intermediate> Preparation of 5-hydroxymethylthiophene-<br>
2-carboxylic acid<br>
MeOH Me° )Me THF<br>
o<br>
2N-NaOH,<br>
HO'<br>
MeOH<br>
Thiophene-2 , 5-dicarboxylic acid (4 g, 23.3 mmol)<br>
was dissolved in methanol (300ml) . Catcilytic amount of<br>
sulfuric acid was slowly added therein. The reaction<br>
mixture was re fluxed to give 3.8 g (yield: 81.7%, white<br>
solid) of thiophene-2 , 5-dicarboxylic acid dimethylester .<br>
The thiophene-2, 5-dicarboxylic acid dimethylester (3.7<br>
g, 18.84 mmol) was dissolved in anhydrous<br>
tetrahydrofuran (50 ml) at room temperature under a<br>
nitrogen atmosphere. 2 . OM Lithiutnborohydrn.de<br>
tetrahydrofuran solution (5.5 ml, 11 mmol) was slowly<br>
added therein at 0°C. The reaction mixture was<br>
refluxed for 3 hours to give 2.1 g (yield: 64. 7 r , white<br>
solid) of 5-hydroxymethyl-thiophene-2-carboxy ic acid<br>
methylester . 5 -Hydroxymethyl -thiophene-2 -corboxylic<br>
acid methyl ester (2.1 g, 12.2 mmol) was dissolved in<br>
methanol (20 ml) . 2N NaOH aqueous solution (15ml) was<br>
slowly added therein. The reaction mixture was stirred<br>
58<br>
at room temperature for l hour to give 1.75 g (yield:<br>
89%, white solid) of the target compound.<br>
1H NMR (400MHz, CDC13): 53.90(Br, 1H) , 4.79(d,<br>
J-O.BHz,, 2H) , 6.97(d, J=4Hz, 1H) , 7 .66 (d, J=4Hz, 1H)J<br><intermediate> Preparation of 2-fluoro-3-<br>
hydroxymethyl-benzoic acid<br>
XT F O: OF' 1 nU ^. urn'-^1. T.r<br>
2-Fluoroisophthalic acid (3 g, 16.3 inmol) (J".<br>
Amer. Chem. Soc. , 1943, 65, 2308) was dissolved in<br>
methanol (150 ml) . Catalytic amount of sulfuric acid<br>
was slowly added therein. The reaction mixture was<br>
refluxed. The resultant was concentrated under reduced<br>
pressure to remove solvent, and dissolved in ethyl<br>
acetate. Combined organic layer was washed with<br>
saturated sodium carbonate, dried over anhydrous sodium<br>
sulfate and concentrated under reduced pressure. The<br>
residue was purified by column chrolmatography (ethyl<br>
acetaterhexane = 1:2), to give 3.1 g (yield: 08%, white<br>
solid), of 2-f luoro-isophthalic acid dimethylester.<br>
59<br>
Thiophene-2,5-dicarboxylic acid dimethylester (3.1 g,<br>
14.6 mmol) was dissolved in anhydrous tetrahydrofuran<br>
(50 ml) at room temperature under a nitrogen atmosphere.<br>
2.0M Lithiumborohydride tetrahydrofuran solution (4.4<br>
ml, 8.7 mmol) • was slowly added therein at 0°C. The<br>
reaction mixture was refluxed for 3 hours. The reaction<br>
mixture was acidified with IN HCl aqueous solution,<br>
concentrated under reduced pressure to remove solvent,<br>
and extracted with chloroform. Combined organic layer<br>
was dried over anhydrous sodium sulfate, filtered, and<br>
solvent was concentrated under reduced pressure. The<br>
residue was purified by column chromatography<br>
(dichloromethane: methanol = 99:1}, to give 1.5 g<br>
(yield: 58%, white solid) of 2-f luor o -3- hydr oxyme thy 1-<br>
benzoic acid methylester. The 2-fluoro-3~<br>
hydroxymethyl-benzpic acid methylester (1.3 g, 7i6<br>
mmol) was dissolved in methanol (20 ml) . 2N NaOH<br>
aqueous solution (14 ml) was slowly added therein. The<br>
reaction mixture was stirred at room temperature for 1<br>
hour. The reaction mixture was acidified (pH=3) with<br>
2N HCl. Solvent was concentrated under reduced<br>
pressure, then, dissolved in methanol and filtered.<br>
The filtrate was concentrated under reduced pressure to<br>
give 1.15 g (yield: 88%, white solid) of the target<br>
compound.<br>
60<br>
MMR (400MHz, DMSO-d6-) : 54.58(d, J=5.2Hz,<br>
2H),5.37(t, J-=5.2HZ, 1H) 7.28(t, J=SHz, 1H) , 7.68(t,<br>
, 7.74(t, J=8Hz,<br> Preparation __ of 3-£luoro-5-<br>
hydroxymethyl -benzole acid<br><sfcep> Preparation of 3-f luoro- 5 -hydroxyme thylbenzoic<br>
acid methyleater<br>
5-Fluoroisophthalic acid dimetliylester (1.6 g,<br>
7.54 mmol) (J. Org. Chem; 1969, 34, 1960-1961) was<br>
dissolved in tetrahydrofuran (15 ml) . Thereafter,<br>
therein 2.0 M lithiutnborohydr ide tetrahydrofuran<br>
solution (2.6 ml, 5.27 mmol) was slowly added dropwise<br>
at 0°C, and the reaction mixture was refluxed for 3<br>
hours. The reaction mixture was acidified with IN HC1<br>
aqueous solution, concentrated under reduced pressure<br>
to remove solvent, and extracted with chloroform.<br>
61<br>
Combined organic layer was dried over anhydrous sodium<br>
sulfate, filtered, and concentrated under reduced<br>
pressure. The residue was purified by column<br>
chromatography (dichloromethane : methanol = 99:1), to<br>
give 800 mg (yield: 57%, white solid) of the target<br>
compound .<br>
XH NMR (400MHz, CDC13): 63.92(d, J"=1.6Hz, 3H) ,<br>
4.75(d, J=4Hz, 2H) , 7.29-7.32(m, 1H) , 7.61(dd, J=9.2,<br>
I<br>
1.6Hz, 1H) , 7.8(d, iJ=0.8ITz,<br><step> Preparation of 3-fluoro-5-hydroxymethy1-<br>
benzoic acid<br>
MeO.<br>
NaOH<br>
MeOH<br>
According to the similar procedure in the method<br>
of intermediate 3, by using a compound prepared in the<br>
step 1, 1.6 g (yield: 94%, white solid) of the target<br>
compound was obtained.<br>
XH NMR(400MHz, CD3OD) : 5-1 . 66 (d, J=O.QHs, 211),<br>
7.33-7.36(m/ 1H), 7.56-7.59(m, 1H), 7.03-7.84(ra/<br>
62<br><intermediate> Preparation of 4-£luoro-3-<br>
hydroxymethyl-benzole acid<br><step> Preparation of 4-fluoro-isophthalic acid<br>
KMn04<br>
HO<br>
H20, reflux<br>
4-Fluoro-3-methyl-benzole acid (2.52 g, 16.346<br>
tnmol) and potassium permanganate (10.33 g, 65.382 mmol)<br>
were dissolved in aqueous solution (300 ml) , and the<br>
mixture was refluxed for 1 day. The reaction mixture<br>
was filtered and the resultant solution was cooled down<br>
at room temperature, then cone. HC1 solution was added<br>
thereto. The produced solid was heated until it was<br>
completely melted. The temperature was lowered again<br>
into room temperature and then the solid was filtered,<br>
to give 2.08 g (yield: 69.1%, white solid) of the<br>
target compound.<br>
H NMR (400MHz, CD3OD) : 57.32(dd, 17=10.4, 8. GHz,<br>
1H), 8.21-8.25(m, 1H) , 8.59(dd, J=7 . 0, .2 . 4Hz, 1H)<br>
63<br><step> Preparation of 4-fluoro-isophthalic acid<br>
dimethylester<br>
O<br>
cat. H2SO4<br>
OH MeO.<br>
MeOH, reflux<br>
,OMe<br>
O<br>
A compound prepared in the step 1 (2.08 g, 11.29<br>
mmol) was dissolved in methanol (30 ml) . Then, 10<br>
drops of cone, sulfuric acid were added therein. The<br>
reaction mixture was refluxed for 1 day, neutralized<br>
with saturated sodium hydrogen carbonate aqueous<br>
solution, and extracted with chloroform. Combined<br>
organic layer was dried over anhydrous sodium sulfate,<br>
filtered, and concentrated under reduced pressure, to<br>
give 2.21 g (yield: 92.2%, white solid) of the target<br>
compound .<br>
XH NMR (400MHz, CDC13) : 53.96(s, 3H) , 3.97(s, 3H) ,<br>
7.22(dd, J-10.3, 8.8Hz, 1H) , 8. 20-8. 23 (m, 1H) , 8.64(dd,<br>
J=7.0, 2.2Hz,<br>
64<br><step _3> _grgparation_ _of 4- l: 1 uoro-3 -hydrpxymethyl -<br>
benzoic acid methylester and 2-fluoro-5-hydroxymethylbenzoic<br>
acid methylester<br>
LiBH4<br>
MeO<br>
THF. reflux<br>
A compound prepared in the step 2 (104.5 mg,<br>
0.493 mmol) was dissolved in tetrahydrofuran solution<br>
(4 ml) . Then, 2M lithiumborohydride tetrahydrofuran<br>
solution (0.123 ml, 0.246 mmol) was slowly added<br>
therein. The reaction mixture was refluxed for 1 day.<br>
The reaction was quenched by water. Then, pH was<br>
adjusted to 5 with 1M HGl solution at 0°C. Extraction<br>
with ethyl acetate was performed. Combined organic<br>
layer was dried over anhydrous sodium sulfate, filtered,<br>
and concentrated under reduced pressure. The residue<br>
was purified by column chromatography<br>
(hexane:ethylacetate = 2:1), to give 4-fluoro-3-<br>
hydroxymethyl-benzoic acid methylester (45.4 mg, yield:<br>
50.1%, colorless liquid) and 2-fluoro-5-hydroxymethylbenzoic<br>
acid methylester (15.4 mg, yield: 17.0%,<br>
colorless liquid).<br>
65<br>
4-fluoro-3-hydroxymethyl-benzoic acid<br>
methylester:<br>
XH NMR (400MHz, CDC13) : 52.73(t, J-S.lHz, 1H) ,<br>
3.90(0, 3H) , 4.78(d, J-5.1HZ, 2H) , 7.07(dd, JW9.2,<br>
9.2Hz, 1H) , 7.93-7-.97(m, 1H) , 8.14(dd, J=7.1, 2.2Hz,<br>
1H)<br>
2-fluoro-5-hydroxymethyl-benzoic acid<br>
methylester:<br>
1H NMR (4 0 0MHz , CDCl3) : 51.96(1;,. J*=4 . 4Hz , 1H} ,<br>
3.94(S, 3H) , 4.70(d, J-4.4Hz, 2H) , 7.13(dd, J=10.6,<br>
8.4Hz, 1H) , 7.52-7.56(m, 1H) , 7.92(dd, J=7.0, 2.2Hz,<br>
1H)<br><step .4> Preparation of 4-fluoro-3-hydroxymethylbenzoic<br>
acid<br>
2N NaOl-l / MeOl-l<br>
- i-io<br>
According to the similar procedure in the method<br>
of intermediate 3, by using a compound prepared in the<br>
step 3 (1.074 g, 5.380 mmol), 0.906 g (yield: 91.3%,<br>
white solid) of the target compound was obtained.<br>
66<br>
XH NMR (400MHz, CD3OD) : 54.69(s, 2H) , 7.13<dd></dd>
J=9.9, 8.8Hz, 1H) , 7. 90-7. 97 (m, 1H) , 8.16(dd, J=7.3,<br>
2.2Hz,<br> _ Pi-eparation _ of _ 2-fluoro-5-<br>
hydroxymethyl -benzole acid<br>
F<br>
2N NaOH / MeOH<br>
'Ma HO<br>
According to the similar procedure in the method<br>
of intermediate 3, by using 2-fluoro-5-hydroxymethylbenzole<br>
acid methylester prepared in the step 3 of<br>
intermediate 7, a target compound was obtained.<br>
XH NMR (400 MHz, CD3OD) : 54.61(s, 2H) , 7.17(dd,<br>
J-11.0, 8.4Hz, 1H) , 7.55-7.59(m, 1H) , 7.93(dd, J=7.l;<br>
2.4Hz,<br>
67<br><intermediate> Preparation of 3-hydroxy-5-<br>
hydr oxyme t hy 1 - ben z ojic_<br>
o<br>
NaOH / MeOH H|<br>
OH<br>
5-Hydroxy-isophthalic acid raethylester (300 mg,<br>
1.42 mmol) was dissolved in tetrahydrofuran (20 ml) at<br>
O°C under a nitrogen atmosphere. Lithium aluminium<br>
hydride (30 mg, 0.7 mmol) was added therein. The<br>
reaction mixture was stirred at room temperature for 3<br>
hours. Water was added to quench the reaction, and<br>
aqueous layer was extracted with ethyl acetate.<br>
Combined organic layer was dried over anhydrous sodium<br>
sulfate, filtered and concentrated under reduced<br>
pressure. The residue was purified by column<br>
chromatography (dichloromethane:methanol = 20:1).<br>
ABbove-obtained 3-hydroxy-5-hydroxymethyl-benzoic acid<br>
methyleater (170 mg, 0.93 mmol) was dissolved in<br>
methanol (1 ml) . IN NaOH aqueous solution (1 ml) was<br>
added therein. The reaction mixture was stirred at<br>
room temperature for 1 hour. The reaction mixtux'e was<br>
acidified (pH=3) with 2N HC1. Solvent was concentrated<br>
under reduced pressure, and then, dissolved in methanol<br>
68<br>
and filtered. The filtrate was concentrated under<br>
reduced pressure to give 150 mg (yield: 96%, white<br>
solid) of the target compound.<br>
XH NMR (400MHz, CD3OD) : 53.87(3, 3H),, 4.57(s, 2H) ,<br>
7.02(s, 1H) , 7.31(s, 1H) , 7.48(s,<br>
^Intermediate 10&gt; Preparation of 3,5-Ms-hydroxymethylbenzoic<br>
acid<br><step> Preparation of 3,S-^is-hydroxymethyl-benzoic<br>
acid methylester<br>
OMe 1 eq. LAH HO'<br>
THF<br>
OMe<br>
Benzene-1 , 3 , 5-tricarboxylic acid trimethylester<br>
(1.010 g, 4.003 mmol) was dissolved in tetrahydrofuran<br>
(15ml) . Thereafter, the temperature was lowered into<br>
0°C, and therein lithium aluminium hydride (0.160 g,<br>
4.003 mmol) was slowly added, and the reaction mixture<br>
was stirred at room temperature for 3 hours. Water<br>
69<br>
(0.15 ml) and 15% NaOH aqueous solution (0.15 ml) were<br>
elowly added to quench the reaction. Aqueous solution<br>
(0.45 ml) was added again. Solvent was concentrated<br>
under reduced pressure. The residue was purified by<br>
column chromatography (hexane:ethyl acetate = 1:2), to<br>
•<br>
give 0.34 g (yield: 43.1%, colorless liquid) of the<br>
target compound.<br>
XH NMR (400MHz, CD3OD) : 53.91(s, 3H) , 4.66(s, 4H),<br>
7.59(3, 1H) , 7.93(3, 2H)<br>
r 
<step> Preparation of 3,5-bis-hydroxvmethyl-benzoic<br>
acid<br>
According to the similar procedure in the method<br>
of intermediate 3, by using a compound prepared in the<br>
Step 1 (1.50 g, 7.65 mmol) , 0.617 g (yijfld: 44.3%,<br>
white solid) of the target compound was obtained.<br>
H NMR (400MHz, CD3OD) : 55.21(s, 4H) , 7.55(s,<br>
7.92(3, 2H)<br>
70<br><intermediate> Preparation of 2-hydroxy-4-<br>
hydroxymethyl-benzole acid<br><step> Preparation of 2 -hydroxy-4 -bydroxymethy1-<br>
benzoic acid methylester<br>
HO.<br>
i) NBS, Benzoyl peroxide, CGI<br>
2) H2O, Dioxane<br>
MeO.<br>
2-Hydroxy-4-methyl-benzole acid methylester (166<br>
mg, 1 mmol) was dissolved in CC14 (1.5ml). NBS (177 mg,<br>
1 mmol) and benzoyl peroxide (5 mg, 0.02 mmol) were<br>
added therein. The reaction mixture was stirred at<br>
70°C for 12 hours. Then, the reaction mixture was<br>
washed with water, dried over anhydrous sodium sulfate,<br>
and filtered. Solvent was concentrated under reduced<br>
pressure. The residue was purified by column<br>
chromatography (dichloromethane:hexane =1:4), to give<br>
4-bromomethyl-2-hydroxy-benzoic acid methylester (130<br>
mg, yield: 53%, white solid). The resultant compound<br>
i1<br>
(130 mg, 0.53 mmol) was dissolved in aqueous solution<br>
(1.5. ml) and 1,4-dioxane (1.5 ml), and the mixture was<br>
stirred at 90°C for 12 hours. The reaction mixture was<br>
71<br>
extracted with chloroform. Combined organic layer was<br>
dried over anhydrous sodium sulfate, filtered and<br>
concentrated under reduced pressure. The residue was<br>
purified by column chromatography (ethyl acetate:hexane<br>
- 1:4), to give 55 nig (yield: 57%, white Solid) of the<br>
barget compound.<br>
H NMR (400MHz, CDC13): 53.95(s, 311) , 4.71(d,<br>
J=6Hz, 2H) , 6.88(d, J=8Hz, III), 6.99 (a, IE), 7.82(d,<br>
J=8Hz, 1H) , 10.79(3, 1H)<br><step> Preparation of 2_- hydroxy-_4 -hydroxyme thy.1 -<br>
benzoic acid<br>
x--^ ^"^<br>
NaOH<br>
MeOH/HoO<br>
According to the similar procedure in the method<br>
of intermediate 3, by using a compound prepared in the<br>
Step 1, 45 mg (yield: 90%, white solid) of the target<br>
compound was obtained..<br>
72<br><intermediate> Preparation of 4-hydroxymethylthiophene-<br>
2-carboxcylic acid<br><step> A: 4-methyl-thiophene-2-carboxylic acid.<br>
B; Preparation of 3-methyl-thiophene-_2-<br>
carboxylic acid<br>
i)n-Bu Li/Ether<br>
2.5M n-Butyllithium (12.2 ml/ 30.55 nunol) was<br>
V,<br>
dissolved in diethyl ether (1 ml) at room temperature<br>
under a nitrogen atmosphere. 3-Methyl-thiophene (3 g,<br>
30.55 mmol) dissolved in cliethyl ether was slowly added<br>
therein. The mixture was refluxed for 2 hours.<br>
Reaction chamber was cooled to 0°C and dry-ice was<br>
slowly added therein. Reaction was quenched with 45 ml<br>
of water, Diethyl ether layer was extracted and<br>
removed. Water layer was acidified with IN HCl<br>
solution and extracted with ethylacetate. Combined<br>
organic layer was dried over anhydrous sodium sulfate,<br>
filtered and concentrated under reduced pressure. The<br>
residue was purified by column chroma tography<br>
73<br>
(hexane:ethyl acetate = 9:1), to give the target<br>
compound A (900 mg, white solid) and B (650 mg, white<br>
solid).<br><step> Preparation of 4 -bromgrnethyl- thiophene- 2-<br>
carboxylic acid methyl ester<br>
4-Methyl-thiophene-2-carboxylic acid (900 mg,<br>
6.33 mmol) prepared in the step 1 was dissolved in<br>
methanol (15 ml) . Catalytic amount of sulfuric acid was<br>
slowly added therein. The reaction mixture was refluxed<br>
to .give 4 -methyl -thiophene -2 -carboxylic acid<br>
methylester (890 mg, yield: 90%, white solid) . 4-<br>
methyl -thiophene -2 -carboxylic acid methyl ester (200 mg,<br>
1.28 mmol) and NBS (215 mg, 1.216 mmol) , and benzoyl<br>
peroxide of catalytic amount were dissolved in<br>
tetrachloromethaiie solution (5 ml) . The reaction<br>
mixture was refluxed (70°C) for 3 hours to give 165 mg<br>
(yield: 55%, white solid) of the target compound.<br>
T3. NMR(400MHz, CDC13) ; 53.89(s, 3H) , 4.46(s, 2H) ,<br>
7.49(S, 1H) , 7.80(s, 1H)<br>
74<br><step> Preparation of 4-hydroxymethyl-thiophene-2-<br>
carboxylic acid<br>
fit • /—.Oil ' " H2Q/M-pio-xariB" Jr.' $ MeO.H/HizO<br>
A compound (150 mg, 0.638 mmol) prepared in the<br>
step 2 was dissolved in 1,4-dioxane (1.5 ml) and water<br>
(1.5 ml). Silver nitrate (130 mg, 0.765 mmol) was<br>
slowly added therein. The reaction mixture was stirred<br>
at room temperature for 12 hours to give 4-<br>
hydroxymethyl-thiophene-2-carboxylic acid methyl ester<br>
(60 mg, yield: 55%, white solid). This compound (60 mg,<br>
0.348 mmol) was dissolved in methanol (1 ml) at room<br>
temperature. IN NaOH aqueous solution (1 ml) was slowly<br>
added therein, and the reaction mixture was stirred at<br>
room temperature for 1 hour, to give 50 mg (yield: 95%,<br>
white solid) of the target compound.<br>
75<br>
intermediate 13 &gt; Preparation of 3-hydroxytnethylthiophene-<br>
2-carboxylic acid<br><step> Preparation of 3 -bromomethyl-thiophene-2-<br>
carboxylic acid methyl ester<br>
E&gt;f<br>
NBS,-Den?pyl peroxide;-<br>
, r - . - " H3CO .<br>
S Me.OH If S' CCL,; 1<br>
Q .U Q<br>
According to the similar procedure in the method<br>
of step 2 of intermediate 12, by using 3-methylthiophene<br>
-2 -carboxyl ic acid (650 mg, 4.57 mmol)<br>
prepared in the step 1 of intermediate 12, 750 mg<br>
(yield: 79%, white solid) of the target compound was<br>
obtained.<br>
H NMR (400MHz, CDC13); 53.90(s, 3H) , 4.91(s, 2H) ,<br>
7.18(d, J=5.2Hz, 1H) , 7 . 4 6 ( d , J=5.2Hz,<br><step> Preparation of 3 -hydroxyme thyl - thiophene -2-<br>
carboxylic acid<br>
76<br>
Br<br>
HUO/'M-Dfoxane: IT ':SX 'MeOH/.H2-0<br>
' •<br>
According to the similar procedure in the method<br>
of step 3 of intermediate 12, by using a compound<br>
prepared in the step 1 (750 mg, 3.19 mmol) , 210 mg<br>
(yield: 92%, white solid) of the target compound was<br>
obtained.<br><intermediate> Preparation of (3-hydroxymethylphenyl)-<br>
acetic acid<br>
CaC.03;<br>
H20/Me.QH.-<br>
m-Tolyl acetic acid ethyl ester (1 g, 5.6 mmol),<br>
NBS (948 mg, 5.33 mmol) and benzoyl peroxide of<br>
catalytic amount were dissolved in tetrachloromethane<br>
(15 ml) . The reaction mixture was refluxed (70°C) for<br>
3 hours to give (3-bromomethyl-phenyl)-acetic acid<br>
ethyl ester (GOO mg, yield: 42%, white solid). And (3-<br>
bromomethyl-phenyl)-acetic acid ethyl ester (130 mg,<br>
0.50 mmol) and calcium carbonate (300 mg, 3 mmol) were<br>
77<br>
dissolved in water (2 ml) and 1,4-dioxane (2 ml). The<br>
reaction mixture was refluxed to give (3-hydroxymethylphenyl)-<br>
acetic acid ethyl ester (85 mg, yield: 87%,<br>
white solid). (3-Hydroxymethyl-phenyl)-acetic acid<br>
ethyl ester (85 mg, 0.43 mmol) was dissolved in<br>
methanol (1 ml) at room temperature. IN NaOH aqueous<br>
solution (1 ml) was added therein. The reaction mixture<br>
was stirred at room temperature for 1 hour, to give 65<br>
mg (yield: 91%, white solid) of the target compound.<br>
H NMR(400MHz, CDC13) ; S3.66(s, 2H) , 4.57{s, 2H) ,<br>
7.21-7. 32 (m, 4H)<br>
•^Intermediate 15&gt; Preparation of 3- (2-hydroxy-ethyl) -<br>
benzoic acid<br>
pec<br>
THF.<br>
NaOK<br>
M^a-LAlr * ^NX^k^W^^h<br>
|"|pf_J<br>
•f'NaHMDS.<br>
«)• (Metivoxyrnelhyl)triphe hyl<br>
rphbsplidniurh Chlafide"<br>
TftF<br>
BOH<br>
OMe<br>
M00<br>
78<br>
Isophthalic acid (5 g, 30 mmol) was dissolved in<br>
methanol (50 ml) . Catalytic amount of sulfuric acid<br>
was added therein. The reaction mixture was stirred at<br>
reflux for 12 hours to give isophthalic acid dimethyl<br>
ester (5.2 g, yield: 90%, white solid). Isophthalic<br>
acid dimethyl ester (5.2 g, 26.7rnmol) was dissolved in<br>
tetrahydrofuran (30 ml) . 2M Li thiumborohydr ide<br>
tetrahydrofuran (13 ml, 26.7 mmol) was added therein.<br>
The reaction mixture was refluxed to give 3-<br>
hydroxymethyl'-benzoic acid methyl ester (2.7 g, yield:<br>
63%, colorless liquid), and 3-hydroxymethyl-benzoic<br>
acid methyl ester (200 mg, 1.20 mmol) was dissolved in<br>
dichloromethane (5 ml) . PCC (388 mg, 1.8 mmol) was<br>
added therein. The reaction mixture was stirred at<br>
room temperature for 3 hours to give 3-formyl-bensbic<br>
acid methyl ester (140 mg, yield: 72%, white solid).<br>
(Methoxymethyl)triphenylphosphonium chloride (770 mg,<br>
2.24 mmol) was dissolved in tetrahydrofuran (5ml) under<br>
a nitrogen atmosphere. 1M NaHMDS tetrahydrofuran (2 ml,<br>
2.04 mmol) was slowly added therein at -78"C, and the<br>
reaction mixture was stirred for 1 hour. 3-Formylbenzoic<br>
acid methyl ester (160 mg, 0.975 mmol)<br>
dissolved in tetrahydrofuran (2 ml) was slowly added<br>
therein. The reaction mixture was stirred at room<br>
79<br>
temperature for 24 hours to give 3- (2-methoxyvinyl) -<br>
benzole acid methyl ester (121 mg, yield: 65%, white<br>
solid). 3- (2-Methoxyvinyl) -benzole acid methyl ester<br>
(120 mg, 0.63 mmol) was dissolved in tetrahydrofuran (3<br>
ml) . 4M HCl (2 ml) was added therein, and the mixture<br>
was stirred at room temperature for 24 hours, to give<br>
3- (2-oxo-ethyl) -benzole acid methyl eater (60 mg,<br>
yield: 54%, white solid). 3- (2-Oxo-ethyl) -benzole acid<br>
methyl ester (60 .mg, 0.036 mmol) was dissolved in<br>
ethanol (2 ml). MaBIli (25 ing, 0 , G7 mmol) was added<br>
therein at 0°C, and the mixture was stirred at1 hour,<br>
to give 3- (2-hydroxyethyl) -benzole acid methyl ester<br>
(50 mg, yield: 84%, white solid). 3 - (2-Hydroxyethyl) -<br>
benzole acid methyl ester (50 mg, 0.28 mmol) was<br>
dissolved in methanol (1 ml) . IN NaOH aqueous solution<br>
(1 ml) was added therein. The reaction mixture was<br>
stirred at room temperature for 1 hour to give 43 mg<br>
(yield: 95%, white solid) of the target compound.<br>
1II NMR(400MH2, CDC13) ; 62 . 32 (br, 1H) , 2.89(t,<br>
J=6.4HZ, 2H) , 3.85(t, J=6.4Hz, 2H) , 7.36(t, i7=7.6Hz,<br>
1H) , 7.42(d, ,J=5.6Hz, 1H) , 7.88(d, .7=8. 8Hz, 1H) , 7. 89 (a,<br>
1H)<br>
80<br>
Example 6: 5-nitrooxymethyl-thiophene-2-carboxylic<br>
acid- [ (7S) -1, 2 , 3-trimethoxy-lO-methylsxilf anyl-9-oxo-<br>
5,6,7,9-tetrahydro~benzo[a]heptalen-7-yl]-amide<br>
MeS<br>
ZH NMR(400MHz, CDC13) ; 62 . 07-2 .11 (m, 1H) , 2.32-<br>
2.45(01, 2H) , 2.45(s, 3H) , 2.53-2.56(m, 1H) , 3.71(s, 3H) ,<br>
3.91(3, 3H) , 3.96(S, 3H) , 4. 84-4. 91 (m, 1H) , 5.46(s, 2H) ,<br>
6.56(s, 1H) , 6.95(d, J=3.6Hs, 1H) , 7.13(d, J-10.8Hzf<br>
1H), 7.37(d, J=10.8Hz, 1H)/ 7.58(d, J«4.0Hz,<br>
7.61(S, 1H), 8.50(d, J=6.SHz,<br>
81<br>
Example 7 : N- [ (7S) -3-cyclopentyjoxy-1-2-dlmethoxy-10<br>
methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a]heptalen-7-yl] -S-nitrooxymethyl-benzamlde<br>
fvleS<br>
^•H NMR(400MHz, CDC13) ; 61. 61-1.73 (m, 2H) , 1.85-<br>
2.00(m, 6H) , 2.21-2.65(m, 4H) , 2.44(s, 3H) , 3.75(s,<br>
3H), 3.93(S, 3H) , 4 . 82-4.88 (m, 1H) , 4.?2-5.00(m, 1H) ,<br>
5.16(dd, J=12, 31.2H2, 2H) , 6.55(s, 1H) , 7.13-7.17 (m,<br>
2H) , 7.28(d, J=6.4Hz, 1H), 7.41(d, J=10.8Hz, 1H) , 7.68-<br>
7.70{m, 1H) , 7.72(s, 1H) , 7.78(s, 1H), 8.78(d, J»7.2Hz,<br>
1H)<br>
Example 8: N- [ (75)-3-ethoxy-l,2-dimethoxy-lQmethylsulfanyl-<br>
9-oxo-5,6,7,9-tetrahydro-<br>
82<br>
benzo[a]heptalen-7-yl3 -2-fluoro-3-nitrooxyTnethylbenzamide<br>
XH NMR(400MHz, CDC13) ; 51.49(t, J=6.9Hz, 3H) ,<br>
1.93-1.98 (m, 1H) , 2.31-2.39(m, 1H) , 2.43(e, 3H) , 2.46-<br>
2.49(m, 1H) , 2.51-2.59 (m, l.H) , 3.73(s, 3H) , 3.96(s, 3H) ,<br>
4.11-4.14(111, 2H) , 4.83-4.86(01, 1H) , 5.53(d, J=12.8Hz,<br>
1H) , 5.59(d, ,7=12.4Hz, 1H) , G.56(s, 1H) , 7.07(d,<br>
j=10.2Hz, 1H) , 7.10-7.15(m, III), 7.20-7.28(m, 1H) ,<br>
7.31(d, J-=10.2Hz, 1H) , 7.57(t, J"=6.4Hz7 1H) , 7.97(t,<br>
J=6.9Ez, IE)<br>
83<br>
Example 9; 2-fluoro-N- [ (7S) -3-isopropoxy-1,2-dimethoxy-<br>
10-methylBulf anyl-9-oxo-5 , 6 , 7 , 9-tetrahydro—<br>
benzo[a]heptalen-7-yl]-3-nitrooxymethyl-benzamide<br>
Me:a<br>
*H NMR (400MHz, CDC13) ; 51.41(q, J=6.0Hz, 6H) ,<br>
2-1.99(m, 1H), 2.31-2.40(m, 1H) , 2.43(s, 3H) , 2.46-<br>
2,52(m, 1H) , 2.55-2.60(m, 1H) , 3 . 7 2 ( s ; 3H) , 3.94(s, 3H)<br>
4.57-4.63(m1, IE), 4.83-4.89 (m, Hi), 5.53(d, J=12.8Hz,<br>
1H), ' 5.59(d, J=12.4Hz, 1H), 6.57(s, 1H) , 7.07(d,<br>
JV.10.6Hz, 1H) , • 7.15-7.19(m, 1H) , 7.23-7.27(m, 1H) ,<br>
7.34(d,. J=10.2Hz, 1H) , 7.56(t, J=7.1Hz, 1H) , 7 . 7 ( t ,<br>
84<br>
Example 10: 2 -f luoro-g-i-i t-CKjxymgLh 1-- [(75) -l:,j,<br>
tritnethoxy- 10 -me thylsulf anyl-9-oxo_--_5, _6 , 7 , 9-tetrahydro<br>
benzo[a]heptalen-7-yl]-benzamide<br>
- NMR (400MHz, GDC13) ; 61. 95-2 . 02 (m, 1H) , 2.31-<br>
2.54(m, 2H) , 2.43(s, 3H) , 2.59-2.63(m, 1H) , 3.73(s,<br>
3H), 3.87(s, 3H) , 3.92(s, 3H) , 4.82-4.88(^1, 1H) ,<br>
5.51(d, J-=12.8Hz, 1H) , 5.60(d, .J=12 . QIIz, 1H) , 6.50(s,<br>
1H) , 7.06(d, J=10.6Hz, 1H) , 7.22-7.27'(m, 2H) , 7.28(s,<br>
1H) , 7.32(d, J=10.6Hz, 1H) , 7.54-7.58(m, 1H) , 7.93-<br>
7.98(m,<br>
Example 11; N- [ (7S) -3-cycloperityloxy-1, 2 -dlmethoxy-10-<br>
methylsulfanyl-9-oxo-5,6,7,9-betrahydro-<br>
85<br>
benzo [a]heptalen-7'yl]-2-fluoro-3-nitrooxymethylbenzamide<br>
TH NMR(400MHz, CDC13) ; 51. 61-1. 73 (m, 2H) , 1.85-<br>
2.00(10, 6H) , 2.35-2.52 (m, . 4H) , 2.42(s, 3H) , 3.72(s,<br>
3H) , 3.93(3, 3H) , 4. 82-4. 88 (m, 2H) , 5.57(dd, J"=12 . 8 ,<br>
37.6HZ, 2H), 6.55(s, 1H), 7.05(d, J=10.4Hz, 1H), 7.09-<br>
7.13(m, 1H) , 7.26(d, i7=7.2Hz, 2I-I) , 7.32(d, .7=10.4PIz,<br>
1H), 7.55-7.59(m, 1H), 7.96-8.00(m, 1H)<br>
Example 12; S-fluoro-S-nitrooxymethyl-Jf-[ (7S)-1,2 , 3-<br>
trimethoxy-10-methylsul£anyl-9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a]heptalen-7-yl] -benzamlclf<br>
86<br>
•fvleS<br>
F<br>
XH NMR(400MHz, CDC13); 62.31-2.45(m, 3H) , 2.46(3,<br>
3H) , 2.59-2.63(m, 1H) , 3.75(g, 3H) , 3.93(s, 3H) , 3.98(S,<br>
3H) , 4.90-4.95(m, 1H) , 5.11(dd, J=12.8, 45.6Hz, 2H) ,<br>
6.57(s, 1H) , 7.03(d, iJ=7 . 6Hz , Hi) , 7.19(d, iJ=8.8Hz, Hi) ,<br>
7.30-7.33(111, 1H) , 7.42(d, J=10.0Hz, 1H) , 7.55(s, 1H) ,<br>
7.68(s, 1H), 8.7S(d, J=7.2Hz,<br>
Example 13: N- [ (75) -3 - e L hqxy--1, 2-dimethoxy-10-<br>
methylsulfanyl-9-oxo-5, 6, 7, 9-tetrahydrobenzo[<br>
a]heptalen-7-yl) -3-£luoro-5-nitrooxymethylbenzamide<br>
'MeS<br>
87<br>
XH NMR(400MHz, CDC13) ; 51.50(t, J=6.9, 3H) ,<br>
2.33-2.42 (m, 3H) , 2.46(s, 311), 2 . 51-2 . 59 (m, 1H) , 3.75(s,<br>
3H) , 3.98(s, 3H) , 4.11-4.16(m, 2H) , 4.90-4.93(m, 1H) ,<br>
5.05{d,. J=12.4, 1H) , 5.17 (d, J=12.4, 1H) , 6.56(s, 1H) /<br>
7.03(d, J=7.3, 1H) , 7.20(d, J=10.6, 1H), 7.31(d, J=9.1,<br>
»<br>
1H) , 7.45(d, J=10.6, 1H) , 7.55(s, 1H) , 7.69(s,<br>
8.88(d, J=7.3, 1PI)<br>
Example 14: 3-fluoro-N-[(75)-3-isopropoxy-l,2-<br>
dimethoxy-lO-methylsulfanyl-g-oxo-S,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-5-nitrooxymethyl-benzamide<br>
LH NMR(400MHz, CDC13) ; 61. 37-1. 44 (m, 6H) ,<br>
2.34-2.41(m, 3H), 2.46(s/3H), 2.51-2.58(m, 1H), 3.75(s,<br>
3H) , 3.96(3, 3H) , 4. 57-4. 62 (m, III), 4. 91-4. 95 (m, 1H) ,<br>
5.05(d, J=12.4, 1H), 5.17(d, J=12.4, 1H), 6.56(s, 1H),<br>
7.03(d, J=8.4, 1H), 7.20(d, J=10.6, 1H) , 7.31(d, J=7.3,<br>
1H) , 7.45(d, J=10.6, III) , 7 . 5 : 5 ( 3 , 1H) , 7 . 7 0 ( s , 1I-I) ,<br>
8.91(d, J-7.3, III)<br>
Example 15; N- [ (75) -3-cyclopentyloxy-l,2-dimethoxy-10-<br>
methyleulfanyl-9-oxo-5,6,7, 9-tetrahycIrobenzo[<br>
a]heptalen-7-yl3 -3-fluoro-5-nitrooxyjnethylbenzamide<br>
WeS 0. •QNO&gt;&gt;<br>
XH NMR(400MHz, CDC13) ; 61.64-1.69(m, 2H) ,<br>
1.83-1.98(m, 6H) , 2.35-2.43(m7 3H) , 2.46(s, 3H) ,<br>
2.51-2.58(m, 1H) , 3.74(s, 3H) , 3 . 9 4 ( s , 3H) , 4 . 8 2 ~ 4 . 8 4 ( m ,<br>
1H), 4.91-4. 94 (m, III) ,. 5.04(d, ,7=12.4, III), 5.16(d,<br>
J-12.4, 1H) , 6.55(S j III), 7 . 0 2 ( d , J=8.4, 1H) , 7.20(d,<br>
J=10.6, 1H) , 7.31(d, J=7.3f 1H) , 7.45(d, J=10.2,<br>
7.55(S, 1H) , 7.70(s, III), 8.93(d, J=6.9, 1H)<br>
89<br>
Example 16: 4-fluoro-3-nitrooxymethyl-N- [ (75) -1, 2, 3-<br>
trimethoxy-lO-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-<br>
*beh2oIa]heptalen.-7-yl] -benzamide<br>
H NMR (400MHz, CDC13) ; 62 . 22-2 .51 (m, 3H) , 2.46(s,<br>
3H)2.55-2.63(m, 1H) , 3.76(s, 3H) , 3 . 9 2 ( s , 3H) , 3 . 9 8 ( s ,<br>
3H)4.90-4.97 (m, 1H) , 5.10(d, J=12.1Hz, 1H) , 5.35(d,<br>
J=12.1Hz, 1H) , 6 . 5 7 ( s , 1H), 6 . 8 6 ( d d , J=9.2, 8.8Hz, 1H),<br>
7.18(d, J=10.3Hz, 1H) , 7.43(d, J=10.3B2, 1H) , 7.72(s,<br>
1H) , 7.76-7.80 (m, 1H) , 7.91(dd, J=6.80, 2.2Hz, HI),<br>
a.93(d, J=7.2Hz,<br>
Example 17: 2-fluoro-5-nitrooxymethyl-JJ'- [ (7S) -1,2,3-<br>
tritnethoxy-lO-methylsulfanyl-g-oxo-S, 6,7,9-tetrahydrobenzo<br>
[a]heptalen-7-yl]-benzamide<br>
90<br>
•f<br>
XH NMR(400MHz, CDC13) ; 51.94-2.01(m, 1H) , 2.31-<br>
2.54{m, 2H) , 2.43(s, 3H) , 2 . 50-2 . 63 (m, 1H) , 3.73(s, 3H) ,<br>
3.92(S, 3H) , 3.97(s, 3H) , 4.81-4.87 (m, 1H) , 5.36(s, 2H) ,<br>
6.5.7(8, 1H) , 7.06(d, J=10.3Hz, HI), 7.16-7.28 (m, 2H) ,<br>
7.26(s, 1H) , 7.33(d, J=10.3H-z, I I I ) , 7 . 51-7.55 (m, I I I ) ,<br>
7.99(dd, j=7.3, 2.6Hz, II!)<br>
Example 18: 3-hydroxy-5-nitrooxymethyl-J7- [ (75) -1, 2, 3-<br>
triTnetho3cy-10-methylsulfanyl-9-oxo-5, 6 , 7 , 9-tetrahydrobenzo<br>
[a]heptalen-7-yl] -benzamide<br>
MeS ON.09'<br>
91<br>
4H NMR(400MHz, CDC13) ; 52 . 30-2 . 43 (m, 6H) , 2.56-<br>
2.57(m, 1H) , 3.51(s, 3H) , 3 . 9 0 ( s , 311) , 3.92(s, 3H) ,<br>
4.82-4.85(m, 1H), 5.00(dd, J=30.8Hz, 12.8Hz, 2H) ,<br>
6.56(s, 1H) , 6.62(s, 1H) , 7.11(s, 2H) , 7.16-7.19(m, 2H) ,<br>
7.41(d, J=10.8Hz, 1H), 7 . 6 6 ( s , 1H), 8.57(brs, 1H, NH),<br>
8.78(brs, 1H, OH)<br>
Example 19: 3,5-bia-nitrooxymebhyl-Jf- [ (7S) -1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5, 6,7, 9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide<br>
ON.O-&gt;<br>
XH NMR (400MHz, CDC13) ; 52 . 29-2 . 51 {m, 3H) , 2.46(3,<br>
3H), 2.60-2.62(m, 1H), 3.77(s, 3H), 3.93{s, 3H), 3.99(s,<br>
3H) , 4.94-4.98 (m, 1H) , 5.18(s, 411), 6.58(s, 1H) , 7 . 2 0 ( d ,<br>
J=10.6Hz, 1H) , 7.26(s, III), 7.45(d, J=10.6Hz, 1H) ,<br>
7-.77(s, 2H) , 7.81(8, 1H) , 9.12(d, J=7.0Hz, 1H)<br>
Example 20 : 2-hydroxy-4-riitrooxymethyl-N- [ (7S)-1, 2, 3 -<br>
trimethoxy-10-methyl3ulfanYl-9-oxo-5 , 6 , 7 , g-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide<br>
MeS<br>
a'H NMR (400MHz, CDC13); 52 . 25-2 . 63 (m, 4H) , 2.47(s,<br>
3H), 3.74(s, 3H) , 3.91(s, 3H) , 3.97{S, 3H), 4.85-4.92(111,<br>
, 5.27{d, J=4.8Hz, 2H), 6.53(d, <j></j>
.6.61(0, 1H) , 7.20(d, J=10.4Hz, 1H) , 7.42(d, iJ=10Hz,<br>
, 7.63(s, IE) , 7.72(d, J=8Hz, Hi), 9.13(d, ^7=6.8112,<br>
1H) , 12.29(3, 1H)<br>
Example 21: 4-nitrooxyrnethyl-t hiophene - 2 - carboxyl i c<br>
acid [ (7S) -1,2, 3-trimethoxy-l0-methylsulf ariyl-9-oxo-<br>
5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide<br>
93<br>
Hi NMR(400MHz, CDC13); 52.21-2.29(m, 1H) , 2.34-<br>
2.46(m, 5H), 2.51-2.58(m, 1H), 3.71(s, 3H) , 3.91(s, 3H),<br>
3.96(5, 3H), 4.88-4.95(m, 1H) , 5.18(dd, J-12.8, 20Hz,<br>
2H), 6.56(s, 1H) , 7.17(d, J=10.4Hz, 1H) , 7.30(s, 1H) ,<br>
j7.41(d, J=10.4Hz, 1H) , 7.61 (a, III), 7.74(s, 1H) , 8.81(d,<br>
j=6.4Hz, 1H)<br>
Example 22; 3-nitrooxymethyl-thiophene-2-carboxylic<br>
acid [(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-<br>
5,6,7,9-tetrahydro-benzq[a]heptalen-7-yl]-amide<br>
94<br>
XH NMR (400MHz, CDC13) ; 52 . 04-2 .17 (m, 1H) , 2.30-<br>
2.45(m, 5H) , 2.57-2.64(m, 1H) , 3.73(s, 3H) , 3.91(s, 1H) ,<br>
3.96(S, 3H) , 4.67-4.88(m, 1H) , 5.66(d, J-=»13.6Hz, 1H) ,<br>
i<br>
5.80(d, J=13.6Hz, 1H) , 6.56(s, 1H) , 7 . 02 (d, .7=4.4112,<br>
1H) , 7.08(d, J=l0.4Hs, Hi), 7.26(d, iJ=4.4Hz, 1H) ,<br>
*<br>
7.29(d, i7=10.4Hz, 1H) , 7.43(s, 1H) , 7.45(d, J=7.2H2,<br>
1H)<br>
Example 23 ; 2- (3-nitrooxymethyl-phenyl)-N-[(7S) -1,2,3-<br>
trinlethoxy-lQ-Tnethylsulfanyl-9-oxo-5, 6, 7, 9~tetrahydrobenzo<br>
[a] heptalen-7-yl-] -acetamide<br>
NMR(400MHz, CDC13) ; 51.82-1.95(m, 1H) , 2.21-<br>
2.28(m, 1H) , 2.31-2.42(01, 1H) , 2.45(s/3H), 2,47-2.53(m,<br>
1H), 3.51(d, J=14.0Hz, 1H) , 3.64(s, 3H) , 3.66(d,<br>
J=14.0Hz, 1H) , 3.88(s, 3H) , 3.93(s, 3H) , 4.66-4.72(m,<br>
5.40(s, 2H) , 6.51(s, 1H) , 7.11(d, J=10.4Hz,<br>
7.24-7.38(tn, 5H) , 7.48(3, 1H) , 7.90(3, J=7.2Hz, 1H)<br>
95<br>
Example 24: 3-(2-nitrooxy-ethyl)-N-[(75)-1,2,3-<br>
trimethoxy-lO-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl] -benzamide<br>
MeS<br>
NMR (400MHz, CDC13) ; 52 . 05-2 .11 (m, 1H) , 2.17-<br>
, 2H) , 2.46(s, 3H), 2.56-2.60(m, 1H), 2.81-2.91(m,<br>
2H), 3.69(s, 3H) , 3.91(s, '3H), 3.97(s, 3H) , 4.45(t,<br>
J=6.a,Hz, 2H) , 4.89-4.95(m, 1H) , 6.56(s, 1H) , 7.12-<br>
7.24(m, 3H), 7.39(d, J=10.4Hz, 1H), 7.61-7.64(m, 2H),<br>
7.69(8, 1H) , 8.22(d, J-=6.8Hz, 1H)<br>
96<br>
Example 25: Preparation of 3 -nihrooxy- benzole acid-S-<br>
[(7S) -1,2, 3-trimethoxy-10-Tnethylsulfanyl-9-oxo-5, 6,7,9-<br>
tetrahydro-benzo [a] heptalen-7-yl-carbamoyl] -pyridine-2 -<br>
l -Methyles t er<br><step> Preparation of 3 -chlorome.thyl -benzole acid- (5-<br>
_[_{7S) - 1 ,2 , 3 - trime thoxy- 1 0 -me t hyJLsu- If a n.yl- 9 -oxo- 5 ,6,7, 9 ^<br>
tetrahydro-benzo [a] heptalen-7 -yl-carbamonyl] -pyridine-<br>
2~yl } -methylester<br>
MeO<br>
WeO<br>
MeO<br>
A compotond prepared in step 1 of the Example, i<br>
(100 mg, 0.19 mmol) was dissolved in 3 uifi of<br>
dlchlororaethane. 3-(Chloromethyl) benzoylchloride<br>
(0.030 ml, 0.21 mmol) and triethylamine (0.082 ml, 0.59<br>
mmol) were slowly added therein, and the mixture was<br>
reacted at room temperature for 10 minutes. Water was.<br>
added to quench the reaction, arid aqueous layer was<br>
97<br>
extracted with dichlorornethane. Combined organic layer<br>
was dried over anhydrous sodium sulfate, filtered and<br>
concentrated under reduced pressure. The residue was<br>
purified by column chromatoqraphy (ethyl acetate) , to<br>
give 99 mg (yield: 79%, yellow solid) of the target<br>
compound .<br>
aH NMR (400MHz, CDC13) : 62 . 14-2 .16 (m, 1H) , 2.30-<br>
2.39(m, 1H) , 2. 43-2. 45 (m, 1H) , 2. 48 (a, 3H) , 2. 68-2. 96 (m,<br>
1H) , 3.67(s, 3H) , 3.90(sf 3H) , 3.91(s, 3H) , 4.83-4.93(m,<br>
1H), 4.88(8, 2H) , 5.51(8, 2H) , 6.77(s, 1H) , 7.27(s, 1H) ,<br>
7.52(t, J=7.7Hz, 1H) , 7. 65-7. 70 (m, 2H) , 8.05(d, J=7.7Hz,<br>
8.14(8, 1H) , 8.28(d, J=10.6Hz, l H ) , - 9 . 0 2 ( s ,<br><step> Preparation of 3 ~ ji itrooxy-benzoic acid- { 5 -<br>
[(7S) -1 ,2,3 -trimethoxy- 10 -methylsulfanyl-g-oxo-S, 6,7,9 -<br>
fcetrahydro-benzo [a] heptalen-7-yl-car-bamoyl] -pyridine-2-<br>
yl } -methylester<br>
// 1)Nal, acetone<br>
2)AgNO3, MeCN<br>
98<br>
A compound prepared in the step 1 (90 mg, 0.13<br>
mmol) and sodium iodide (31 mg, 0.20 mmol) were<br>
dissolved in 3 ml of acetone, and the mixture was<br>
reacted at room temperature for 1 day. Water was added<br>
to quench the reaction, and aqueous layer was extracted<br>
with ethyl acetate. Solvent was concentrated under<br>
reduced pressure. The reaction concentrate and silver<br>
nitrate (3 Omg, 0.045 mmol) were dissolved in 5 ml of<br>
•<br>
acetonitrile, and the mixture was reacted at room<br>
temperature for l hour. Water was added to quench the<br>
reaction, and aqueous layer war; extracted with ethyl<br>
acetate. Solvent was concentrated under reduced<br>
pressure. The residue was purified by short column<br>
nhromatography (ethyl acetate) and PLC, to give 26 mg<br>
[yield: 29%, yellow solid) of the target compound.<br>
XH NMR (400MH2, CDC13) : 52 . 09-2 .17 (m, 1H) , 2.35-<br>
2.41(m, 2H) , 2.44(s, 3H) , 2.55-2.58(m, 1H) , 3.74(s, 3H) ,<br>
43.91(8, 3H) , 3.96(3, 3H) , 4.92-4.95 (m, 1H) , 5.45(8,<br>
2H) , 5.47(s, 2H) , 6.56(s, 1H) , 7.13(d, J=10.2Hz, 1H) ,<br>
7.35(t, J-9.1HZ, 2H), 7.50(t, J=Q.5Hz, 1H), 7.54(s, 1H),<br>
7.62(d, J=7.3Hz, 1H) , 8.14(d, J=B.3Hz, 2H) , 8.24(dd,<br>
J«2.2, 6.2Hz, 1H, ArH), 8.36(d, J-6.9Hz, 1H) , 9.09(s,<br>
1H)<br>
99<br>
Example 26~34<br>
Compounds of Example 26 - Example 34 were<br>
synthesized in analogy to the procedure as described in<br>
Example 25, and intermediates were prepared by the<br>
method described as follows.<br>
intermediate 16&gt; Preparation of 2-hyebco3cy-N- [ (7S) -<br>
1,2/3-trimsthoxy-10-methylsulfanyl-9-oxo-5,6,7,9-<br>
tetrahydro-benzo [a]I heptalen-7 - yl] - be nz amide<br>
MeC .. ,, x<br>
EDCI, HOBt, Et3N J—4 ] n I<br>
OH<br>
DMF<br>
MeS ° MeS °<br>
2-Hydroxy-benzoic acid (203 mg, 1.47 mmol) , EDCI<br>
(385 mg/ 2.01 mmol) and HOBt (271 mg, 2.01 mmol) were<br>
dissolved in dimethylforniamide (10 ml) . Triethylamine<br>
(0.37 ml, 2.67 mmol) was added therein, and the mixture<br>
was stirred at room temperature for 1 day. 7-Aminol,<br>
2,3-trimethoxy-10-methylsulfonyl-6,7-dihydro-5Hbenzo[<br>
al-heptalen-9-one (500 mg, 1.34 mmol) was added<br>
100<br>
therein, and the mixture was stirred at room<br>
temperature for l day. Water was added to quench the<br>
reaction, and aqueous layer was extracted with diethyl<br>
ether. Combined organic layer was dried over anhydrous<br>
sodium sulfate, filtered and concentrated under reduced<br>
pressure. The residue was purified by column<br>
chromatography (hexane: ethyl acetate = 1:5) and<br>
recrystallized in methanol, to give 516 mg (yield: 78%,<br>
yellow solid) of the target compound.<br>
XH NMR (400MHz, CDCl3) : 52 . 14-2 . 17 (m, 1H) , 2.31-<br>
2.37(m, 1H) , 2.40-2.44(3, 1H) , 2.45(s, 3H) , 2.56-2.60(m,<br>
ev 3.74(S, 3H) , 3.91(8, 3H) , 3.97(s, 3H) , 4.85-<br>
, 6.56(8, 1H) , 6.64(d, J=7.7Hz, 1H) , 6.77(d,<br>
, 7.15(d, J=10.6Hz, 1H) , 7.22(d, J-7.3H3,<br>
1H) , 7.38(d, J=10.6Hz, III), 7.57(s, 1H) , 7.71(d,<br>
J=8.0Hz,<br><lntermediate> Preparation of 3-hydroxy-Jf- [ (7S) -<br>
1, 2,3-trimethoxy-lO-methylsulf anyl-9-oxo-5, 6,7,9-<br>
tetrahydro-benzo [a] heptalen-7-yl 3 -benzamide<br>
101<br>
MeQ<br>
EDCI, HOST<br>
•OH / DMF<br>
MeS Me!<br>
According to the similar procedure in the<br>
preparation method of intermediate 16, by using 3-<br>
hydroxybenzoicacid (497 mg, 1.33 mmol), 558 mg (yield:<br>
85%, yellow solid) of the target compound was obtained.<br>
XH NMR (400MHz, DMSO-d6): 62.07-2.15 (m, 1H) , 2.10-<br>
2.35(m, 6H) , 3.55(s, 3H) , 3.80(s, 3H) , 3.84(s, 3H) ,<br>
4.53-4.56(m, 1H) , 6.81(s, 1H) , 6.92 (d, J-6.8HZ, 1H) ,<br>
7.10(8, 1H), 7.15-7.31(m, 5H) , 8.98(d, J-7.6H2, 1H, -<br>
NH), 9.70(s, 1H, -OH)<br>
Example 26; 4-nitrooxybutyric acid-5- [ (_7S) -1,2,3-<br>
trimethoxy-lO-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a] heptalen-7-Yl-cairbainoyl ] -- p y r i d .1 tie - 2 - y 1 -<br>
methylester<br>
102<br>
aH NMR (400MHz, CDC13) : 52 . 06-2 . 16 (m, 1H) , 2.08-<br>
2.11(m, 2H) , 2.31-2.49{m, 1H) , 2.45(3, 3H) , 2.57(t,<br>
J-7.1HZ, 2H), 3.75(s, 3H), 3.91(s, 3H) , 3.96(s,<br>
3H) , 4.52(t, J=6.4Hz, 2H) , 4.91-4.94(m, 1H) , 5.21(s,<br>
2H) , -6.56(8, 1H) , 7.13(d, J=i0.y][-., 1H) , 7.21-7.25 ( m ,<br>
1H) , 7.38(01, J=10.6Hz, 111} , 7.52(s, 1H) , 8.22 (a.,<br>
J-8.0HZ, 1H), 9.05(s, 1H)<br>
27 : 3 -nitrooxymethyl -benzoicacid- 6- [ (7S) -1,2,3-<br>
triraethoxy-10-methylsulfanyl-9-oxo-5, 6,1, 9-tetrahydrobenzo[<br>
a]heptalen-7-yl-carbamoyl]-pyridine-2-ylmethylester<br>
XH NMR (400MH2, CDCla) : SI. 84-1.92 (m, 1H) , 2.33-<br>
2.60(m, 1H), 2.43(s, 3H), 2.46-2.54(m, 1H) 2.55-2.60(m,<br>
1H), 3.73(S, 3H) , 3.92(3, 3H) , 3.96(3, 3H) , 4.74-4 .81 (m,<br>
1H), 5.51(s, 2H) 5.57(d, J=4.0Hz, 1H) , 6.56(s, HI),<br>
»<br>
7.04(d, J=10.4Hz, 1H) , 7.25(d, J=10.4Hz, 1H) , 7.54-<br>
7.60(m, 2H), 7.65(d, J=7.GHz, 1H), 7.87(t, J-8.0HZ, 1H),<br>
7.99(d, J-=7.6Hz, 1H) , 8.21(s, 2H) , 8.22(8, 1H) , 8.41(d,<br>
J«7.2Hz,<br>
Example 28; 4-nitrooxybutyric acid-6- [ (7S)-1,2,3-<br>
trimethoxy-10-methylsul£anyl-9-oxo-5,6,7,9~tetrahydrobenzo[<br>
a]heptalen-7-yl-carbamoyl]-pyridine-2-ylme,<br>
thyl ester<br>
MeS<br>
XH NMR (400MHz, CDC13) : 52 . 02-2 . 09 (tn, 1H) , 2.11-<br>
2.18(m, 2H), 2.21-2.40(m, 2H), 2 . 4 3 ( s , 3H) , 2.47-2.56(m,<br>
1H) . 2.63(t, J=7.2Hz, 2H) , 3.73(s, 311), 3 . 9 2 ( s , 311),<br>
104<br>
3.96(S, 3H) , 4.57(t, J=6.4Hz, 2H) , 4.77-4.83(m,<br>
5.30(d, J-A.8llz, 2H) , 6.58(s, 1H) , 7.05(d, J=10.4Hz,<br>
1H), 7.25(S, 1H) , 7.32(d, J=10.4Hz, 1H) , 7.52(d,<br>
J-8.0HZ, 1H) , 7.84(t, J=a.OHz, 1H) , 7.98(d, J=8.0Hz,<br>
1H) , 8.45(d, i7=6.8Hz, IB)<br>
Example 29; 3-nitrooxymethyl-benzole acid-2-[(7S)-<br>
1,2,3-trimethoxy-10-methylsu1fanyl-9-oxo-5,6,7,9-<br>
tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester<br>
•Me<br>
XH NMR (400MHz, CDC13): 51. 48-1.55 (m, 1H) , 1.83-<br>
1.89(m, 1H) , 2.22 -2.3 9 (m, 211), 2.42(s, 3H) f 3.62(s, 3H) ,<br>
3.87(8, 3H) , 3.92(g, 3H) , 4 .63-4 . 70 (m, 1H) , 5.54(s, 2H) ,<br>
6.47(s, 1H) , 6.89(d, J=7.4Hz, 1H) , 7.03(d/ J=10.2Hz,<br>
1H), 7.17(s, 1H) , 7.23(d, J=10.1Hz, 1H) , 7.35(t,<br>
J-7.3HZ, 1H) , 7.54(t, J=7.4Hz, III), 7.58(t, J=7.6I!::,<br>
1H) , 7.72(d, J=8.0I-I2, III) ,7.03 (cl, J=7.7Hz, 1H) , 8.26(m,<br>
2H)<br>
105<br>
Example 30: 4-nitrooxybutyric acid-2-[(7S)-1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl-carbamoyl] -phenylesfrer<br>
XH NMR (400MHz, CDG13) : 51.60-1.90 (m, 1H) , 2.10-<br>
2.14(m, 2H) , 2.26-2.39(m, 1H) , 2.44(s, 3H) , 2.46-2.51(m,<br>
1H) .2.56-2.61(01, 1H) , 2.80(t, J=7.1Hz, 2H) , 3.70(s,<br>
3H), 3.92(s, 3H) , 3.96(s, 3H) , 4.55(t, J=6.2Hz, 2H) ,<br>
4.74-4.81 (m, 1H) , G.57(s, 1I-I) , 6 . 82 (d, J=6.9Hz, IK),<br>
7.08(d, J=10.6Hz, 1H) , 7.13(d, J=9.1Hz, 1H) , 7.23(s,<br>
1H), 7.28-7.36 (m, III), 7.47 ( t , J=9.9Hz, 1H) , 7.68(d,<br>
J=9.5Hz,<br>
106<br>
Example 31: 3-nitrogoxyrnebhyl-benzole acid-3- [ (7S) -<br>
1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-<br>
tetrahydro-benzo [a]heptalen-7-yl-carbamoyl]-phenylesber<br>
XH NMR (400MHz, CDC13) : 62 . 05-2 .15 (m, 1H) , 2.23-<br>
2.59(m, 6H) , 3.75(s, 3H) , 3.91(3', 3H) , 3.97(s, 3H) ,<br>
4,90-5.00(01, 1H), 5.49(8, 2H) , 6.56(3, 1H) , 7.03(d,<br>
J-10.4HZ, 1H) , 7.27(s, 2H) , 7.34(d, J-8.8HZ, 2H) 7.53-<br>
7.65(m, 2H), 7.76(3, 1H) , 7 . 7 7 ( d , J-6.4HZ, 1H), 8.13(m,<br>
3H)<br>
Example 32; 4-nitrooxybutyric acid-3-[(7S)-1,2,3-<br>
trimethoxy-lO-methylsulfanyl-S-oxo-S,6,7,9-tetrahydrobenzo[<br>
a]heptalen-7-yl-carbamoyl]-phenylester<br>
107<br>
XH NMR (400MHz, CDC13) : 62.04-2.18 (m, 3H) , 2.25-<br>
2.60(m, 6H) , 2.65(t, iT=6.8Hs, 211), 3.74 (a, 3H) , 3.91(5,<br>
3 H ) , - 3 . 9 6 ( s , 3H) , 4 . 5 6 ( t , J-6.4HZ, 2H) , 4 . 8 7 - 4 . 9 4 ( m ,<br>
1H), .6.56(3, 1H) , 7.08-7.12 (m, 2H) , 7.26-7.35(m, 2H) ,<br>
7.48(S7 1H) , 7.59(8, 1H) , 7.7l(d/ J=8.0Hz, 1H), 7.75 (d,<br>
J=7.6Hz, 1H, -NH)<br>
Example 33; 3-nitrooxymethyl-benzole acid-3-[ (7S)-<br>
1/2,3-triTnethoxy-lO-methyl-sulfanyl-9-oxo-5y 6,7, 9-<br>
tietrahydro-benzo [a] heptalen-7-yl-carbamoyl] -benzylester<br>
"0-<br>
108<br>
XH NMR (400MHz, CDC13) : 52 . 05-2 .18 (m, 1H) , 2.31-<br>
2H) , 2.40(s, 3H) , 2.55-2.59 (m, 1H) , 3.75(8, 3H) ,<br>
3.91(s, 3H) , 3.97(s, 3H) , 4 . 90--1 . 96 (m, 1H) , 5.24(s, 211} ,<br>
5.44(s, 2H) , 6.56(s, 1H) , 7.09(d, J=10.6Hz,<br>
7.27(dd, J=7.S, 7.6Hz, 1H), 7.36(d, J=10.6Hz,<br>
»<br>
7.44(d, J"=7-.6Hz, 1H) , 7.45(dd, J=8..0, 7.6HZ,<br>
7.58(d, J=8.0Hz, 1H) , 7.59(s, 1H) , 7.79(d, J=7.6Hz, 1H)<br>
7.91(3, 1H) , 8.05(cl, J=7.6IIa, I I I ) , 0 . 0 6 ( 3 , 1H) , 8.10(d,<br>
J=7.2Hz,<br>
Example 34; 4-nitrooxybutyric acid-3- [(7S)-1,2,3-<br>
trimethO3cy-10-methylsulfa.nyl-9-oxp-5, 6 , 7, 9-tetrahydrobenzo[<br>
a]heptalen-7-yl-carbamoyl]-benzylester<br>
.MeO<br>
'B;<br>
JH NMR (400MHz, CDC13) : 52 . 00-2 .14 (m, 3H) , 2.31-<br>
2.51(01, 4H) , 2 . 4 4 ( s , 3H) , 2 . 5 6 - 2 . 6 0 ( m , 1H) , 3.75(s, 3PI) ,<br>
3.92(8, 3H) , 3.97(s, 3H) , 4.49(t, J=6.2HZ, 2H) , 4.89-<br>
4.95(m, 1H) , 4.99(d, J=12.4Hz, 1H) , 5.04(d, J-12.4HZ,<br>
109<br>
6.56(s,'lH), 7.11(d, J=10.6Hz, 1H) , 7.26(dd, J=7.6,<br>
7.6H2, 1H) , 7. 35-7. 37 (m, 211), 7.54(s, 1H) ; 7.76(d,<br>
J-B.OHz, 1H) , 7.81(S, 1H) , 8.00(d. J=7.6Hz, 1H)<br>
Example 35 ; Preparation of 2 -nitrosothio-N- [ (7S) -1 , 2 , 3 -<br>
trimethoxy- 10 -me thyl sul f anyl-9-oxo-5, 6,7, 9-tetrahydrobengo<br>
[a] heptalen- 7 -yl] -benzamide<br><step> Preparation of 2 -mercapto-N- [ (7S) -1,2 , 3 -<br>
trimethoxy-10 -me thyl sul fanyl - 9 - oxo -5,6,7,9 -1 e trahydro -<br>
benzo[a]heptalen-7-yl]-benzamide<br>
M<br>
OH SH ,
2) Et3N, CH2CI2<br>
Excess thionylchloride was added in thiosalycilic<br>
acid (115 mg, 0.75 mmol) , and the mixture was stirred<br>
with heating for 1 day. The reaction mixture was<br>
concentrated under reduced pressure to remove<br>
thionylchloride, and to give a chloride compound. 7-<br>
110<br>
amino-l,2,3-trimethoxy-10-methylGulfonyl-6,7-dihydro-<br>
Eff-benzo [a]-hepcalen-9-one (243 mg, 0.62 BBlol) was<br>
dissolved in purified dichloromethane. Triethylamine<br>
(0.26 ml, 1.86 mmol) was slowly added therein.<br>
Thiosalycilic chloride dissolved in dichloromethane was<br>
also added therein at 0°C, and the mixture was stirred<br>
for 30 minutes. Water was added to quench t&amp;ft reaction,<br>
and aqueous layer was extracted with chloroform.<br>
Combined organic layer was dried over anhydrous sodium<br>
sulfate, filtered and concentrated under reduced<br>
pressure. The residue was purified by column<br>
chromatography (chloroform: me thanol = 12:1), to give<br>
210 mg (yield: 66%, white solid) of the target compound.<br>
XH NMR (400MH2, CDCl3) : 52. 06-2 .17 (m, 1H) , 2.33-<br>
2.49(m, 2H) , 2.42(s, 3H) , 2.54-2.59(m, 1H) , 3.72(s, 3H) ,<br>
3.92(S, 3H) , 3.96(8, 3H) , 4.86-4.93 (in, 1H) , 6.56(s,<br>
1H), 7.06(d, J=10.6Hz, 1H) , 7.14(t, J=7.5Hz,<br>
!7.24(d/ J«=7.7Hz, 1H) , 7.31(d, J=10.6Hz,<br>
7.51(s, 1H) , 7.58(d, J=7.3Hz, Hi), 7.63(t, J=8<br>
2H)<br>
111<br><step> Preparation of 2-nitrosothio-W- ( (78) -1, 2, 3-<br>
trimetho3cy-10-Tnethylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a] heptalen-7-yl] -benzamide<br>
r~\ I<br>
MeO ^^'<u></u>
1A/-HCI. NaN02<br>
Me°H<br>
MeS MeS<br>
Compound prepared in step 1 (40 mg/ 0.078 mmol)<br>
was dissolved in methanol. 1 N HC1 aqueous solution (3<br>
ml) was added therein. Sodium nitrite (NalNO2, 6.5 mg,<br>
0.094 mmol) dissolved in water (1.5 ml) was also added<br>
therein; and the mixture was stirred at room<br>
temperature for 1 hour. Sodium hydrogen carbonate was<br>
added to quench the reaction, and aqueous layer was<br>
extracted with chloroform. Combined, organic layer was<br>
dried over anhydrous sodium sulfate, filtered and<br>
concentrated under reduced pressure. The residue was<br>
purified by column chromatography (chlorbform:methanol<br>
12:1) and recrystallized in methanol, to give 34.1 mg<br>
(yield: 81%, yellow solid) of the target compound.<br>
112<br>
XH NMR (400MHz, CDC13) : S2 . 07-2 .14 (m, 1H) , 2.31-<br>
2.37(m, 1H), 2 . 4 2 ( s , 3H), 2 . 4 5 - 2 . 4 8 ( m , 1H), 2.54-2.59(ra,<br>
1H) , 3.72(s, 311), 3.91(s, 311), 3.96(s, 3H) . 4.88-<br>
4.94(m, 1H) , 6.56(s, 1H) , 7.06(d, J=10.6Hz, 1H) , 7.10(t,<br>
J=7.5Hz, 1H) , 7.21(t, J=6.9Hz, 1H) , 7.31(d, J»10.6Hz,<br>
»<br>
1H), 7.54(8, 1H) , 7.64(t, J=8.6Hz, 2H) , 7.72(d,<br>
J-7.3HZ, 1H)<br>
Example 36; Preparation of 3-nitroBooxytnatfcarly-[ (7S)-<br>
l, 2,3-trimethoxy-10-methylsulf anyl-9-oxo-5, 6,7,9-<br>
tetrahydro-benzo [a] heptalen -7- yl ] - ben garni de<br>
Me<br>
-M-x<br>
1) Nal, Acetone<br>
2) AgNO2, MeCN<br>
MeS<br>
3-Chloromethyl-W- [(7S)-1,2,3-trimethoxy-10-<br>
methylsulfanyl-S-oxo-S, 6, 7, 9-tet.rahydrobenzo [a]heptalen<br>
-7-yl] -benzamide (119.8 mg, 0.22.8 mmol) and sodium<br>
iodide (136,5 mg, 0.911 mmol) were dissolved in acetone<br>
(15 ml) , and the mixture was stirred at 55°C for 1 day.<br>
The reaction mixture was extracted with chloroform and<br>
113<br>
washed with saturated sodium chloride aqueous solution.<br>
Combined organic layer was dried over anhydrous sodium<br>
sulfate, filtered and concentrated under reduced<br>
pressure. The residue and silver nitrite (125.5 mg,<br>
0.812 mmol) were dissolved in acetonitrile (5 ml) , and<br>
the mixture was stirred at room temperature for 1 day.<br>
The reaction mixture was extracted with chloroform.<br>
Combined organic layer was dried over anhydrous sodium<br>
sulfate, filtered and concentrated under reduced<br>
pressure. The residue was purified by column<br>
chromatography (ethyl acetate:chloroform = 4:1), to<br>
give 35.4 mg (yield: 32.4%, yellow solid) of the target<br>
compound.<br>
XH NMR (400MHz, CDC13) : 52 . 35-2 . 55 (m, 3H) , 2.48{s,<br>
3H) , 2.62-2.66 (m, 1H) , 3.76(s, 311) , 3.84(d, •J=12.ailz,<br>
1H), 3.92(s, 3H) , 3.98(3, 3H) , 4.26{d, J=»12.8Hz, 1H) ,<br>
4.91-4.97(m, 1H) , 6.58(a, 1H) , 6.96(dd, J^7.7, 7.7Hz,<br>
1H), 7.22(d, J=10.6Hz, 1H) , 7.26-7.30 (m, 2H) , 7.44-<br>
7.47(m, 2H) , 7.86(s, 1H) , 9.30(rl, J=6<br>
114<br>
Example 37 ; 3 -f luoro-S-iiitrosooxymethyl-jy- [ (75) -1, 2 ,.3 -<br>
t r ime thoxy-10 - me thy 1 sul f anyl - 9 - oxo -5,6,7,9- tetrahydr o -<br>
benzo[a]heptalen-7-yl] -benzamide<br>
A target compound was synthesized in analogy to<br>
the procedure as described in the Example 36.<br>
•.Meo;<br>
Me a<br>
H NMR (400 MHz, CDC13) : 52 . 04-2 . 20 (m, 1H) , 2.47(s,<br>
3H), 2. 52-2. 62 (m, 2H) , 2. 67-2. 72 (m, 1H) , 3.81(s, 3H) ,<br>
3.91(S, 3H), 3.97(s, 3H), 4.71(s, 2H) , 4.93-4.96(m, 1H),<br>
6.42(d, J=6.2, 1H), 6.58(s, III), 7.14-7.21 (m, 2H) ,<br>
7.30(d, J=8.4, 1H), 7.42(s, 1H), 7.53(d, J=10.6,<br>
115<br>
Example 38; Preparation of 3-nitrosothiomethyl-jy- [ (75) -<br>
1,2,3-trimethoxy-10-methylsulfanyl- 9-oxo-5,6,7,9-<br>
tetrahydro-benzo[a]heptalen-7-yl]-benzamide<br><step> Preparation of methanesulfonic acid-3- [ (7SJ-<br>
1,2,3-trimethoxy-10-methylsulfanyl- 9 -oxo-5,6,7,9-<br>
tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-benzyl<br>
ester<br>
M<br>
MeS<br>
MeQ<br>
MfiO<br>
O<br>
MeO<br>
MeS MsO<br>
3-Hydroxymethyl-N-[(7S)-1,2,3 -trimethoxy-10-<br>
methylsul£anyl-9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a]heptalen-7-yl]-benzamide (252.5 rag, 0.497 mmol)<br>
was dissolved in dichloromethane (10 ml), and the<br>
temperature was lowered into o°C.<br>
Methanesulfonylchloride (42.4 ìl 0.547 mmol) and<br>
triethylamine (0.104 ml, 0.745 mmol) were added therein,<br>
and the mixture was stirred at room temperature for 2<br>
116<br>
hours. The reaction mixture was extracted with<br>
chloroform. combined organic layer was dried over<br>
anhydrous sodium sulfate, filtered and concentrated<br>
under reduced pressure. The residue was purified by<br>
column chromatography (ethyl acetate: chloroform a 3:2),<br>
to give 182.3 mg (yield: 62.6%, yellow solid) of the<br>
target compound.<br>
XH NMR (400 MHz, CDC13) : 62 . 14-2 .21 (m, 1H) , 2.31-<br>
2.50(m, 2H) , 2.46(3, 3H) , 2. 57-2. 62 (m, 1H) , 2.85(s, 3H) ,<br>
3.76(S, 3H) , 3.92(s, 3H) , 3. 97 (a, 3H) , 4.87-4.94(m, 1H) ,<br>
5.06(d, i7=12.7Hz, III), 5.10(d, J-.i2.7Hz, 1H) , 6.57(s,<br>
1H) , 7.14(d, J-10.6HZ, HI), 7.28(dd, J=7 .7 , 7.7HZ, 1H) ,<br>
1.38-7. 42 (m, 2H) , 7.56(s, 1H) , 7.'74(d, J=8HZ1H) ,<br>
df J=7.7Hz,<br><step> Preparation of thioacetic acid-_S-3-_[ (7S) -<br>
1, 2, 3-trimethoxy- 10 -methylsulfanyl- 9-oxo-5, 6, 7,9-<br>
tetrahydro-benzp [a] heptalen-7-yl-carbamoyl] -benzyl<br>
ester<br>
117<br>
MeQ<br>
A compound prepared in the step 1 (162.3 mg,<br>
0.311 mol) was dissolved in acetone (6 ml) , and the<br>
temperature was lowered into 0°C. Potassium thioacetate<br>
(53.2 mg, 0.467 mmol) was slowly added therein at 0°C,<br>
and the mixture was stirred for 1 hour. The reaction<br>
mixture was extracted with chloroform. Combined<br>
organic layer was dried over anhydrous sodium sulfate,<br>
filtered and concentrated under reduced pressure, to<br>
give 173.6 mg (yield: 90.6%, yellow solid) of the<br>
target compound.<br>
*H NMR (400MHz, CDC13) : 52 . 05-2 . 14 (m, 1H) , 2.30(s,<br>
2H) , 2.32-2.49(m, 211), 2.44(0, 311), 2 . 52-2 . 61 (m, III),<br>
3.74(s, 3H), 3.92(s, 3H) , 3.97(s, 3H) , 4.0l(d, 47=13. 9Hz,<br>
1H) , 4.05(d, JXL3.9HZ, 1H) , 4. 87-4. 93 (m, |£) , 6.56(s,<br>
7.10(d, J=10.3Hz, 1H) , 7.21(dd, J=7.7, 7.7H2,<br>
.36(m, 2H) , 7.49(s, 1H) , 7. 64 -7. 71 (m, 3H)<br>
118<br><step> Preparation of 3-mercaptomethylfsjpi-(7S) -1,2,3-<br>
trimethoxy-10-methylsulfanyl-9-oxo-5,6,7, 9-tetrahydrobenzo<br>
[a] heptalen-7-yl] -benzaml.de<br>
MeS<br>
HS<br>
A compound prepared in the step 2 (165.2 mg,<br>
0.292 mol) was dissolved in methanol (6 ml) , and the<br>
temperature was lowered into o"0. Sodium thiomethoxide<br>
(21.5 mg, 0.307 mmol) was slowly added therein at 0°C,<br>
and the mixture was stirred at room temperature for 30<br>
minutes. Reaction was quenched by adding 0.1N HCl<br>
aqueous solution. The reaction mixture was extracted<br>
with chloroform and washed with saturated sodium<br>
chloride aqueous solution. Combined organic layer was<br>
dried over anhydrous sodium sulfate, filtered and<br>
concentrated under reduced pressure. The residue was<br>
purified by column chromatography (ethyl<br>
acetate:chloroform = 1:1), to give 182.3 mg (yield:<br>
62.6%, yellow solid) of the target: compound.<br>
119<br>
H NMR (400MHz, CDC13): 51.70(t, J-7.3HZ, HI),<br>
2.12-2.19(m, 1H) , 2.31-2.50(m, 2H) , 2.18(s, 3H) , 2.57-<br>
2.61(m, 1H) , 3.58(d, J-=7.3Hz, 1H) , 3.'74(s, 3H) , 3.92(s,<br>
3H), 3. 97 (a, 3H) , 4 .89-4 .95 (m, 1H) , 6.57(s/ 1H|, 7.12(d,<br>
|7-10.3HZ, 1H) , 7.19(dd, J"=7.7, 7.7Hz, 1H) , 7.34(d,<br>
r»7.7H2, 1H), 7.37(d, J-10.3II7., Ill), 7.55(s, I I I ) ,<br>
7.59(d, J=7.7Hz, 1H) , 7 . 7 0 ( s , 1H) , 7,93(d, J=7.3Hz, HI)<br><step> Preparation of 3-nitrosothiomethyl-JV- [ (7S) -<br>
1,2,3-trimethoxy-lO-methylsulf any 1 - 9 - oxo -5,6,7,9-<br>
tetrahydro-benzo [a] heptalen-7-yl] -benzamide<br>
MeQ<br>
1N-HCI/NaN02<br>
MeOH<br>
O<br>
MeS MeS<br>
A compound prepared in the step 3 (101.2 mg,<br>
0.193 tnol) was dissolved in rnethanol (3 ml) and<br>
dimethylformamide (3ml) , and the temperature was<br>
lowered into 0°C. 0.1N HCl aqueous solution (3 ml) and<br>
120<br>
sodium nitrite (16.0 mg) were slowly added therein at<br>
0°C, and the mixture was stirred at room temperature<br>
for 2 hours. The reaction mixture was extracted with<br>
Chloroform and washed with saturated sodium carbonate<br>
solution. Combined organic layer was dried over<br>
anhydrous sodium sulfate, filtered and concentrated<br>
under reduced pressure. The residue was purified by<br>
column chromatography (ethyl acetate:chloroform:hexane<br>
3:2:1.5), to give 19.5 mg (yield: 18.3%, yellow<br>
solid) of the target compound.<br>
aH NMR (400MHz, CDC13) : 52.08-2 .16 (mf 1H) , 2.31-<br>
2.51(m, 2H) , 2.45(8, 3H), 2.57-2.61(m, 1H) , 3.57(s, 3H),<br>
3.80(s, 2H), 3.92(s, 3H) , 3.97(s, 3H) , 4.89-4.96(m, 1H) ,<br>
6.57(S, 1H), 7.10(d, J=10.3Hz, 1H) , 7.25(dd, J=7.7,<br>
7.7HZ, 1H) , 7.36(d, J=10.3I-Iz, 1.11), 7.38(d, J=7.7Hz, III),<br>
7.53(3, 1H) , 7.68(d, J=7.7Il2'./ 111), 7.77(8, 1H) , 7.79(d;<br>
i7«7.0Hz,<br>
121<br>
Example 39; 3-fluoro-5-nitrosothiomethyl-N- f (78) -1,2,3 -<br>
trimethoxy- 1 0 -me thy 1 sul f anyl - 9 - oxo -5,6,7,9- te trahydro -<br>
benzo [a] heptalen-7-yl] -benzamide<br>
A target compound of Example 39 was , synthesized<br>
in analogy to the procedure as described iti^trHBi Example<br>
38.<br>
McD-<br>
•.Me<br>
H NMR (400MHz, CDC13): 62.30-2.48(m, 3H) , 2.44(s,<br>
3H), 2.56-2. 59 (m, 1H) , 3.57(q, J=13.9, 16.5, 2H) ,<br>
3.73(s, 3H), 3.91(3, 3H) , 3.97(s, 3H) , 4.97-5.03(m, 1H)<br>
6.57(8, 1H), 7.02(d, J=8.4, 1H) , 7.15(d, J«10.6, 1H) ,<br>
7.39(d, J=10.2, 1H) , 7.43(s, 1H) , 7.64 (d, J=9.1, HI),<br>
7.73(s, 1H) , B.96(d, J=7.3, III)<br>
122<br>
Example 40; Preparation of 3-fluorg-j-nitrooxymethyl-M-<br>
[(7S) -l,2,3,10-tetrametho:Ky-9-o:x:o-5, 6,7, 9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide<br><step preparation of></step>
[ (78) -1,2,3,10-tetramethoxy-9-0X0-5, 6,1, 9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamide<br>
DH<br>
:DMF<br>
Jpeacetylcolchicine (150 mg, 0.42 mmol), 3-fluoroithyl-<br>
benzoic acid (85 mg, 0.50 nvmol) and<br>
HOBt (67 mg, 0.50 mmol) were dissolved in<br>
dimethylformamide solution (2 ml) , and the temperature<br>
was lowered into 0"C. EDCI (95 mg, 0.50 mmol) was<br>
slowly added therein at 0°C, and the mixture was<br>
Stirred at room temperature. Water was added to quench<br>
*^ ' •<br>
the reaction, and aqueous layer was extracted with<br>
ethyl acetate. Combined organic layer was dried over<br>
anhydrous sodium sulfate, filtered and<br>
123<br>
under reduced pressure. The residue was purified by<br>
column chromatography (chloroform: ethyl acetate = 2:1),<br>
to give 110 mg (yield: 52%, yellow solid) of the target<br>
compound.<br>
1H NMR (400MHz, CDC13) : 52 . 40-2 . 58 (m, 3H) , 2.62-<br>
2.69(tn, 1H) , 3.64-3.70 (in, 1H) , 3.74(s, 3H) , 3.92(s, 311),<br>
3.98(8, 3H) , 4.07(S, 311), 4 . 23-4 . 20 (m, 1H) , 4 .81-4 . 88 (m,<br>
1H), 6.58(a, 1H) , 6.87(d, J=9.2Hz, 1H), 6.97(d, J=9.2Hz,<br>
1H), 7.03(d, i7=10.4Hz, 1H) , 7.38(8, 1H) , 7.50(d,<br>
•7-10.4Hz, 1H) , 7.96(s, 1H) , 9.64 (A, J=6.0Hz, 1H)<br><step> Preparation of 3-fluoro-5-nitrooxyreethyl-N-<br>
[ (78) -1,2,3,10-tetramethoxy-9_-oxo-5_/ 6,_7 / 9-tetrahydrobenzo[<br>
a]heptalen-7-yl]-benzamidc<br>
MeO •^QFf MeO<br>
According to the similar procedure in the step 2<br>
and 3 of Example 5, by using a compound prepare in the<br>
124<br>
step 1 (90 mg, 0.10 mmol), 30 mg (yield: 30%, yellow<br>
solid) of the target compound was obtained.<br>
H NMR (400MHz, CDC13) : 52.30-2.49(m, 3H) , 2.58-<br>
2.59(m, 1H) , 3.75(8, 3H) , 3.92(s, 311)3.98(8, 311),<br>
4.05(S, 3H) , 4.89-4.93(m, 1H) , 4.94(d, J=12.8Hz, 1H) ,<br>
5.10(d, ,J=12.eHz:, 1H) , 6.58(s, 1H) , 6.96 (d, J-8.4H2,<br>
1H) , 7.01(d, J=10.4Hz, 1H) , 7.17(d, J=8.4Hz, 1H) ,<br>
,7.45(8, 1H) , 7.48(d, J=10.4Hz, 1H) , 7.89{s, 1H) , 9.25(d,<br>
Example 41; Preparation of 3-nitrooxymethyl-i^i^thyl-N-<br>
[ (75) -l^^-trimethoxy-lO-methylsulfanyl-g-oxo-S^,?, 9-<br>
tetrahydro-benzo [a] heptal «3n~_7_-yl_] - be viz amide<br> Preparation of 3-chloromethy|^i^|ethyl-N-<br>
*-l,2,3-brimethpxy-10-methylsulfanyl-9-oxo-5<.6></.6>
tetrahydro-benzo[a] heptalen-7-yl]-benzamide<br>
PJridih.il-<br>
MC<br>
Ma<br>
Mei<br>
125<br>
Thiodemecolcine (50 mg, 0.129 mmol) and pyridine<br>
(0.012 ml, 0.154 mmol) were dissolved in<br>
dichloromethane, and the temperature was lowered into<br>
O°C. 3-(Chloromethyl)benzoyl chloride (0.022 ml, 0.154<br>
mmol) was slowly added therein at 0°C, and the mixture<br>
was stirred at room temperature. Water was added to<br>
guench the reaction, and aqueous layer was extracted<br>
with ethyl acetate. Combined organic layer was dried<br>
over anhydrous sodium sulfate, filtered and<br>
concentrated under reduced pressure. The residue was<br>
purified by column chromatography (chloroform:ethyl<br>
-acetate 
solid) of the target compound.<br>
aH NMR (400MHz, CDC13) : 52.24-2.38 (m, 2H), 2.44(s,<br>
3H),2.45-2.58(m, 1H) , 2.61-2.74(m, 1H) , 3.25{s, 3H) ,<br>
3.72(8, 3H) , 3.91(s, 3H) , 3.92(s, 3H) , 4.54(s, 2H) ,<br>
5.05(br, 1H) , 6.57(3, 1H) , 7.06(3, J=10.0Hz, 1PI) ,<br>
7.09(S, 1H) , 7.22-7.41(m, 511)<br>
126<br><step> Preparation of 3-nitrooxymethyl-N-methyl-N-<br>
[(7S)-1,2,3-trimethoxy-lQ-methylsulfanyl-9-oxo-5y6,7,9-<br>
tetrahydro-benzo[a3heptalen-7-yl3-benzamide<br>
iJNal/Acetone<br>
•ii)AaN03/;c:H3CN<br>
According to the similar procedure in the step 2<br>
of Example 25, by using a compound prepared in the step<br>
1 (45 mg, 0.085 mmol), 40 mg (yield: 83%, yellow solid)<br>
pf the target compound was obtained.<br>
XH NMR {400MHz, CDC13): 52.24-2.38(m, 2H), 2.44(a;<br>
3H) ,2.45-2.58 (m, 1H) , 2 . 61-2 . 74 (in, Hi), 3.24(s, 311),<br>
3.71(8, 3H) , 3.91(s, 311), 3.92(s, 3H) , 4.77(br, 1H) ,<br>
5.58(s, 2H), 6.85(s, 2H), 7.21(d, J=10.0Hz, 1H), 7.29{d,<br>
J-10.4HZ, 1H), 7.40-7.53(m, 4H)<br>
Example 42: Preparation of 3 -fluoro-N-methyl-5-<br>
taltrooxymethyl -N- [ (75) -1,2, 3-l:rimethoxy-10-<br>
127<br>
mebhylsulfanyl-9-oxo-5,6,7,9-tetrahydrobenzo<br>
[a]heptalen-7-yl]-benzamide<br><step> Preparation of 3-fluoro-5-hydroxytnethyl-Nmethyl-<br>
N- [(75)-1,2,3-trimethoxy-10-methylsulfanyl-9-<br>
oxo-5,6,1, 9-tetrahydro-ben2O[a]heptalen-7-yl}-benzamide<br>
MoO<br>
HO<br>
&gt;=0 i)Bhyl diloroforma(e,.TEA<br>
' lOPjfriiljha<br>
.MP<br>
HO'<br>
3-Pluoro-5-hydroxymel:hyl-benzoic acid (52 mg,<br>
0.309 mmol) was dissolved in dichloromethane (3 ml)<br>
under a nitrogen atmosphere. Ethylchloroformate (0.022<br>
ml, 0.231 mmol) and TEA (0.042 ml, 0.309 mmol) were<br>
Slowly added therein at 0°C, and the mixture was<br>
Stirred at 0°C for 30 minutes. Pyridine (0.012 ml,<br>
0.154 mmol) and thiodemecolcine (60 mg, 0.154 mmol)<br>
were also added therein, and the mixture was stirred at<br>
room temperature f or 3 hours. Water was added to<br>
guench the reaction, and aqueous layer was extracted<br>
with ethyl acetate. Combined organic layer was dried<br>
over anhydrous sodium sulfate, filtered and<br>
128<br>
concentrated under reduced pressure. The residue was<br>
purified by column chromatography (chloroform: ethyl<br>
acetate = 2:1), to give 30 rag (yield: 21%, yellow<br>
solid) of the target compound.<br>
aH NMR (400MHz, CDC13) : 51.76(br, 1H) , 2.24-2.38(m,<br>
2H) , 2.44(s, 3H) ,2.45-2.58 (m, III), 2 . 61-2 . 74 (m, Hi),<br>
3.23(8, 3H) , 3.72(s, 311), 3.93(s, 3H) , 3.97(s, 3H) ,<br>
4.65(s, 2H) , 5.02(br, 1H) , 6.57(8, 1H) , 6.92(s, 1H) ,<br>
6.99-7.24 (m, 4H) , 7.34(s, III)<br><step> Preparation o£ 3-f luoro-N-methyl- 5 -<br>
nitrooxymethyl-N- [ (7S) -1,2,3-trimethoxy-lOmethylsuIf<br>
anyl-9-oxo-5,6,7, 9-1etrahydrobenzo<br>
[a] heptalen-7 -yl] -benzamicle<br>
^CH-<br>
0'.<br>
According to the similar procedure in the step 2<br>
and 3 of Example 5, by using a compound prepared in the<br>
129<br>
step 1 (55 mg, 0.101 mmol) , 20 mg (yield: 37%, yellow<br>
solid) of the target compound was obtained.<br>
XH NMR (400MHz, CDC13) : 52. 22-2 .41 (m, 2H) , 2.45(s,<br>
3H) , 2.45-2. 58 (m, 1H) , 2 . 61-2 . 74 (in, 1H) , 3.24(s, 3H) ,<br>
»<br>
3.75(s, 3H) , 3.91(8, 311), 3.95 ( a , 3H) , 5.02(br, 1H) ,<br>
5.39(s, 2H) , 6.57(s, 1H) , 7 . 0 5 ~ 7 . 2 4 ( m , 5H) , 7.34(s,<br>
Example 43 : _Prepcirati_o_n. of 2- (3-£luoro:1 bnitrooxymethyl-<br>
phenyl) -N- [ (7S) -l, 2, S-trimethQanr-lOmethylsulfanyl-<br>
9-oxo-5,6, 7, 9-tetrahydrobenzo[<br>
a]heptalen-7 -y1]- acetamide<br><step> Preparation of (3-fluoro-5-hydpq«ymethylphenyl)-<br>
acetic acid<br>
Matt<br>
THF<br>
KCM, iQ-'Crovvn-B.-<br>
Br — —- - MeO:<br>
BOH/:-H2o; H0_, OH<br>
A compound prepared in the step 1 of intermediate<br>
6 (2.5 g, 13.57 mmol) was dissolved in dichloromethane<br>
130<br>
(30 ml). PBr3 (1.15 ml, 12.21 mmol) was slowly added<br>
therein, and the m.ixture wan stirred at room<br>
temperature for 3 hours to give 3-bromomethyl-5-fluorobenzoic<br>
acid methyl ester (1.6 g, yield: 50%, white<br>
solid). 3-Bromomethyl-5-fluoro-benzoic acid methyl<br>
»<br>
ester (1.5 g, 6.1 mmol), KCM (l.G g, 24.4 mmol) and 18-<br>
crown-6 (820 mg, 3.1 rmnol) were dissolved In<br>
acetonitrile (10 nil) . The re si CM. ion mixture was stirred<br>
at room temperature ior 10 houra to give 3-cyanomethyl-<br>
5-fluoro-benzoic acid methyl ester (900 mg, yield: 77%,<br>
white solid). 3-Cyanomethyl-5-fluoro-benzoic acid<br>
methyl ester (900 mg, 4.65 mmol) was dissolved in<br>
tetrahydrofuran (10ml) . 2M Lithiutnborohydride<br>
tetrahydrofuran (2.3 ml, 4.6 mmol) was slowly added<br>
therein, and the mixture was re fluxed, to give (3-<br>
fluoro-5-hydroxymethyl-phenyl)-acetonitrile (430 mg,<br>
yield: 56%, white Kc.licl) . (3 1'luoro-5-hydroxymethylphenyl)<br>
-acetonitrile (400 ny, 2.42 mmol) and<br>
potassiumhydroxide (1.34 g, 23.8 mmol) were dissolved<br>
in ethanol (10 ml) and water (5 ml) . The reaction<br>
mixture was re fluxed for 24 hour;:: to give 356 mq<br>
(yield: 80%, white uolid) of the target compound.<br>
1H NMR(400MHz, CD3OD); 53.62(s, 2H), 4.59(3, 2H),<br>
6.94(d, J=9.6Hz, 1H), 7.04(d, J=9.6Hz, 1H), 7.08(s,<br>
131<br><step> Preparation of 2- (3-fluoro-5-hydroxytneth&gt;lphenyl)-<br>
N-[(7S)-1,2,3-trimethoxy-lO-methylsulfanyl-9-<br>
oxo-5,6,7,g-tetrahydro-benzo[a]heptalen-7-yl3-acetamide<br>
Me<br>
OH<br>
&gt;+ V fr<br>
HO^<br>
:0<br>
EDCI,.H0Bt<br>
DMF<br>
MeS<br>
According to the similar procedure in the step 1<br>
of Example 40, by using a compound prepared in the step<br>
1 (30 mg, 0.16 mmol) , 58 mg (yield: 70%, yellow solid)<br>
of the target compound was obtained.<br>
:H NMR (400MHz, CDC13) : 51 . 92-2 . 01 (m, 1H) , 2.19-<br>
2.40(m, 2H) , 2.4l(s, 3H) , 2 . 46-2 . 52 (m, 1H) , 3.4S(d,<br>
J=14.0,Hz, 1H) , 3.52(d, J=14.0,Hz, 1H) , 3.63(s, 3H) ,<br>
3.89(s, 3H) , 3.91(0, 3H) , 4 . 64-4 . 74 (m, 1H) , 4.75(s, 2H) ,<br>
6.53(s, 1H) , 6.86-6.94(m, 3H) , 7.07(d, J-=10.8Hz, III),<br>
7.13(s, 1H) , 7.30(d, J=10.8Hz, 1H) , 7.39(s,<br>
132<br><step> Preparation of methanesulfonic acid 3-fluoro-<br>
5-[(7S)-(l,2,3-trimethoxy-lO-methylsul£anyl-9-oxo-<br>
5,6,7, 9 - tet r ahydro - ben20 [a ]lie;p t: ci1 on ~ 7-ylcarbamoyl) -<br>
methyl]-benzyl ester<br>
MSCI;TEA<br>
MC.<br>
'Mi<br>
According to the similar procedure in the step 1<br>
of Example 38, by using a compound prepared in the step<br>
2 (58 mg, 0.107 mmol) , GO mg (yield: 90%, yellow solid)<br>
of the target compound was obtained.<br><step> Preparation of 2-(3-flu o r o - 5 - n i t rooxytne t hy 1 -<br>
phenyl) -N- [ (7S) -.1 ,_2 , 3 - triiuethoxy-10 - me thy 1 sul f anyl - 9 -<br>
oxo-5,6,7,9-tetrahydro-benzo[a] heptalen-7-yl]-acetamide<br>
133<br>
Me'p<br>
'i)|\lal/Acetone- MeQ-if<br>
—<br>
According to the similar procedure in the step 2<br>
of Example 25, by using a compound prepared in the step<br>
3 (60 mg, 0.097 mmol) , 30 nig (y:u-:ld: 83%, yellow solid)<br>
of the target compound was obtained.<br>
H NMR (400MHz, CDC13) : 51. 92-1.98 {m, 1H) , 2.22-<br>
2.42(m, 2H) , 2.46(s, 311), 2.49-2.52(m, 1H) , 3.50(d,<br>
J=14.0,Hz, 1H) , 3.651::;, 3ii:, 3 . b6 (d, iJ=14 . 0 , Hz<br>
1H) , 3.89(s, 311), 3.93(s, 311), 4. 64-4. 74 (m, 111),<br>
5.37(s, 2H) , 6. 52 (a, 1H) , 6.97(d, Jr=8.8Hz/ 1H) , 7.11-<br>
7.17(m, 3H) , 7.35(d, J=10.8Hz, 1H) , 7. 50 (a, 1H) ,<br>
8.04(d, J=7<br>
Example 44 ; 2- (2-f luoro-5-niti-ooxymethyl-phenyl) -N-<br>
[{7S) -l/Z/B-trimethoxy-lO-methylsulfanyl-g-oxp-S, 6, 7, 9-<br>
tetrahydro-benzo [a ] hep I; a 1 e 1 1 - 7 - y 1 ]_-acetaamide<br>
A compound of Example 44 was synthesized in<br>
t<br>
analogy to the procedure as described in Example 43,<br>
134<br>
and an intermediate was prepared by the<br>
described as follows.<br>
Me<br>
XH NMR (400MHz, CDC13) : 61. 09-1. 93 (m, 1H) , 2.26-<br>
2.29(m, 1H), 2.34-2.40(m, Hi), 2.43(8, 3H), 2.49-2.54(m,<br>
1H) , 3.61(s, 311), 3.G2(d, .T. l-;, . lil, h i 1 H ) , 3.72(0,<br>
J=15.2Hz, 1H) , 3.89(s, 311), 3.92(0, 311), 4.70-4.75(m,<br>
1H) , 5.49(s, 2H) , 6.53(s, 1H) , 7.06-7.11(01, 2H) , 7.25-<br>
7.31(01, 2H) , 7.35(t, J=7.6Hz/ 1H) , 7.44(s, 1H) , 7.57(d,<br>
J«7.2Hz,<br><intermediate> Preparation of (2-£luoro-5-<br>
hydroxymethyl-phenyl)-acetic acid<br>
MeO<br>
XOH<br>
135<br>
According to the similar procedure in the step 1<br>
of Example 43, by using a compound prepared in the<br>
intermediate 5 (2.2 g, 11.94 mmol), 400 mg (yield: 90%,<br>
white solid) of the target compound was obtained.<br>
Experimental Example 1: Cytotoxicity test to cancer<br>
cell lines<br>
Cytotoxicity to A549 (Korea Research Institute of<br>
Chemical Technology) , SK-OV-3 (Korea Research Institute<br>
of Chemical Technology), SK-MEL-2 (Korea Research<br>
Institute of Chemical Technology), HCT-15 (Korea<br>
Research Institute of Chemical Technology) and MCF7<br>
(Korean Cell Line Bank, Seoul National University<br>
School of medicine} cells was measured by<br>
Sulforhodamin-B (SRB) method (1909, National Cancer<br>
Institute (NCI)) which was developed for the<br>
measurement of in vitro anticancer activity of a drug.<br>
Cells were separated using 0.25% trypsin-EDTA solution,<br>
leading to the preparation of a cell suspension by<br>
5xl03 - 2xl04 cells/well. Then, the suspension was<br>
distributed into a 96 well plate by 100 ìl/well, which<br>
Was cultured in a 37°C, 5% CO-, incubator for 24 hours.<br>
Compounds prepared in examples of the present invention<br>
were used as a sample. Precisely, the compound way<br>
136<br>
dissolved in dimethylsulfoxide and diluted with RPMI<br>
1640 medium before being uso.d a.s a sample. The final<br>
concentration of the sample used varied ranging 1 ìM ~<br>
0.00001 ìM. The medium was removed from the 96 well<br>
plate and then diluted sample solution was added by 100<br>
ìl/well, followed by further culture in a 37 C, 5% C02<br>
incubator for 48 hours. Tz (time zero) plate was<br>
collected from the point of adding the sample. Upon<br>
completing the culture, the medium was removed from<br>
each well along with Tz plate, then 10%<br>
trichloroacetic acid (TCA) was added by 100 ìl/well.<br>
The plate was left at 4 C for 1 hour to let cells be<br>
fixed on the floor of the plate. After cells were<br>
fixed completely, the plate was washed with water 5-6<br>
times to remove the remaining trichloroacetic acid<br>
solution completely and moisture was completely dried<br>
at room temperature. 0.4% Sulforhodamine-B was<br>
dissolved in 1% acetic acid solution to prepare a<br>
staining solution. Cell.s were stained for 30 minutes<br>
with a dye added by 100 ^ to each well of the<br>
completely dried plate. Then, the plate was washed<br>
with 1% acetic acid solution 5-6 times to remove<br>
sulforhodamine-B remained uncombined with cells. Then,<br>
the plate was dried at room temperuture. 10 mM Tris<br>
solution was added by 100 ìl/well thereto to dissolve<br>
137<br>
the dye, and optical density (OD) was measured ' at 520<br>
nm with a micro plate reader.<br>
ED50 (concentration that inhibits cancer cell<br>
growth 50%, 50% effective dose., nM/ml) of the sample to<br>
cancer cell was calculated aa follows. OD value at the<br>
point of beginning the culture with the sample was<br>
determined as Tz (time zero) value. OD value of a well<br>
to be cultured without the cample was determined as a<br>
control value (C) . OD vaJue of a well pretreated with<br>
the sample was determined as experimental value (T) .<br>
After calculating T?. , C and T, cytotoxicity of the<br>
sample was measured by the: below ^Mathematical 'Formula<br><mathematical formula><br>
T£ Tz, (T-Tz) / (C-Tz) .x 100<br>
T &gt; Tz., (T-T2.) /Tz -A 100<br>
ED50, the concentration that can inhibit cancer<br>
cell growth by 50%, wan calculated by using, a<br>
regression analysis of .lotus program based on the<br>
degree of cytotoxicity obtained by the <mathematical></mathematical>
Formula 1&gt;.<br>
138<br>
Each EDSO of paclitaxed, doxorubicin and<br>
colchicine, which were used as controls, was also<br>
calculated by the same way as described in the above.<br>
Results were presented in Table 1.<br><table></table>
Cytotoxicity to cancer cell lines (NT: Not tested)<br>
Example<br>
Paclitaxel<br>
Doxorub i c i n<br>
Colchicine<br>
Example 1<br>
Example 2<br>
'Example 3<br>
Example 4<br>
Example 5<br>
Example 6<br>
Example 7<br>
Example 8<br>
Example 9<br>
Example 10<br>
Example 11<br>
Example 12<br>
Example 13<br>
Example 14<br>
Example 15<br>
Cytotoxicity [ED50 : nM]<br>
A549<br>
0.3<br>
13 .0<br>
21.0<br>
1.8<br>
15.8<br>
2.4<br>
0. 01<br>
.1. . 0<br>
0.70<br>
&gt;50<br>
0.02<br>
0.49<br>
0 .20<br>
&gt;50<br>
0.05<br>
0.13<br>
28 .2<br>
30.2<br>
SK-OV-3<br>
1.2<br>
47.0<br>
18.0<br>
1.0<br>
9.3<br>
4.0<br>
0 . 01<br>
1 . U<br>
0.37<br>
&gt;50<br>
0.04<br>
0.34<br>
0.23<br>
&gt;50<br>
0.27<br>
0.10<br>
30.6<br>
&gt;50<br>
SK-MEL-2<br>
0.1<br>
16.0<br>
6.0<br>
0.4 '<br>
5.4<br>
1.0<br>
0 . 0 1<br>
.1 . 1<br>
0 .08<br>
&gt;50<br>
0.01<br>
0 .22<br>
0 .12<br>
&gt;50<br>
0.11<br>
0.04<br>
32. 0<br>
22.5<br>
HCT15<br>
0.1<br>
25.0<br>
9.0<br>
0.6<br>
2.3<br>
4.8<br>
0.03<br>
4.4<br>
0.27<br>
&gt;50<br>
0.03<br>
0.64<br>
0.39<br>
&gt;50<br>
0.05<br>
0.11<br>
9.9<br>
23.4<br>
MCF-7<br>
0.9<br>
50.0<br>
NT<br>
NT<br>
2.9<br>
2.3<br>
0.01<br>
NT<br>
0.16<br>
&gt;50<br>
0.01<br>
0.13<br>
0.09<br>
39.0<br>
0.03<br>
0.02<br>
11.2<br>
18.8<br>
139<br>
OH<br>
os
e-Z.fr<br>
S'OI<br>
O'S<br>
.IN<br>
e foi<br>
•IN<br>
L'TrZ<br>
T O ' O<br>
,IN<br>
•LN<br>
,IN<br>
UN<br>
iN<br>
IN<br>
JIN<br>
£N<br>
£N<br>
e-e<br>
T Z 'O<br>
O T ' O<br>
S T ' T<br>
2'8<br>
J.JST<br>
80'0<br>
IM<br>
OS
&gt;'9e<br>
E ' f r S<br>
6'6<br>
0' E<br>
S'Z,<br>
/ L ' O<br>
6*02<br>
T O ' O<br>
O ' T<br>
80 '0<br>
8*0<br>
Z'S<br>
8*0<br>
o- e<br>
0' Z<br>
0'OS
OVSI<br>
fr-e<br>
S6**0<br>
ei'o<br>
E O ' T<br>
T'OI<br>
£ 'S<br>
S I 'O<br>
O ' T<br>
os
os
L' 09<br>
OG
E' E<br>
T &gt; ' 6<br>
T ' O<br>
6 'T17<br>
TO' 0<br>
n i ,<br>
5 0 ' 0<br>
6 • 0<br>
. 9 ' £<br>
6 ' 0<br>
0' t'<br>
0 ' /.<br>
Q'LT?<br>
O ' T r T<br>
S'e<br>
/L8'0<br>
62 - 0<br>
L I- • Z<br>
0 ' T E<br>
0 ' 1<br>
LI' 0<br>
0 ' T<br>
os
os
9'S!&gt;<br>
Z ' K Z<br>
I' :l7<br>
8'8E<br>
T ' T<br>
OS
TO' 0<br>
9 ' D<br>
O ' T<br>
0' E<br>
Z ' B<br>
O ' E<br>
0 ' S'l<br>
( ) ' 9 't:<br>
0'OS
fr'S<br>
9 'S<br>
T^'T<br>
G S ' O<br>
E O ' T<br>
O ' ^ E<br>
8' e<br>
G T ' O<br>
O ' T<br>
os
os
6 ' £ ^<br>
^,'01&gt;<br>
17' 2<br>
os
6'Z<br>
05
9 0 ' 0<br>
» ' E<br>
Z'S<br>
O T ' T<br>
S ' E<br>
T ' T<br>
0 ' 9<br>
o - g<br>
O ' T C<br>
8'8<br>
fr'9<br>
T T ' T<br>
L G ' O<br>
E 6 ' E<br>
S'ES<br>
T ' 8<br>
T S ' O<br>
9 ' T<br>
Zf. stduiBxg<br>
Tfr siduiBxg<br>
0^ s"[duiBxg<br>
6E sjdujBxg<br>
8£ aiduiBXg<br>
^e STduiBxa<br>
9E ajduiBXH<br>
5E siduiHxa<br>
^e 3T.durexg<br>
EE ajduiHxg<br>
SE aiduiexg<br>
IE s-[durexa<br>
oe siduiexg<br>
62 9-[duiBX3<br>
82 sfduiexg<br>
Z^S 9-[duiexg<br>
92 afdurexg<br>
92 atduiexg<br>
E2 aiduiHxg<br>
ZZ ai;duiexg<br>
is ajduiexg<br>
OZ aidurexg<br>
6T sidui^xa<br>
8T STduiBxg<br>
LI 9-[duiBxg<br>
9T aiduiexg<br>
As shown in Table 1, tricyclic derivatives<br>
according to the present invention showed very strong<br>
cytotoxicity to cancer cell lines.<br>
Experimental Example 2: Inhibiting effect of tricyclic<br>
derivatives of the present invention on tumor growth<br>
In order to investigate inhibiting effect of<br>
tricyclic derivatives of the invention on tumor growth,<br>
following experiments were performed.<br>
Samples for the experiment were stored in a<br>
refrigerator all the time. Different dosages of<br>
compounds were administered to a test animal; dosage of<br>
a compound prepared in the Example 8 was 10 mg/kg,<br>
dosage of a compound prepared in the Example 12 was 1,<br>
3, 10 mg/kg respectively and dosage of a positive<br>
control was 2.5 mg/kg (Taxol) and 2 mg/kg (Adriamycin).<br>
The compound of the Example 12 was dissolved in 4%<br>
tween 80, and the positive control Taxol was dissolved<br>
in a mixed solvent of 5% athanol + 25% cremophor + 75%<br>
PBS. The prepared sample is subject to be precipitated,<br>
so that tip sonication was performed right before the<br>
administration to disperse it well.<br>
7 week-old female S.P.F. BALB/c nude mice,<br>
provided by Charles Rivet: Co., Japan, were used as teat<br>
141<br>
animals. The test animals were adapted in a Hepafilter<br>
room over a week before the test. The<br>
temperature was 21±2°C, humidity was 55±5% and 12-hour<br>
light and dark cycle was automatically repeated in that<br>
lab. Solid feed (CheilJedang) was sterilized by<br>
radioactive rays and drinking water was also sterilized<br>
by autoclave. Feed and water were taken by the animal<br>
freely. Cancer cell line used .in this experiment was<br>
NCI-H460 (human lung tumor cell line) provided by Korea<br>
Research Institute of Bioscience and Biotechnology.<br>
The tumor cell line, stored in liquid nitrogen,<br>
was thawed and cultured in a 37 °C, 5% C02 incubator for<br>
a required time. Upon completing the culture, all the<br>
cells were recovered and cell concentration of the<br>
culture fluid was adjusted using PBS to 3xl07 cells/ml.<br>
The adjusted cell culture solution was injected<br>
hypodermically into armpit between right shoulder<br>
girdle and chest wall by 0.3 ml per mouse. From the<br>
next day of grafting, NCI-H460 xenografted nude mice<br>
were administered intraperitoneal everyday with the<br>
sample solution by 0.2 ml/20 g of weight, once a day.<br>
After the grafting of tumor cells, the volume of<br>
a tumor in each individual was measured in three<br>
dimensions by using a vernier caliper, which was<br>
represented in the below Mathematical Formula 2&gt;.<br>
142<br>
Mathematical Formula 2&gt;<br>
Tumor volume = (lengUixwidthxhoight) /2<br>
Body weight changes of animal were measured three<br>
times a week. Each xenografted nude mouse was<br>
sacrificed to separate a tumor, which was then weighed.<br>
All the test results of experimental groups were<br>
compared with those of control groups by t-Test to see<br>
if there is any significant difference between the two<br>
groups.<br>
Changes of the volume and the weight of a tumor<br>
were shown in Table 2 and in FIG. 1, 3, and 5, and<br>
changes of the body weight of a mouse were shown in<br>
Table 3, in FIG. 2 and in FIG. 4.<br><table>
<br>
Experime<br>
ntal<br>
Group<br>
V.C-1<br>
V.C-2<br>
Example<br>
8<br>
Example<br>
12<br>
Dosage<br>
(mg/ks)<br>
0<br>
0<br>
10<br>
1<br>
3<br>
Tumor volume (mm1)<br>
Day 0<br>
0.0±<br>
0.0<br>
0.0 +<br>
0.0<br>
o.o±<br>
0.0<br>
0.0±<br>
0.0<br>
o.o±<br>
0.0<br>
Day 4<br>
28.3 +<br>
8.1<br>
26.7 +<br>
3.8<br>
18. 0±<br>
3.7*<br>
20. 7±<br>
3.1<br>
16 . 9±<br>
5 . 1 *<br>
Day 7<br>
53. 5±<br>
13 .7<br>
•iy .6+<br>
12.3<br>
25. 2±<br>
12.8**<br>
49.2+<br>
12.2<br>
31.2 +<br>
1 1 . 7 *<br>
Day 9<br>
90.3 +<br>
2 _S . 5<br>
00 . !) +<br>
26.7<br>
29.6 +<br>
13.0**<br>
*<br>
78.1 +<br>
13 . 0<br>
49.7 +<br>
1 r^ . 0 A *<br>
Day 11<br>
167. 5±<br>
43.8<br>
130.2±<br>
54.9<br>
35. 2±<br>
14.0**<br>
*<br>
146.S±<br>
n .B<br>
9S.1 +<br>
2n . 1**<br>
Day 14<br>
295. 2±<br>
62.2<br>
289. 0±<br>
53.1<br>
44. 5±<br>
15.0***<br>
299. 3±<br>
41.5<br>
206. 8±<br>
48. 0*<br>
Tumor<br>
Weight<br>
(mg)<br>
Day 14<br>
1171.2<br>
±303 .5<br>
1087 .9<br>
±300.5<br>
143.4+<br>
57.8**<br>
*<br>
950 . 9+<br>
174.8<br>
714.5+<br>
103 . B *<br>
Taxol<br>
Adriamyc<br>
in<br>
10<br>
2.5<br>
2<br>
0 . 0±<br>
0 . 0<br>
o.o±<br>
0 . 0<br>
0.0±<br>
0.0<br>
.'LS.l-J;<br>
6.7*<br>
17. 5±<br>
4.6***<br>
21. 8±<br>
8.3<br>
2 
9.0* *<br>
32. 7±<br>
3.8**<br>
33.7+<br>
8.7*<br>
3 b . 2 ±<br>
12.9 * *<br>
*<br>
47.2±0<br>
47. 6±<br>
16.2**<br>
G9.4±<br>
26.9**<br>
*<br>
~*<br>
81. 6±<br>
24.5**<br>
103. 0±0<br>
~<br>
138. 1±<br>
39.9***<br>
390 .9:1;<br>
0<br>
"<br>
534. 1±<br>
87.9<br>
* Significance test (t-Test) : *(p
***(p
V.C-1 : 4% tween 80,<br>
V.C-2 : 5% ethanol + 25% cremophor -i- 75% PBS<br><table>
<br>
Experime<br>
Til- nc 9a 1x<br>
Group<br>
V.C-1<br>
V.C-2<br>
Example<br>
8<br>
Example<br>
12<br>
Taxol<br>
Adriamyc<br>
in<br>
Dosage<br>
(nig/ kg)<br>
0<br>
0<br>
10<br>
1<br>
3<br>
10<br>
2 .5<br>
2<br>
Aniuun 1<br>
(n)<br>
6<br>
6<br>
5<br>
6<br>
6<br>
6<br>
(Day 14-<br>
2}<br>
c&gt;<br>
(Day :)-<br>
9<br>
Day 11,<br>
Day 14-<br>
1)<br>
6<br>
Day<br>
1<br>
100. 0±<br>
0.0<br>
100.0+<br>
0 . 0<br>
100. 0±<br>
0 . 0<br>
100. 0±<br>
0.0<br>
100 .0+<br>
0.0<br>
100. 0±<br>
o . d<br>
100 . 0:i<br>
0 . 0<br>
100. 0±<br>
0 . 0<br>
Hocly<br>
Day<br>
3<br>
105. 4±<br>
2.5<br>
106. 9±<br>
2 . 4<br>
103 .5±<br>
2 9<br>
105.0+<br>
1.4<br>
102.8+<br>
2 . 0<br>
103.9+<br>
0 . 9<br>
ll)o . 0-i<br>
.1. . ' •<br>
105.0+<br>
4.1<br>
w
Day<br>
7<br>
108.7<br>
±<br>
2.4<br>
110. 5±<br>
1 . 5<br>
99. 0 +<br>
4 . 3 * *<br>
104 , 2±<br>
5.3<br>
101. 0±<br>
4.2**<br>
92. 2±<br>
~\ 15 * * *<br>
9 - ' . !!•!;<br>
.' ] . 1 •'• * 'A'<br>
103 . 9+<br>
5.5<br>
Change<br>
Day<br>
9<br>
107. 2±<br>
3.7<br>
108. 5±<br>
2 .6<br>
92. 3±<br>
4 _ 1***<br>
99. 6±<br>
4.4**<br>
99. 3±<br>
3.3*<br>
89. 4±<br>
2 .0**<br>
y v . i ± o<br>
100. 5±<br>
4.6*<br>
1 (%)<br>
Day<br>
11<br>
107. 8±<br>
4.6<br>
109. 0±<br>
52.6<br>
89. 3±<br>
3.7***<br>
97. S±<br>
3.6**<br>
99. 1±<br>
2.8**<br>
92. 3±<br>
2.9***<br>
96. 4±<br>
3 .5***<br>
Day<br>
14<br>
107. 8±<br>
3.2<br>
108.9+<br>
3.6<br>
89.4 +<br>
5.3***<br>
98.3-1<br>
3.2***<br>
94. 5±<br>
3 _ 9 * * *<br>
93.4±0<br>
85.1 +<br>
1.8***<br>
)K Significance test (t-Test)<br>
***(p
(p
144<br>
V.C-1 : 4% tween 8O,<br>
V.C-2 : 5% ethanol + 25% cremophor + 75% PBS<br>
As shown in Table 2, and FIG. 1, 3 and 5, the<br>
size and the weight of a tumor of NCI-H460 xenografted<br>
BALB/c nude mouse were remarkably decreased when it was<br>
administered with tricyclic derivatives of the present<br>
invention (prepared in Example 8 and Example 12),<br>
comparing to when being administered with a solvent<br>
only (V.C-1, V.C-2) or with a positive control (taxol,<br>
adriamycin) . In particular, in the case of the<br>
compound of the Example 12, the volume and the weight<br>
of a tumor were much decreased with dosage of 10 mg/kg<br>
than with the dosage of 1. mg/kg. And in the case of the<br>
compound of the Example 8, inhibition rate of the tumor<br>
volume showed 85% when it was administered with 10 mg/kg.<br>
Therefore, decreasing rate of the volume and the weight<br>
of a tumor can appreciate in proportion to dosage of<br>
tricyclic derivatives of the present invention.<br>
As shown in Table 3 and in FIG. 2 and 4, the<br>
weight of NCI-H460 xenografted BALB/c nude mouse was<br>
decreased about 10% when it was administered with<br>
tricyclic of the present invention (prepared in Example<br>
8 and Example 12), comparing to when being administered<br>
145<br>
With a solvent only (V.C-1, V.C-2) or with a positive<br>
control (taxol, adriamycin).<br>
Therefore, tricyclic derivatives of the present<br>
invention make the volume and the weight of a tumor<br>
smaller and lighter dose-dependently, and also show<br>
excellent anticancer effect. So, tricyclic derivatives<br>
of the invention can be effectively used as an<br>
anticancer agent and as a anti-proliferation agent.<br>
Experimental Example 3; Inhibitory affect of tricyclic<br>
derivatives of the present invention on capillary-like<br>
tube formation in HUVEG cells (Capillary-like tube<br>
formation assay)<br>
Matrigel used in this experiment was a product of<br>
BioCoat. Matrigel was thawed in. a refrigerator for 24<br>
hours before use. Thawing matrigel, 96 well plate and<br>
yellow tip were put on ice. Then, matrigel was<br>
distributed into each well of the plate by 40 (d. The<br>
polymerization of the plate was performed in a 37C<br>
incubator for 30 minutes. Each well of the plate was<br>
inoculated with 180 ìl of HUVEC cell solution (2xl04<br>
cells/ml) along with 20 ìl of the compound of the<br>
Example 12 in serum-free media (0.3, l, 3, 10 and 30 /;g<br>
146<br>
/ml), followed by further culture for 24 hours.<br>
Tube formation was observed under a microscope to<br>
investigate-inhibition activity of angiogenesis.<br>
Fumagilin and doxorubicin were used as a positive<br>
control.<br>
The results were shown in PIG. 6.<br>
As shown in FIG. 6, tricyclic derivatives of the<br>
present invention (prepared in the Example 12) had<br>
angiogenesis inhibition activity with dosage over 0.3<br>
ìg/ml, which was as good effect a a that of fumagilin, a<br>
positive control, with the dosage of. 10 ìg/ml. Further,<br>
tricyclic derivatives of the invention (prepared in the<br>
Example 12) totally inhibited angiogenesis with the<br>
dosage over 10 ìg/ml.<br>
Thus, tricyclic derivatives of the present<br>
invention can be effectively lined as an angiogenesifj<br>
inhibitor.<br>
Experimental Example 4: Acute toxicity test<br>
5-week-old ICR thrice having the weight of 25-35 g<br>
(SPF, SLC Co. Japan) were: m;ed ur. uei:;t animals. A pair<br>
of female and male of the mice was given for the test<br>
of each compound. Group T2, T3, T4 and T5 were<br>
arranged (10 animals per group) for the test of acute<br>
147<br>
toxicity of the compound prepared in the Example 12.<br>
The compound of the Example 12 was dissolved in a<br>
Solvent [5% DMSO; 20% tween 80; 75% PBS(-)], which was<br>
injected into the abdominal cavity of the mouse (dosage<br>
was shown in Table 4), followed by observation for 7<br>
days. Control group (Tl) was administered with only a<br>
solvent without the compound of (-he Example 12. Arul<br>
the results were shown in Table 1 .<br>
For comparison, colchicine was injected in the<br>
test animals by the same method as described in the<br>
above. The group treated with colchicine was<br>
composed of 6 mice. The test results were shown in<br>
Table 5.<br>
Taxol produced by Bristol Myers Sqibb Co. was<br>
also used for comparison, and the injection and the<br>
test of acute toxicity were performed by the same<br>
method as described in the. above. The results were<br>
shown in Table 6.<br><table>
<br>
Acute toxicity test with a compound prepared in Example<br>
12<br>
Group Animal<br>
Number<br>
rDosage<br>
(mg/kg)<br>
Test Day (Death)<br>
1 2 M4!5 6 7 Total<br>
148<br>
Tl<br>
T2<br>
T3<br>
T4<br>
T5<br>
10<br>
10<br>
10<br>
10<br>
10<br>
Solvent<br>
30<br>
40<br>
50<br>
60<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
_<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
-<br>
0/10<br>
0/10<br>
0/10<br>
0/10<br>
0/10<br><table>
<br>
Acute toxicity test with colchicine<br>
Group<br>
Tl<br>
T2<br>
T3<br>
T4<br>
T5<br>
Animal<br>
Number<br>
6<br>
6<br>
6<br>
6<br>
5<br>
Dosage<br>
(mg/kg)<br>
Solvent<br>
0.5<br>
1.0<br>
2.0<br>
5.0<br>
Test Day (Death)<br>
1<br>
-<br>
-<br>
-<br>
-<br>
2<br>
-<br>
-<br>
-<br>
3<br>
3<br>
-<br>
1<br>
-<br>
4<br>
-<br>
1<br>
5<br>
-<br>
-<br>
-<br>
1<br>
6<br>
-<br>
-<br>
-<br>
2<br>
-<br>
7<br>
-<br>
-<br>
-<br>
-<br>
-<br>
Total<br>
0/6<br>
0/6<br>
0/6<br>
3/6<br>
5/5<br><table>
<br>
Acute toxicity test with Taxol<br>
Group<br>
Tl<br>
T2<br>
T3<br>
T4<br>
T5<br>
Animal<br>
Number<br>
5<br>
5<br>
5<br>
5<br>
5<br>
Dosage<br>
(mg/kg)<br>
4.0<br>
6.0<br>
9.0<br>
13.0<br>
20.0<br>
Test Day (Death)<br>
1<br>
-<br>
-<br>
-<br>
2<br>
5<br>
2<br>
-<br>
1<br>
-<br>
2<br>
-<br>
3<br>
-<br>
-<br>
-<br>
-<br>
-<br>
4<br>
-<br>
-<br>
-<br>
-<br>
-<br>
5<br>
-<br>
-<br>
2<br>
-<br>
-<br>
6<br>
-<br>
-<br>
-<br>
-<br>
-<br>
7<br>
-<br>
-<br>
-<br>
-<br>
-<br>
Total<br>
0/5<br>
1/5<br>
2/5<br>
4/5<br>
5/5<br>
As shown in Table 4, 5 and 6, toxicity of natural<br>
colchicine to a mouse was confirmed to be LD50 = 2mg/kg,<br>
which was very similar to earlier reported value of<br>
LDSO = 1.6mg/kg [Medicinal Research Reviews, Vol.8,<br>
No.l, 77-94 (1988)]. Toxicity of taxol injection,<br>
»<br>
paclitaxel, was LDSO = 9 - 13 mg/kg. (i.v.<br>
administration) . But toxicity of the compound of the<br>
Example 12 of the present invention was LDso = 60mg/kg,<br>
which was 30 times as week toxicity as that of<br>
colchicine and also weaker than v.hat of taxol injection.<br>
Thus, the compound of the present invention was proved<br>
to have less toxicity to normal cells than colchicine<br>
or Taxol injection.<br>
INDUSTRIAL APPL1 CA'RILITY<br>
Tricyclic derivatives of the present invention<br>
have very strong cytotoxicity to cancer cell lines but<br>
less toxicity to animals themselves than colchicine or<br>
Taxol injection has. Tricylic: derivatives of the<br>
invention further decrease the volume and the weight of:<br>
a tumor and inhibit angiogenesis in HUVEC cells<br>
excellently. Therefore, the derivatives can b<br>
effectively used as an anticancer agent, antiproliferation<br>
agent and an angiogenesis inhibitor as<br>
150<br>
e<br>
well. In addition, tricyclic derivatives of the<br>
present invention can be obtained with ease and be<br>
formulated easily for oral. administration or for<br>
injection owing to its water-solubility.<br><br><br><br><br><br><br>
We claim:<br>
1. A 5,6,7,9-tetrahydro-benzo[a]heptalen derivative of general Formula 1 <formula> Rj-O<br>
(Formula Removed)<br>
Wherein,<br>
(l)R,is-T,-B,;<br>
in which Ti is -N(Rs)C(0)-, in that R5 is H or Ci~Cs alkyl group; and Bi is selected from a group consisting of following (a)-(c);<br>
(Formula Removed)<br>
wherein,<br>
(Formula Removed)<br>
R6 is H or halogen;<br>
R7 is hydroxy or -ONO2, with the proviso that when R6 is H, R7 is -ONO2;<br>
T2 is -O-C(O)-;<br>
B2 is said (a) or — (CH2)n3-R7.<br>
n1 is an integer of 0-1;<br>
n2 is an integer of 0-5; and<br>
n3 is an integer of 2~5;<br>
(2)	R2 is CH3;<br>
(3)	R3 is C1~C4 straight-chain or branched-chain alkyl or C3~C7cycloalkyl, with the proviso that when B1 is (a) and R6 is H, R3 is C2H5;<br><br>
(4)	R4 is OCH3, SCH3 or NR10R11, in which R10 and R11 are each independently H or C1-5 alkyl;<br>
(5)	X is O<br>
or a pharmaceutically acceptable salt thereof. 2. The compound as claimed in claim 1, selected from the group consisting of:<br>
1)	6-nitrooxymethyl-N-[(7S)-l,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-<br>
tetrahydro-benzo[a]heptalen-7-yl]-nicotineamide;<br>
2)	N-[(7S)-3-ethoxy-l,2-dimethoxy-10-methyl-sulfanyl-9-oxo-5,6,7,9-<br>
tetrahydro-benzo[a]heptalen-7-yl]-3-nitrooxymethyl-benzamide;<br>
3)	6-nitrooxymethyl-pyridine-2-carboxylic     acid-[(7S)-l,2,3-trimethoxy-10-<br>
methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;<br>
4)	5-nitrooxymethyl-thiophene-2-carboxylic    acid-[(7S)-1,2,3-trimethoxy-10-<br>
methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;<br>
5)	N-[(7S)-3-ethoxy-l,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-<br>
benzo[a]heptalen-7-yl]-2-fluoro-3-nitrooxymethyl-benzamide;<br>
6)	2-fluoro-N-[(7S)-3-isopropoxy-l,2-dimethoxy-10-methylsulfanyl-9-oxo-<br>
5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-3-nitrooxymethyl-benzamide;<br>
7)	2-fluoro-3-nitrooxymethyl-N-[(7S)-l,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;<br>
8)	3-fIuoro-5-nitrooxymethyl-N-[(7S)-l,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;<br>
9)	N-[(7S)-3-ethoxy-l,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-<br>
benzo[a]heptalen-7-yl]-3-fluoro-5-nitrooxymethyl-benzamide;<br>
10)	3-fluoro-N-[(7S)-3-isopropoxy-l,2-dimethoxy-10-methylsulfanyl-9-oxo-<br>
5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-5-nitrooxymethyl-benzamide;<br>
11)	N-[(7S)-3-cyclopentyloxy-l,2-dimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-<br>
tetrahydro-benzo[a]heptalen-7-yl]-3-fluoro-5-nitrooxymethyl-benzamide;<br>
12)	2-fluoro-5-nitrooxymethyl-N-[(7S)-l,2,3-trimethoxy-10-methylsulfanyl-9-<br>
oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-benzamide;<br>
13)	4-nitrooxymethyl-thiophene-2-carboxylic  acid   [(7S)-l,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;<br>
14)	3-nitrooxymethyl-thiophene-2-carboxylic  acid   [(7S)-l,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl]-amide;<br>
15)	3-nitrooxymethyl-benzoic acid-2-[(7S)-l,2,3-trimethoxy-10-methylsulfanyl-<br>
9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester;<br>
16)	4-nitrooxybutyric   acid-2-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-<br>
5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester;<br>
17)	3-nitrooxymethyl-benzoic acid-3-[(7S)-l,2,3-trimethoxy-10-rnethylsulfanyl-<br>
9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester;<br>
18)	4-nitrooxybutyric   acid-3-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-<br>
5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-phenylester;<br>
19)	3-nitrooxymethyl-benzoic acid-3-[(7S)-l,2,3-trimethoxy-10-methylsulfanyl-<br>
9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-benzylester;<br>
20)	4-nitrooxybutyric   acid-3-[(7S)-1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-<br>
5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl-carbamoyl]-benzylester;<br>
3. A method for preparing the compound as claimed in claim 1 comprising the following steps:<br>
(Formula Removed)<br>
     respectively at room temperature, or; reaction of the resultant compound of formula VII with the compound of formula IV to give the compound of formula V at room temperature (Step 1); and<br>
(2) Nitration or nitrosation of the compound of formula (V) prepared by step 1 or<br><br>
(Formula Removed)<br>
the compound of formula (VII) to give compound	at room<br>
temperature (Step 2).<br>
(Formula Removed)<br><br>
(Wherein, D is	, and R2, R3, R4 and X are same as defined in the<br><formula> of claim 1;<br>
R5 is H or C1~ C5 alkyl group;<br>
X1 is O;<br>
Hal1 and Hal2 are halogens;<br>
Hal1 and Hal2 of formula (IV) are each same or different halogens, for example F, C1,<br>
Br or I; Y is selected from the group consisting of formula (a') and (b'),<br>
(Formula Removed)<br>
wherein, 	, R6, n1, and n2 are same as defined in the <formula> of claim<br>
1).<br>
4. The compound as claimed in claim 1 as and when used in the preparation of a pharmaceutical composition for treatment or prevention of cancer and/or angiogenesis related disorders.<br></formula></formula></formula>
</table>
<br><span id="LblCompatibility" style="color:White;font-family:Arial;font-size:Small;">Best View in Resolution of 1024x768 or later. Enable Javascript for Better Performance.</span>
        
    

<script type="text/javascript">
//<![CDATA[
(function() {var fn = function() {$get("ToolkitScriptManager_HiddenField").value = '';Sys.Application.remove_init(fn);};Sys.Application.add_init(fn);})();//]]>
</script>
</table>
</table>
</table>
</table></mathematical></intermediate></step></step></step></step></step></step></step></step></step></step></step></step></step></step></lntermediate></step></step></intermediate></step></step></step></step></step></intermediate></step></step></intermediate></step></step></intermediate></step></step></step></step></intermediate></step></sfcep></intermediate></intermediate></intermediate></step></step></step></intermediate></intermediate></step></step></formula></method></method></method></method></method></method></methgd></method></formula></formula></scheme></scheme></scheme></scheme></scheme></scheme></scheme></formula></formula></formula></formula></formula></formula></formula></x></formula></formula></formula></formula></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LURFTE5QLTIwMDYtQWJzdHJhY3QtKDE2LTAyLTIwMDkpLnBkZg==" target="_blank" style="word-wrap:break-word;">384-DELNP-2006-Abstract-(16-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtYWJzdHJhY3QucGRm" target="_blank" style="word-wrap:break-word;">384-delnp-2006-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtYXNzaWdubWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LURFTE5QLTIwMDYtQ2xhaW1zLSgxNi0wMi0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-DELNP-2006-Claims-(16-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtY2xhaW1zLSgxOS0wMy0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-claims-(19-03-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtY2xhaW1zLSgyNC0wMy0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-claims-(24-03-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtY29tcGxldGUgc3BlY2lmaWNhdGlvbiAoZ3JhbnRlZCkucGRm" target="_blank" style="word-wrap:break-word;">384-delnp-2006-complete specification (granted).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LURFTE5QLTIwMDYtQ29ycmVzcG9uZGVuY2UtT3RoZXJzLSgxNi0wMi0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-DELNP-2006-Correspondence-Others-(16-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtY29ycmVzcG9uZGVuY2Utb3RoZXJzLSgxOS0wMy0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-correspondence-others-(19-03-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LURFTE5QLTIwMDYtQ29ycmVzcG9uZGVuY2UtT3RoZXJzLSgyMC0xMC0yMDA4KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-DELNP-2006-Correspondence-Others-(20-10-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtY29ycmVzcG9uZGVuY2Utb3RoZXJzLSgyNC0wMy0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-correspondence-others-(24-03-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtY29ycmVzcG9uZGVuY2Utb3RoZXJzLTEucGRm" target="_blank" style="word-wrap:break-word;">384-delnp-2006-correspondence-others-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtY29ycmVzcG9uZGVuY2Utb3RoZXJzLnBkZg==" target="_blank" style="word-wrap:break-word;">384-delnp-2006-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtZGVzY3JpcHRpb24gKGNvbXBsZXRlKS0oMTktMDMtMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">384-delnp-2006-description (complete)-(19-03-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtZGVzY3JpcHRpb24gKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtZHJhd2luZ3MucGRm" target="_blank" style="word-wrap:break-word;">384-delnp-2006-drawings.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LURFTE5QLTIwMDYtRm9ybS0xLSgxNi0wMi0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-DELNP-2006-Form-1-(16-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtZm9ybS0xLnBkZg==" target="_blank" style="word-wrap:break-word;">384-delnp-2006-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtZm9ybS0xMy0oMTYtMDItMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">384-delnp-2006-form-13-(16-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtZm9ybS0xMy0oMjAtMTAtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">384-delnp-2006-form-13-(20-10-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtZm9ybS0xOC5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LURFTE5QLTIwMDYtRm9ybS0yLSgxNi0wMi0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-DELNP-2006-Form-2-(16-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtZm9ybS0yLnBkZg==" target="_blank" style="word-wrap:break-word;">384-delnp-2006-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LURFTE5QLTIwMDYtRm9ybS0zLSgxNi0wMi0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-DELNP-2006-Form-3-(16-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtZm9ybS0zLnBkZg==" target="_blank" style="word-wrap:break-word;">384-delnp-2006-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtZm9ybS01LnBkZg==" target="_blank" style="word-wrap:break-word;">384-delnp-2006-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtZ3BhLSgxOS0wMy0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-gpa-(19-03-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LURFTE5QLTIwMDYtT3RoZXJzLURvY3VtZW50LSgxNi0wMi0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-DELNP-2006-Others-Document-(16-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtcGN0LTEwMS5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-pct-101.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtcGN0LTIxMC5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-pct-210.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtcGN0LTIzNy5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-pct-237.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtcGN0LTMwMS5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-pct-301.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtcGN0LTMwNC5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-pct-304.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtcGN0LTMwOC5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-pct-308.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtcGN0LTMxMS5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-pct-311.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtcGN0LTQwMS5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-pct-401.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtcGN0LTQwMi5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-pct-402.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtcGN0LTQwOS5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-pct-409.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LWRlbG5wLTIwMDYtcGN0LTQxNi5wZGY=" target="_blank" style="word-wrap:break-word;">384-delnp-2006-pct-416.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LURFTE5QLTIwMDYtUGV0aXRpb24tMTM3LSgxNi0wMi0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-DELNP-2006-Petition-137-(16-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Mzg0LURFTE5QLTIwMDYtUGV0aXRpb24tMTM4LSgxNi0wMi0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">384-DELNP-2006-Petition-138-(16-02-2009).pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="233338-polymer-conjugates-of-mutated-neublastin.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="233340-a-phenylamine-compound-having-pde4-inbibitor-activity.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>233339</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>384/DELNP/2006</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>13/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>27-Mar-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>28-Mar-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>20-Jan-2006</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>JE IL PHARMACEUTICAL CO., LTD</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>745-4 BANPO-I DONG, SEOCHO-GU, SEOUL 137-810, REPUBLIC OF KOREA.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>JOE, BO-YOUNG</td>
											<td>#101-813 INJUNG-MELODY APT., DUNJEON-RI, POGOK-MYUN, YONGIN CITY, KYUNGGI-DO 449-812, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>2</td>
											<td>PARK, SANG-WOO</td>
											<td>13/3 205 SUNGWON JUTAEK, 366-I YULJEON-DONG, JANGAN-GU, SUWON CITY, KYUNGGI-DO 440-827, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>3</td>
											<td>KIM, KWANG HEE</td>
											<td>#112-035 HANSUNG APT., 380, GUGAL-RI, KIHUNG-EUB, YONGIN CITY, KYUNGGI-DO 449-735, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>4</td>
											<td>OH, BYUNG-KYU</td>
											<td>B-301 JIN-HEUNG PARK, 74-16 GIMNYANGJANG-DONG, YONGIN CITY, KYUNGGI-DO 449-924, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>5</td>
											<td>CHOI, JONG-HEE</td>
											<td>16/2 1029-13 GWONSEON-DONG, GWONSEON-GU, SUWON CITY, KYUNGGI-DO 441-822, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>6</td>
											<td>KIM, MYUNG-HWA</td>
											<td>#304-1202 SSANG-YONG APT., 621, SANGHA-RI, GUSUNG-MYUN, YONGIN CITY, KYUNGGI-DO 449-942, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>7</td>
											<td>CHUN, KWANGWOO</td>
											<td>#102-1502 JINWOO APT., 265, SAMGA-DONG, YONGIN CITY, KYUNGGI-DO 449-718, REPUBLIC OF KOREA</td>
										</tr>
										<tr>
											<td>8</td>
											<td>CHOI, JAE-WON</td>
											<td>2/9 29-53 SUSAK-DONG, EUNPYUNG-GU, SEOUL 122-090, REPUBLIC OF KOREA</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07C 317/30</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/KR2004/001518</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2004-06-23</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>10-2003-0041547</td>
									<td>2003-06-25</td>
								    <td>Republic of Korea</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/233339-tricyclic-derivatives-or-pharmaceutically-acceptable-salts-thereof-their-preparations-and-pharmaceutical-compositions-containing-them by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:39:18 GMT -->
</html>
